var title_f15_19_15664="Ultrasound image of normal axillary lymph node";
var content_f15_19_15664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67261&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound image of normal axillary lymph node",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 395px; height: 244px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ultrasound image of normal lymph node. The arrow indicates the normal fatty (hyperechoic) hilum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15664=[""].join("\n");
var outline_f15_19_15664=null;
var title_f15_19_15665="Bambuterol: International drug information";
var content_f15_19_15665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bambuterol: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4324018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Bambec (AT, DE, DK, ES, GB, HU, IT, LU, NO, SE);",
"     </li>",
"     <li>",
"      Oxeol (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1977806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Bambuterol Hydrochloride",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1977813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1977816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bronchospasm in bronchial asthma, chronic bronchitis, and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1977809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children 2-5 years: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children 6-12 years: See Adult dose; due to differences in kinetics, doses &gt;10 mg are not recommended in Asian children",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: Initial: 10 mg/day; may be increased to 20 mg/day after 1-2 weeks based on clinical effect. Patients previously treated with oral beta",
"     <sub>",
"      2",
"     </sub>",
"     agonists may be started at 20 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;50 mL/minute: 5 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1977815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Solution, oral: 1 mg/mL [contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 10 mg, 20 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10531 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-F1EFE81ED1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15665=[""].join("\n");
var outline_f15_19_15665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4324018\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977806\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977813\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977816\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977809\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821080\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1977815\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10531\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10531|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_19_15666="Mild compression fracture of L2";
var content_f15_19_15666=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83217&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mild compression fracture of second lumbar vertebra",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 350px; height: 584px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAJIAV4DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6K8YeJofDFvYSS2F9qEt9dfZIYLPyt5fypJCSZHRQAsTd/SsD/hY8v/Qm+JP+/lj/APJNN+Lh2yeDj/1GW/8ASG7rmdA0l9c/4Sm/v/E+q6XZaXe+SqWqWvlpEtpBKzEyQuxOZHPXpjigDqP+Fjyf9Cb4k/77sf8A5Jo/4WPJ/wBCb4k/77sf/kmuJ+F/9kfEnTby90Hxf4xhFpMIZYbuHT0kGVBVsLAw2nnHP8J4p3hHUZ9Q8I6Je3kvmXVzYwTSvgDc7RqWOBwMknpQB2f/AAsiT/oTvEn/AH3Y/wDyTTl+I0rdPBviT/v5Y/8AyTWFG3zbm/KrAmAxtPNAGofiNKo58G+JP+/lj/8AJNRv8Tdhw3g/xID/AL9j/wDJNY88+Op59KoyS7idx5NAHSj4n5OB4Q8SZ/37H/5JqRPiRI+Nvg3xIc/7dj/8k1yUUnzHmrsF0Y1AAz9aAOmXx/csfl8F+JT/ANtLD/5Kpx8eXY6+CvEo/wC2lh/8lVlWdzKGVjEQnrmrZvSW2k8e4oAsjx7dHp4K8Sf9/bD/AOSqafiDcA/8iX4k/wC/lh/8k0yG5Gxm+Uc4pk0qiY8KQeRzQBOPH9yRn/hC/EuB/wBNLD/5KqCX4kvF9/wd4kH/AAOx/wDkmo2vVCNmMZx61kXF/ayDLqEP1oA1X+KSooLeEPEgB6fNZf8AyTUQ+LUBOB4T8SE/71l/8k1yuq3cZjAjxkHtXPNckSHnGe9AHpv/AAtiHGf+ET8Sf99WX/yTTW+LUCg58J+JOPey/wDkmvNo7wtkZzg1N5+/GTu9qAO/PxhtB18K+JP/ACT/APkimH4y2Q6+FvEv/kn/APJFefSYYE+lUpTtOc9+maAPfPAvi+18Y6fe3VnZX1kbS6NpLFeCMOH8tJMjY7AjbIvf1rjLL42abe2kFzbeGPEjwToskbYsxuUjIODcZ6GpfgBzpXin/sM/+2drXjvw9sH1lPAukfbbmyhvkSOWW2EZkCrZyyADerKPmjXt0zQB7KPjBaHp4V8SfnZf/JFPX4uW7fd8J+JTj3sv/kmvMLk+GrXUr63l1Tx+LWy1YaNPfCPTDEtwTgDb5fmFT6hK19b0Z/DXjS70dNTvtQtRp9tdq14It6u8lwrAGONBjES9Qe9AHdj4sQnp4S8SfnZf/JNL/wALWjyR/wAIl4k/76sv/kmuHDkfhTZZccA5Y+9AHbt8WoFGT4T8SfnZf/JNA+LUB/5lPxJ+dl/8k1580pMnHWpFfoc0Ad9/wtmH/oU/En52X/yTUkfxTST7nhHxIf8AgVj/APJNefeYdw2nk9KsR7sdGJ7kUAd4fieFznwh4kGPV7H/AOSajb4qxIcN4T8RA+8lj/8AJNcFcGTkAMx79eKzXhmLk7GI96APS2+Ldsuc+FvEIx1/eWP/AMk1GfjDZA4PhjxBn/rpY/8AyTXmkttP0Efb1FUJrCcnlVUerNQB6w3xksVUsfC/iLA6ndZf/JNVZfjppEQ+fw34kH4Wh/8AbivJ7jR5GjZhMCBycdDWZPa+WhJYN7UAe32/xu0y4Vmh8MeJWC9eLQf+3FEvxt0yJgsnhjxKCenFof8A24rxzQ3MQkXkbhzkVaELzjzEBYJxwKAPYdK+MFrqupxafYeFPEst3KGKR/6GuQBk8m4AHHvVDWPjxo2j6rc6bqPhzxJFe2zbJYwto204zjK3BHf1rB+EFgX8dLO3IitXIOehOBXkHxEnjufHviC5BGZL2TI+hx/SgD3H/horw3/0AfEn/fu2/wDj9eteHtVg17QNM1ezWVLbULWK7iWUAOqSIGAYAkZwRnBNfA00+N3Tk4Ffb/wn/wCSWeDf+wLZf+iEoAxfjIcL4QP/AFGW/wDSG7rj7bQtZ8VeAfiDonh25tLW7v8AWEgkmuWYKsJs7TzMbVJJK5XHuea6z42Ntg8In01o/wDpFd15tqGh6Jf3T3N9o+m3Nw+N0s1qju2BgZJGTwAPwoA7zwJ8MtQ8D/EKXUtK1Rbvw/d6ZFZ3UV1sScSwgLEyrFGqFQgC888knNcl4BcDwJ4b4GRptt/6KWslfC/hv/oXtG/8Aov/AImtiCVIII4LaNIoY1CIkahVVQMAADoAO1AG55uRuPNMe64+Wsxbokbfz96jkuB/DwKALkkxZtxOahkmzwMVWNwnqBmm+arNwQT9aALcLgqTmtvT7RJShkZ2HUha5tGySqBi3oK6/wAPgx2w8w8rwfrQBrrBCB0fp61AY7ck/K/4GpzKrEjuF61lyXaxu24gDNAGmLWFolGXAJ9agvreEyLiQrgY6ZrKTWiJDux5fQDvTY9TSQqsmeOAaALT2G/eI5Qx/KsLXdMmjhDLCdqAHKjNdFaNuj3AjnvT7s5jbY5DAUAeaTyBfx6YrNmLNL2AzWz4jYNdhlQK5+9jofesVuMEnvxQAcouc81HDMd2STSyg9CTg1ASBgAe5oA0Tc8c4zVaVtxJPPeqybmT1xT1z3IOKAPWP2eiTo3icn/oMn/0jta8u+Dn/If+Gn4/+m64r1H9nk50XxOf+o0f/SO1rxLwzZWd94S0WLUbWC5iFpAwSeNXXPlgZwfqaAPQtW+DOvXuo+J3hj8PW8+ra1/aNtrizSfbrCLeG2IoiHJAPHmAcn61pfEnK/FK7+YkjRbHk9/395Xn8fhnQP4tD0rP/XpH/hWjp9hp2mbzptha2fmY3+RCse7GcZwOcZP50AajSY5POO1VppwoZifmNU5bzJJPGKp3E5cgAUAXvta5UDNWoJxIDn8qwUkJkI74q2sxjjYgYY0AbKSAHPBJ4q7HdEINrY+hrlP7QMYCpyT71d027MqkHkA96ANia6kb+M7TVRp8nGck1BNMADzk1XV88/jzQBcMuB061HvDE81Gp9eRj8qjkcLHnoRxzQA+ScKrDPQVkzSwtIeAG70lzKcuA3LDms0uQSOv9KANCBU3SMBg4zwa3/C/jV/CKXEaWEV1Hc4Ztx2sMcYBx0rlrW5EO8kbiMfl70y/Rrn5kHPJwD0oA9Lj+NGm2ZMzaDIkoHWFk59icDvXzxqlwbi5ubiT/WTSNKec8sSa2b1JMskibUrmNQkPzL3oApM+5ic8V94fCf8A5JZ4N/7Atl/6ISvgzotfefwn/wCSWeDf+wLZf+iEoA5v47vssPCjems/+2V1XmV1feUu9mCj/aOK9A/aRna28O+G5lOGXWRjPvaXIr5u1vWZJroorltvU570AehyaxGSAZ85/uir9hOJEJVty9RivIbTUXRhuJJ9a7vwvd+Yhw3DDpQB1/nAjGcZqleXgjyqE5qGacxxsx69BWPNOSxJNAGhHdMPmJ5NW4rjA3HrWJDNnGR06GrSzcn5c+tAHRWGqlGw4BWuw0S6E1lI0fdhn8q8yjuIx8rBlJ44ruPDc0NlCI5Zgd3DHtQB0cVzhpDg524Nc/fFmdic8nIrdnjRFYoQd46is2QJjD43HvQBkuxXG4ED+dSIWZFJHfv3rWaBPsLSELknAqlEihl3Hn0NAGlaSNDZsM85A5pyz7op5HI2KtRiIywlAcc5qpq37rS5YI8BivPuKAOZ1WSO5mMinb6Cs7YBnmlyxJIHBph4ODz3oAZdbSo6iquB9Tmp7nA24649arxjB45HvQBIF+Vhg4FMKqRhe9TjlSPXvShdmOn1oA9Q/Z5BGi+JwRg/2z0/7c7WvDfCb58NaRz0s4Rj/gAr3T9n050jxR/2Gv8A2zta8K8KJt8MaQc9bSH/ANAFAHT20gC/MOKdJMWB/IVQMoLFAQcHBNOEvXrQBBLIwJ9KjQMzfL3oumJwFHXjirNphI8n75oAdDDtOf4jS3YKxletSJINpA/Oq73AL9M0AZvzK/zDmtDTXKRD1Y/pTZAjkbhn/Cr0UKgAx4IA4oASVjjFOgFIsLEkvnNTImBjrQAsj4HTBxWddS/wg8evrVmfqeciqMgzkgj86AK5QtuI4+nYVSkuYQSCePWp7pisEoHHAGc+9c/fkgBex7UAa8dxasjB3+Q917GtGymj+wzMvzNj9K4ZJWSTK9BXS2E7Nbsg53LnFAFXxJdxRxIUOWYcVw10c5561v64d4IJOUOB9K5ubI4oArtX3r8J/wDklng3/sC2X/ohK+CHPFfe/wAJ/wDklng3/sC2X/ohKAPPv2r5vs/gfQpf7usp/wCk1xXyi1wWcknJPJNfUv7YGf8AhXmi4/6DUf8A6T3FfK0ERPP86ALlu5Zun413/g9iCR2RCTXDWELPKsaIWdjwB3r0TR4FsbYRZzK/zSEfyoA172QmNeeKy3bJwO/NaLDfGVJ56g1TkjZSSw/KgB0a8Z7YqZc7c5qGItnA59an2sQccfWgCW1XdLv67en+Na9rIAeCR/jXPCZ7aTsQeo7VetdTd2wLcMf9k4oA77SNQMlv5b8lGwD7VYmj3HK9PrXKaTq+Q4KtGucc8/rW7aXvnMqgqS3YUAbMyEaUid/vcfWs+KBi4I55rRupAIXRSPlQDrVGG5WMnKn160AWZbhbOPLHBHesG/1N3kbaACfWpNUureSZY2MgOM57Vk3JXBbOVPAzQBjXEsv2lwzYHXA4GKYWxyCaZfyoJQFbLAYOO1QGcYHegC2SCOSCaj3BW4/Oq5nGPWo3nBPegDRV/wAqSV885NUBcYGeBSebkHBIoA9k/Z4OdE8T/wDYaP8A6SWteGeFpMeGdHGefscP/oAr3D9nE7vD/iU/9Rk/+kltXg3hdseHdJ5/5dIv/QBQBj6l4fvIr65vbWSORpZDIWV2glGTwu4ZDAdMHAqFNc1XTOLt22el7FgfhKny/mCa7GZyYyB3qhEpLEGsXS1vFtf12Z6NPMPdVOtTjNLurP8A8CjZ/fcqWniqEqpvLaaEN/y0QedH+BXn8wKv3+shtIa80m4tbho3QEZ3LywGDjkHn8P0rNvNFsJJWZYfImPV4CYyT6nHB/HNYt3p0VtfRnz47jYMu8kQEiHsN6kA9jjHT6isq1SpRg5Ss/w/A9DLsFg8xxMKVLmi29U/eVuvvKzWnl8zrrfW4r61Ywbo5l/1sLfeQ/1HoRwag+2S+aN5GB2rlLi5tUdJFvYre4T7knmKCPYg9QfStXSNQi1PzFIAuI+W2cow/vKfT26j9SYXFe3jqrMM/wAieV1b05KVN7O6uvJr9dn+B1UTM0SSEHDDirEUrJyhINSaKx+zKsgDxEfdIqzd28aDKggY4rrPniI6lMoyCp+opjawUHzwxsx7gVW8lM7VYg9+KintAwIU5+lAEsutK3H2ZMd8Gq51iDPz2u33VqhWwAB3SKMn1pRYQfxSZ+lADbnU7F7dxiXe3AG3pXPXs6Sn91uwO7Vt3Om27QO0bMWHpxmuevY/JOFB2n17UAV2PYfWtGymdcYB4HaqUQzx1ZjitOJdsQ4H3aAKOqxrInmLnmuYulxnBx611l4QIT0POPpXI3cq5POT7dKAKbD8q++PhP8A8ks8G/8AYFsv/RCV8Bs2a+/PhP8A8ks8G/8AYFsv/RCUAea/tf8AHw80X/sNR/8ApPcV8tWxZyqqDzX1P+14M/D/AEQf9RqP/wBJ7ivnPw9Z8faplwg4QEfePrQBt6HarZweaw/fMOCe1bVu4UbhnPWufuNYsreVkuLy2jlX+B5FBH4E0tvr+nbvn1KzAPrOv+NAHVxSs2PerQAxhjn61zkHiHSM5/tSxHpm4T/GtjQbrQte8R6bYTeIYrb7VJ9nR7a5iYiR8BMochhuAXHXDHBFAFqNAo29vWpVXkkHgV0fiD4eeKNB3SC1TWLNc/vtPU+aB6tATu/BC5rkftCSGRYXJljbbJGRhoz6Mp5U+xoA1rWyt7iEedvfjOFOK2tE0OzCF181GfnDcgD61meG4pJbwRMcQsCVrvLbZCvl4UhVIz60AYVxoixW6mFl5OdwNXNJ0pmuomJG1SKuakPKVNo4xSJqkcAEYHz46+lAGjJaFVuGIHIwO/euYvIWWUxAgNnkit651OIeUTIQNvzD+9VS6jWaZHg3MH9PSgDBudLlO2RSGO3pmua1jTbmGVpAkuwjcMZP1r1H7MiiMSHOQeKw/EaOsP7h3yoyAO9AHmJY546dKeCcYyMVPq0iyXgHWQcNx3qr8+cY6+tAD1bg5pJGBGB1ph3Kc8VGWJzn8aAJFcECmySBSPmqm8mxiM1D53J4oA99/ZqO7w14kP8A1Gm/9JLavBvDTY8OaVg9LSL/ANAFe7fsyNu8LeIiP+gy3/pLbV88+HpyNB03Jxi1iA/74FAHQ+bUMh2Euexqmkrbst61Xur1Sm3OCDQBLJOXlJP5U9NO05nMr2Nq0rcs7RKWJz3OM1nRyMz5rVTOxRntk0AWokhhyIY44/ZVAqaMAEFgMelV4+Fz3NKbhIVIYnd1wKANu2ZRbgqMEcHmobnUzxH94Dq1Z327FtgZ5qrFumY7uBQBspcpgkLg+tNa5A4UAGqCDaCM01ySCR0oAsy3BJzVSW544HNRSuR61Fg5VqAJnumWLk/ePpVKScOw4/PmluAxzgHb2qoMrIMfjxQBMkJyWAx71JFjy9rPtIHOKuWCma2kwOR0+tZMqtDOyP2GTzQBT1h2RWjJ6frXJXfDEVsape+dMxQ8ViTEkknvQBWLEV+gfwn/AOSWeDf+wLZf+iEr8+n6Gv0F+E//ACSzwb/2BbL/ANEJQB5/+1ZEs3grQEk+6daTP4W1wa+exJgKBwqjAFfQX7WLmPwNoTDqNaT/ANJrivnK3kLqGxx9aAOk8N+LfEvhuC6t/D+uXFhBcz/aJIUt7eQGTYqZzJGx6IvGccVvw/Ejx67gHxbefhZ2f/xmuIgU8HIxnNa1soDZAoA7OHx143f73i+/xjtZ2X/xitXw3448Rf29Y/2744mg01ZfMuDcQWaK0a8leIQxLcKApzlhiuFjbK46H1FWBt3q+xS65CsRyueuDQB7H4g+MQbdD4V0x5jyBeagDFH9Vi++30bZ9a8w1e4u/EGsx6vrlx9sv4lKRMEWNIlPVVVe3+8WPvVBJwrjPNWUnVlJBxQBueHHJ1K1VV43ZJHpXVrLtlYd8kfnXKaBiGPzGIDNgj2FdfEsNxGkpIBHJHvQAmtTDYVUjeBgcdDXLpLJvO4ndmtm7k3Ssxyeck+tU44A7EknaRQBVe4ZmG9txx0rS0O8Y4DZwOmaSazijQRqACR1qntNswHfPWgDo76ciWMA4wv51j+I5mj05QPvOcAjtmr0KfaRHMW3YXBA7Vz/AIqvN9s3ln5YzkfTpQByZYByxYY6VHK6kjvzVNZ0IOXJOegprTDHAIH1oAtEjHrVGV9rkdKeJeKqSgsx3HmgCK4cdQarFyeeop0wwrHJrOaRlGM9e1AH0l+y2c+EPEB/6jTf+kttXzd4flK6Pp4xwLeP/wBBFfRv7Khz4K18/wDUZf8A9JravnPR0UaHp/zcm2jP/jooA0DcqOT0FUpJI5JQwOD6U/yC2RkYqqluDPnJIoA07V0J5HtWijhTyDWbbgI61b3l2IWgB013sQYO3JqqJw82Wzg9SaS5UGRQQQQM5qJYs87vwoA247cyLujIcH0p620iDJBAPtWTG7r9xiD6g1bhvbmMcyMQKANAqRxux/SkdMDrmqg12Yf6xY5APUCnQ6rbzHM9uoH+zxQASKVPSmCVQdzdFBOBVvNrcJ/os67v+ebnmqF9BLFE+5CM8ZoAo3GpBeApBP6VHFceY24c5/Ws24IMrAdqihnMbbc/KT0oA7DTriO3hwAcck4GawvEkweP93wG688mrOnNuikB7dKyNUJCAZ6E0AYMwzVSbIHPFXJTzVOY9c0AU5D1r9B/hP8A8ks8G/8AYFsv/RCV+e0vSv0J+E//ACSzwb/2BbL/ANEJQB59+1eu7wPoIPfWk/8ASa4r5xgRQoHSvo/9q3/kSdB/7DSf+k1xXzWsuW2pgn1NAGpB1zWjAcCsu2PYkHjrV+JqAL6tgelTGUbM5qiGOMZpBIwzuP40AX0bd1xjvmrMWGZFJwCeazoH44q0GoA6S2uegPA710mkTxyIymXGOee1eexXEqglZCB+dXtOv5PtkZYBgePSgDvriSBlOJlzj061Xt5Yd+C4wKxpLhDn71Rx3MayEl8/1oA6rUWRXiYEDegxVN/Lk+9j8DVfVJA1nayiQDC7TzWS92EYfvQfXnpQBp6lfLYWbRwuweQfpXHX948qFGc8jnnrUuuasj3hSSRdqqAKwpb2BsFWOc+lAFaNfKcp6GnswH0qJ5Q8hYDAprPQBMr8cGoZXwaQOBTHYGgCrO59sVRn4zV6bAJY1nTHLg9qAPpP9lPjwVr3/YZf/wBJrevmzRXI0ewyc/6PHx/wEV9JfsqHPgrXv+wy/wD6TW9fOWjov9g2LHqLaP8A9BFAFqCZRITJwgqNmAc+WOCcg1SeUOpQdTTraQrIBk/jQBq27KYie/rSyT+Svy/eI71GmTgD17VHqJy4wOAMUARvcnBLHPvV/SRHOgaRS3OOtYEm5zgDJPAFdJpcZt7RAw56kmgC5Pb2a9DJG3qDmq9zACuyC4j+j5Wq9zcgvx0B60eYpAyOvegCMaddnlUEg9UYGmeRcxnDQSD/AIDVhZArfLx+NWIbyRPuyuPbOaAM6SCZRuET8e3IqG4vLh0VJJnZV6Amui+0TMUJkPsKwdYiZpnOOhyCOhoAyZXGeKrFsuCPWrCQtI+ArflVmKyCn5+c+lAFjT5isT84zVfVFzACOcmraRYQAYHNMvlzbkdcUAcxODu61Sm6GtG5G1iO1UJu/pQBRl6Gv0I+E/8AySzwb/2BbL/0QlfnvL3r9CPhP/ySzwb/ANgWy/8ARCUAee/tY5PgbQtvX+2U/wDSa4r5pt423KW7Hmvpb9rA48D6Cf8AqNJ/6TXFfN0TcdRigC5EdpJBFWIn6c8VSDZwP0FTxk5yKAL6OABUm4EVWiBPI4FPG7pQBYhbB4NXrRBNIw3bVAyT3rNRXznbn6VPA0qTxnYSCcGgDo7O1s5MJslZmIHBrettGso5UceZgDPPNJ4f07yD58xALDCr1I9TXRxJFyYzyB0oAxzb2Qc/MwH0zU0OnWsysEY/itUr5gtywXOCeuKdDq0VtcwxFd3IDkH7tAG5qOmxnStxeMbHGDyMcYrmm0oFsRuuT6HNdNqF9H9ieAAbsBzjuKwbMh7wccdSKAMfUPCk087N5yfdzya5K80q7tJXjZFkwf4TzXqxiDSFnIGVPB+tcp4o05tv2i3I+UYcj09/egDhVfDkNkfXtTi1QyiSSVnbp2YmgcLyT+NAD9+DUby4NL1HBwary9eaAFd93XpVeQZpWY5FMcnsKAPpH9lI58E69/2Gn/8ASa3r5osJWXQbIAf8u8Y/8dFfS/7KP/Ik69/2Gn/9JrevmPS2ZtJsRjI8iMf+OigB1vEWk5PerwhAZT+tOtYlVCcEc81HK2SQKALqOERpOo7VQuLgzHJYUXMwihWPu3Ue1Vty+nWgDS0u2YSecSCB0rYuDsgAA5xWXpDF0452npVuVndiTQBVdWLDufelIIxVgLluQc08xfLyaAKDEnr0qW2y54HOeama3Bz0z0qe1syB8vPHagADlcY5Ue9RmcOw3rVqSzk8kNt+8eapGEhuCD9KALAiWRSV+8ByAOgql0kYcntWjpalhIMdFOar3URQiRztQ89OtADQBGcHp3rn9XuSxIU4GT0qzfamCxVARnuaxLmTzG46UAVHfnkk1BIetTSCqspI6UAV5vu1+hHwn/5JZ4N/7Atl/wCiEr885pM8YxX6GfCf/klng3/sC2X/AKISgDzz9rP/AJEXQv8AsNJ/6TXFfNcI4HJr6U/ay/5EbQv+w0n/AKTXFfNkZxigCwvXFWI+TjpVdOuSKkU8gigDRVlAAz0p6jnuTVNHGO5NSrOFPANAF2PAHXvUwIIBzz2zVWK4jbgkqfUjrVpNpZFU5YnCj1NAHcLOywxt2Kg+natzT5A0rFWGBzn1GKzJ9OdzGISCFUDjp0FSRxvZwbXI8wrggdhQBS16VY9zITu7YrDhk/frk9eTmtK9JmU5IJxxUWn2KzTfOgxjH50AWb67YJDJnLY2474rQ0p1X5yc7vSsi6tzFIIwvyqcDnNOQsvCHHOOKANe+uQly5JzsUgc1g6nPKdLvCzN8wVQCPU/4Vp3VhJewuYz838YJ6+9ZOtQ3CaLJ5gJCyLge3SgDjZUC/KCCKj2cDNJLcxooyQ7HsKr/aZOyqtAEzkLxVe4YEZHGKjMxJO6mO4PFACcZ60x/c8UEU1z9KAPpT9lH/kSNe/7DT/+k1vXzPpOP7IsMdTAmf8AvkV9Mfsof8iPr3/Yaf8A9JrevmXSB/xLbHn/AJYR/wDoIoA0RkIST+FVi2CWC9BnFWIW83cAOnenzRiGPKD5m6mgDGmZ3nzJ1qyqbyAvU9KTaG+969as20DPMpU8ZzmgDe0S2is0AuR977xHatFrOB13R3EZU+vFVBnADdcVVuIyDlcj6UAaKWnz4Uxvx2cUsthKeRGfwYGspHlVs5z74qUXEig5ZgaALTQSIp3KR65FSQyiJMKBu9TVeO/mTl8SL71YFzZzgu7LFt5PPNAGbrV/Pv2CQ7QQNvaqNtOryAn5T35pNSkSWXMZYrnOSMVQbI56EelAHUWt4UTyODnkcVU1hi4+Y8KOAfSs2ylJeI5JNXr351YjJwCOaAObmwcnpVJ1xVy4yvFVWPFAFWSqc54NXpcEVRnXrigChJ3r9EfhP/ySzwb/ANgWy/8ARCV+dspxX6JfCf8A5JZ4N/7Atl/6ISgDzz9rL/kRdC/7DSf+k1xXzVCa+lf2s+PAmhf9hlP/AEmuK+aIe2KALS5/CpFFRrnFSgZoAkQelSY5/rUadhjNSpjPJoAdGckjirumJi4SQZwp+X61TC5JxWjZMqoFLbcdaAOqttUkMYDFt2cEjuK2LKcTpnBbJ/GuUg1Gzg+9hzj3NbOjeJFMrxwxKqEd16UAXrmDO7aMMKWwgdp4wxUcj8Kc+tztwDB9So4qSw1ad7pAY4cbs5CCgBusQGK+cZXIIPX1qmigPk9ucZrQ1zU5DcRFoYGzEpJK96oLrMSHE0EHvgYoAh1a/khhRVbBJzgGuT1W7luIJI3c7CMHnrW5q13YTzjbOinHAdsVz96AOUdWX2YGgDmtjI2304qQ8CpplXzeOeOahbigCMimMeR/OpD0qJutACb6Y5Bz60Go369aAPpv9k//AJEfXv8AsNP/AOk1vXzZoSD+yLMkZJgj/wDQRX0l+yYc+Bdd/wCwy/8A6TW9fOmiD/iTWGP+fePP/fIoAuKq7eAODVgIsiMGIIqOBMnOBgU+QqoBzk0AZ9zBtYhehqxpsEgYkdhV2DZMBwKnISJQMZagDUhkhgiQGNSxHJIzTjFazLjyQD6gkVVk2M4B7ACrKAAECgCM6dbk4EksR9xuFIdHdsmKaCT/AIFg/rUxZtuBQPpQBVfRLrqypgejZrOvtKktyHfaQQSMVvp6F2x9aLy2M8CgEZHNAHEOuW4zimtCxBOM1stpEqTE5G3PAokg8tArL+PrQBkWsTLICMjArQY7oGB69aljiypO3mlaILGwbGDQBy96uGYe9UHrRv2XzXxjrWfJjmgCrJVKZutXJfSqVx0xQBnzmv0U+E//ACSzwb/2BbL/ANEJX50zniv0W+E//JLPBv8A2BbL/wBEJQB53+1p/wAiJoX/AGGk/wDSa4r5pi6V9Lfta8eA9D/7DSf+k1xXzNAwYDvQBdU5qeMA4qBBVmPpmgB4FOX6UDAWgI2MgDFADgRu61YXntk/SqgJBORW9pD5MQiUDPJPrQBHZ2TyncyMEAzjBya1rbS57WNm8tiG56dK7DQ0uDaszfLkfxCtSWRlGHVfu8HAOaAPPHVi+XRvy5JrS0WB2uGOxhhSRWm9zKshVdnXgbRVvStR3Xywu0JeRWAG0ZzQBia7bOFgdlflAK5yQsJiu0semMV3uvapCZPJ2xsYxhgVx+VZVkttPPk2wJUcc0Ac5Pp6vbBnALk46dK5m9tWt3bA+X27V7DJbQPH89pFnjBJ5rlvEmmW32UyizAAJ3bc5+tAHn0Y4J4ppBJNTOqI5VMkdfpSBcnmgCuVqFxVx4yO9V2IoAr9KY9SOcmomzQB9M/smf8AIi67/wBhp/8A0mt6+b9GlZdIsR6W8f8A6CK+kf2Tf+RF13/sMv8A+k1vXzHpUwGj2mBkiBP/AEEUAbqXPy4woJ6ZqCeYqwDEHPYVnsS+1lPQYwKfHuEgJP4UAa9irbgSCRV1I2adFYHGc07SAsqEbSAK27e0DEsOnQUAUo4C0uSpOTnpVwQSbuhxmtCO2wQWqcQZHvQBjrFJkZU+v0puDg7sg1t+Tgnj8aU2qvjd29aAMbbtIXPPpUdzIwBwcAcVrPb28a5LMfw4rBuLtTIVQAqT1JoAkifzCRgn6d/aotRTa42jgHtU0YX5MNtPbNOuExauAd5wSfWgDJllSJcv8q9c1hanfmdyI8pGKdq8jvIFzx/SsyVSOvNAFSRjk1C/IqZx2qvJxmgCGTrVK4+7Vp5DjnBqhdMT9KAKE54Nfoz8J/8Aklng3/sC2X/ohK/OSav0b+E//JLPBv8A2BbL/wBEJQB5z+1x/wAiDon/AGGU/wDSa4r5kg4AxX07+1qofwHoanodZT/0muK+YoVKDrkUAaEZqzGflqpEenNWl7YoAnAzUyMowCfaooxwKcy+nFAEhX5zjoa3/BUUUl9+9XKR/PjPBrnUYpkE/LXSeDVdrp0ToVY9OtAHcNdMHdQQARnB6fSrkE2+2G7kY61jW9lPNMBKhUqcEt3HtU96xhVI0yEH3iOpNAGPr9xJDNthO0MDkgcisywuUgv4ZZHIUd8d6uXJMpAI+bvUmnacblx5iHjIHc0AZus3O+8aSFg3JPFbOgzKAjE7XbqG7VjapavbTyfLwDgDHao7C5cuAnJAGARQB1VxqQQOSwwp24Hr6VQvr9mSZZMFRG20++OB+dSvatc2wZCscifMQe9ZOpW1zHbTF0wAoO7tzQByGGYMxHJ6n3poGOe9TTOF3Nn5Qe1UZJt2c/KPSgBZXHIFVXH1qTcMZqKRh25oAhbvUTMMcU9m561E5oA+nP2Tf+RF13/sNP8A+k1vXzNp8aDRbJweTBHn/vkV9M/sm/8AIi67/wBhp/8A0mt6+a9H+bSLBQpw0EYP/fIoAaISQNp/Kp4kwwHvUwhZCVwSOtXtOsGndBtNAG1oUKrE2RnccCuosVhZAjkIw7nvWdZwKhVFBAUY+taSIAvHNAF5bOM4xPFjsDU620KgZkBx6LWeqlSO1DyyAHDcUAaBW3XGcflTZIYJwfLk2t6VlSXMpHAH5VXeeYcrwfUUAT39sYVP3mxXI3Ea73HXnpit2+1C6aPYTj37msZbS4kdmxx15NAGfA8qM8Zcsg5AJrVgm3Qtu5yMc+tJDphkYktgfSnzWEsKttyy46igDnNST9+cgDjjjpWRMfmx39q6XU4GeINjDAcg1z80eeo57YoAz5gDVSRD61fkXrmqcuOmaAKMwI6is+5OK05j+VZt1wfagDOm+9X6OfCf/klng3/sC2X/AKISvzhl6mv0e+E//JLPBv8A2BbL/wBEJQB55+1l/wAiLoX/AGGU/wDSa4r5jUAZ5GTX07+1irN4G0IKMn+2U4/7drivmAEBienYj0oAuQdieKuR9KqW33ee54q7GM4OaAJ04Gakxmo0GOKmUc0ARTKAK1/Cd3Nb3RaM8JGRk9s1mSDKn0ra0iDyolG0ln5IoA1o9Qu1lLPPIc+prqg3mwo0mC20ZNYthp++QGcbFPPI7V1EbWiRAAZoA56aKMMWVQST1NaGi5W43ncAAcfWr0iwNH8oVfTPerOnW/79FQxlfXdQBzHiqAi+ncfxqHAx6jmsDSQhYSbOOR+VejeIbSIrE0oXmMAg98VzUFhaI0gV9gPPNAGNq95JEAkZ+9+grE1TUrn+zCrOx6ZGcAiun1XS3df3Z345GO9cxqto8UeJB8pBBGOlAHPSSPIMsevbsKrtzxU2NuVboKjxQBHimEVK4pnNAEDgYqs5x0q5IKqyg9KAPpz9kv8A5ETXf+wy/wD6TW9eF+G9PEmhaWwIBNtEef8AcFe6fslceA9c/wCw0/8A6TW9eN+E2A8O6T1/49Yv/QBQBdTS029BuPSrdparbs2ACRxmrKH5QcUoUFs0AT2sZzgck9BWvFaLgGR8H0ArPgwJFOela69cdaAAWsJGPnP40n2CBzjc6e5GatxIW4I5qYRkdRQBQ/sSN/uzKAaeNFhU4Klz71oKhGfTpUiAqeOKAOeu/D6GTeh2R9SDzVU2cfIjXJ78V2M+BCC4y1ZUpC5OxR2GKAOclgCEYTC9uKY4VgRJ6dav3KsXck4UflWDc3aoG5z79qAKWqRxxq4ZQQB1NcRfSqHIRTtre1K+M6ujdzXPXSjnP4GgClIQwz61SnXBqxKShIOaruwPegCpKOtZl2efpWlOwAIFZd0etAGdN3r9H/hP/wAks8G/9gWy/wDRCV+cEvev0f8AhP8A8ks8G/8AYFsv/RCUAcF+1OceDfD54/5DSdf+vW5r5zubJbgB41AYf55r6O/aiAPhHw8D0/tpf/SW5rwa3VUYYTnHFAGNHEYztcYYdRVqJQ3ygcmrWpwnaswHT73tRpyBnJBwaAJvsgA5JB7Un2dl56jvV4IQTnJHepEQA5HSgDJYg4XBzmup0TzUCu4VsYAJFU7LTxc3Me5Qfm5x1rqbXTJZZByqJngHoBQBaWeRxghQwH5VUubuaJSDjrxitpNKMZAPznvxVLU7QpEWEJODngUAYx1KZDkYz155pNO8WTprFtEQn2dm2O+O57/Sqd9avNwyOE7KBVV9MCnIjbIOQQKAOv8AFWuiVIoowA8RIJB61gRaq5kXMStn071SvEmlw7KTIO4XFSaSqyXYEkeCBzjvQB0FndRhd7oykjNUtZe3uImQqTkf3ea0G0yWSPMCnHp2rNvrC4UHdGx+nNAHnWpx+XcsFzt7Z61VByorpfENkJUWZo3jlzgjGMj1rEFuig4BP17UAVG9hTf51dVeOmR6Cq9yu1+nWgCnIck1Xl6GrDnOc1XkbB9aAPpv9kv/AJEPXf8AsNP/AOk1vXjXhOPb4e0o44NrEf8AxwV7N+yYD/wgmu5GD/bL/wDpNb15D4WH/FMaQf8Apzh/9AFAGynPQ1OE4AHXNMtkBIAq9FCwJOBmgB9rAzA5H+NbqQ/Ip6cA1Tt0HljA+prWhQtGh9uaAHRoADTwuceg5qQJgc1LGgxwO/WgCJIj2HHpVqK22rubFSxLg8gmi6lAXkfh3oAzr07lAPHNVDb7upA/GotUnkCfKMc/jWDPNOzYjJPrigDT1GKNVK7s57+tcRrNuVJ2gLzxXWJIzIFbLEH86o6hZ+bFICu9MZx6UAeb3cLBzuJ3VRnQsh45ro9Rs3QHGWT1rDdCCRQBjTruHTkVnSdTmtq5TaTis25j5JAoAzZe9Z10MVpTAjNZl2cGgDOl6Gv0f+E//JLPBv8A2BbL/wBEJX5wSc9K/R/4T/8AJLPBv/YFsv8A0QlAHDftP/8AIp+Hf+w0v/pLc14faruw4/Cvcv2mxnwt4cH/AFGl/wDSW5rxOyj24Cj8/WgBZo87lIHI/Os+GFre6BGfLx6VufZ/MO4ce9SPZqbbYQc9Rn1oAqRspXgcmp4rd5Cp6J39hVKEhGO7OQeQKvwzgnKnbnsOlAGxpZFtLnYMkYBq8Lxy/ORn271iw3AAGTlfXpW5pSW9zgtMMDrk4oA0re+lUxnzGB6Adveor+5N0koB29hz3q79ntng8uBgZMY3D+lZrWckUmGwMdDnrQBkNE56HJ+tXrDSLi/8zy8gqpwCxGacMIy7Vy3Q1v6U7RIH3YYuOR/KgDiXSZSyuGVhxgmrFi8kUDMZNx681ra9Mo1O4Ty1YZzyKpQ28bg4yoI+6aALQ1GaSBQrMQODiqN1dyKw8ssc8Ek1sabaQW67iytwMlqq+Ixa/ZUeAAsTj5eMUAcpqsklyp3MSV4Jx1rnZoAM4YH+dalzOzl4yMAc49/esm4kwSoHyigCNgP09OlZ943zYB6VNLKwJAqm+SfegCtKcjin2dsXcO44B4FWI7RpGywIUda1bO33PnGFUcUAe+/stjb4P8QDGMay3/pLbV5B4TQyeFtIwP8Al0h5/wCACvZf2Zl2+F/EY/6jLf8ApJbV5X4KiJ8J6KccfYoeP+ACgDStIgi5xn+taOzIBK8UyKPB5GKtxIQQSCRQBJCnycCtaFG8tfTGDmqkMZK8CtCCSRVAwpx6igCWOEtjgmriQrGvzHHtVb7TKeM4+gpF8x88k80AXVkjVTgZ9Ko3l0oB+SrqWsr4VFYinjSkzmYZ9s0AcjfubjCqgAz271GLXyYjuA3twa7QaVaDLiMcVlXsUauyhePrQByxjKjJyOarSyNGc9fXNbd+ECLs4xxWBevsYgn6YoAx9WaAI7srDjtXD3EisxKZxnvW74guWYvjjccD6Vzb5+agCtdjIrLk6Fa1JSMfhWbcEdQPagDMugM1kXnWtm6XIOax73r9aAM5+hr9H/hP/wAks8G/9gWy/wDRCV+cT9K/R34T/wDJLPBv/YFsv/RCUAcV+0wM+GPDg/6jK/8ApJc147bgIY2GCf5CvZP2lP8AkXPDWP8AoNL/AOklzXktiqu6emeRQBPCyr8jrg9s1L5RfJznHf3p62wlLF87eeneldQmEQHAHGKAMPVrUxsJRk7uPaq9sTjsfc8YrcmUODDNlo279xXOXdtLCGEmfK6Bh/WgDVs2icFVcSN6Ia2LXTnm+dpCMjhe1c5otu0simEYVeSw45+tdzYsGRGX7zDBNAElmHt1AZQpHcVPcSqQAW+bb0qV9pUHHTrk1RvHAwQVZvTNACqqqA0jqoJ6nitjSzDKjLFIj4IOPxrk7pXmOZGDY6AdBU+lXX2CeVs53RkDnoe1AFjWbmzOoT/vV8zJUgVWS4jjfkNisa5ELbvPm+dmJOBnmlgmii2rHJIwJ6HkUAb00qbQYydp5x71XnWR4iBlVxjJ6n8KWxuYZwyAjPb2ovHKIxB6A0AchrBMJLRYfn5x6Vz7SK+44wPSuruYvNRcDkmuXuIGt7pozG3zHgAZoAqsCxwOSfSpYYBvx1f19KvQWLRZMoIc/wAPoKnt4RubAxjmgAWFViEXXnk+pqazh/fFSMHpU8EWWzycirbRbZoenpQB7J+zgNvh/wASj/qNH/0ktq868Dwg+DdBPc2Fv/6LWvSv2eV2aN4oUdtaP/pHa1wXgVAPBXh4jr/Z9v8A+i1oAuvEATx2qzBHxls1J5O73OeatwwdgORQA2GPGBVyKMYpFTBwOlWIBhgcA4oAlhtAQDJwD0FaltAsa5VQPQ1Dar50gI6d60UUdhgCgBhJVetVWBdyDVqTnPNRhOM+tAFW6k2R7FPWue1FiVBBOe9a1/JmTI6dqxbvLZoAybqQMCvPPbNYuqpmMBc5A7dRWlcgpJ8vb1qrdgSKCo5/nQBwutWxd93JOKwLiB1Y/Lx6iu91K0BIcDIPXPauXvbf526qwoA52VTg5BrPuF4Nbk6bWIPSsu5UbyRQBkXA+WsS9HIFb04GSKxNQGJAaAM6QcV+jfwn/wCSWeDf+wLZf+iEr85pBwa/Rn4T/wDJLPBv/YFsv/RCUAcZ+0rz4b8Njp/xOl/9JLmvLNIjCS9d2OSP8a9T/aTGfDnhoD/oNL/6SXNeaaJFwuASXIoA0Y0Gwg9d2T+dNeMs+cHH0qxaof3oGWIOeacwUjO78O9AGfPFuxnt1PrVZYFEjLwyn5tp6VrSKrKT36Cs2RgjhucDoPegCwsISMJEqKOp2/4Vd0+Fiu5XQgD7p4NZ+9JTjdg8D61NCzRupLN8vY96ANUxTyRycBRt4rBuEccsxB6cV01reM1uDIAx6ccVR1Ax7wCpXHcc0AYKwMSfn4xnpTHtWBY7+celbaRQuvDYPTip7DT45bsGU5jUdezH0oA46Szl55DfhTobCTBJDYz16V2epGDccRhSDjgYNZ0bxqxIUkHqTQBn6dYSLIJM44NWp7aWSMl2VAO5qx9o8v7qgDjBrLvb2R5nQkjHQYoAha0CceZn9KrTbUkJUKx6b/8APepd+3jdn1wKguMBu+e4HagCjcxqWJz8x65GKlsLXKDgFmprruYJwwPrWnbxrEMJ91RgY7mgBqW20HgE9vYU+aEfaIEwC3U1at4i8iDHOemalRRLqspPWNcZoA9O/Z//AOQV4q/7DR/9I7WuJ8BpnwN4dPX/AIl1t+H7pa7f4Af8gvxT/wBhr/2zta5H4eJv8C+HOv8AyDbb/wBFLQBsxQZGRyasrER/jVqCL5Rkc1KY80AUAvQYq1DFnjBpUiJYZ61o2sIVcuOnNABFH5EQCjDtyfpVyMhoQR+VREEnmnDKjFACKN7BaS7/AHalV6nip4RsG89T0+lR3abwSOaAOduRwc81k3X05HAFb93C2TgEfWsi7RlOAMse9AHP3kTNnGB3yayXlKP06dvWty9Xrk7m/lWTcIm05HzD0oAqTN5i8da57xHDtg86LjnDcdK2hMv3B17Cqs+y6hkhPcdDQB5/MGbJzkHvVG4HP+Nal7bvBI6EHIOKzZx8vJoAybleTWJqYw61uzZJOe9YWpn98PpQBnOOK/Rj4T/8ks8G/wDYFsv/AEQlfnQ44r9F/hP/AMks8G/9gWy/9EJQBx37R/Ph/wAM4/6DQ/8ASS5rz7RD5cqDAxkd69F/aI/5Anhj/sND/wBJLqvPNKAaSMjBA4oAvqoTVpY14Vlx+NVp/wBw3XJz+VWLtvL1YShuOBgHiqt2Nly+ScMc9O1AEoYIDxknpms7UEDAADI780+SQv8Au0yGzxk9qJ8Jbkc5wSW/oKAMtw45RiPpWtYSfaVVH4bt7isJDucA5GOBnpVve8aAqCwBwGHagDqQoMSAEHByR606aB2UMOT9eazbacvGo6HHXHWr8MhJCnnsaAKhiZVPykZ6+lXYpGitWK9W6k0swJAAPHakjDSwvAuMkfLmgDNW7M5InO4jjf6/X1qSGAbvlNUXhdJ8MDgdq1IEwuOdpGM0ARXFuQ5Xjpwfesq9tTLIJIycZ59q1bl9qsOoPWsG6v2Qsynaf5igCtdyJEcc+YOo9KqvMSuce/rTbkhiSc5bnntVMSEPjPIoAt28g+0r3VRnPpWvAQTkD8RWPbkb3YgAEAMAO9a1qf3Yz2oA09PUGbn7oGaTTBlbub+8f84ohxFZzydWIC8VPpqKmnOD0P6UAejfAH/kF+Kv+w1/7Z2tcx8M4z/wg/hw9v7Ntj/5CWun+AJzpfik/wDUa/8AbO1rF+GcX/Fv/DRwOdMtf/RS0AdLEo2+lKyZYep61YjjyCRUix8DjmgCvFDgmrQGABTlTAoxnkUAG3mpFjHVugpYk9RmntwtAEUp5qvJLtGT+dTSkkVUmGAaAI2QSZJI/Csi+QklV6E9KvO7R5AY/T1qJgJELECgDmb2EgkdTWHeJkkAdO/rXXXkDKC2Mgjg+tYF3B94gUAcdqSFXLpxk/rVIyGOeOUHAc8gfrW9qVvtZs4x6VizQAwENwBzQBQ1u3D7mxx1zXIXXcAdK7rBuYtuc7R+YrjdahFtcMq9+R7UAYd4dq+hJrntQ/1gNb11yck5NYepDDj6UAZ7dK/Rb4T/APJLPBv/AGBbL/0QlfnVjjiv0V+E/wDySzwb/wBgWy/9EJQByf7Q3Oi+GP8AsND/ANI7quA0tCG9h+tehftADOleFgf+g1/7Z3VcJaRlFCgY7mgB06F7sgoOBkE9qq3uSoG75hx9TVqNv3Erlueg9qr3EOUHUgHJ75NAGfE2ATtGehJpLo4iHBLN29BTrkFMqchgcn2qmyNISCTnPNAFc/cBHOT0qeI7UB6Gjyc7ACdpORxTJtquQBz6dhQBfS6C7QDj0NacF2I4lbaN7cDPb3rnFJkdQvPsK0YjifDElQMAduKANh7jcFHBNS25EZMjt8xHyj+tZ5UoFOO1SR3HIJPPrQBLeoDOJgRkj5hjpVdrkQkK3zRvx70jTkvIzEKpIUZ71VvE2ISBnB60AMu7zafLPAHOaw76RCwJAJDZDHtVm/JaGJuQRwSf61RyrjBwfoeaAIZWJkbuW5qo4csCRjnBFaXkMGBXt/KopLU7txOPYDNADbUE7sEg4xWlAfuqTyefSqlqvkthhnIzV1EO/emcHr7GgDV2s+nqo4LEkfWrrlY7NI/QZPrmqlmpL4f+Fc/SppCXXJ6j1oA9G+AGTpXinJz/AMTrr/252tUfhohPw88L45/4ldr/AOiVq9+z9u/snxTu6/20f/SO1qL4ZL/xbrwq3/UKtP8A0StAHRqnPSpFU4zT0XJ9KkVRigCHbSonepdopQBjFACcAVG/Y1JikIoArPz+FV5VBB4xVt1zmonHy9aAMyVeuenSqpXapGav3csMSkyvtHvWVNew/wAJYehxwaAJSFZSjjK/yrJvrVVDHcCD7U+W7OTsbj25qB5zcAqchvQ9xQBzOqqMkY9+lcvdxSks5G2P3rttRtZFRm2jOM/SuVvYZlfewLEdAegoAxo5fscw87jd29KxPGNtskjnQHY4zWpq0cryKWXBC8/SnPbvfaMqsu4xkj8KAPOZ+SSe9YuojJHrXTajZyQMcjv+Vc9exsW6UAZTfd4r9FPhP/ySzwb/ANgWy/8ARCV+drqeeOBX6JfCf/klng3/ALAtl/6ISgCj8WPDOq+J9M0dND+xG5sdQF2y3kzxIy+RNHgMqOc5lB6djXEr4E8cqu1bTw0B6/2rPn/0lrrvjJrGq6RpmgjRdRm06W81P7PLNDFE7GP7NPJgCRGUfNGvOM8V5TeeP9Wsrpre8+JEtvOmN0cq6cjLkZGQYM9DmgDpk8A+NxB5T2fhpwepOqz5/wDSWm/8K/8AHGABbeGxjp/xNZ//AJFrlh8SL0nn4oYH103/AOMVs2/iHxTcQJND431OSKRQ6OltYsrKeQQRb8gjvQBal+G/jaVmZrbw3luv/E1n/wDkao0+GnjdRj7P4a9/+JpP/wDI1M/t3xZ/0Oerj/t0sf8A5HpDrvi0dfGerD/t1sf/AJHoAsD4ceNREVFr4b3Hv/as/wDL7LWZcfCfx9M5IbwyinsL+f8A+R6uR654tc/8jlqwX/r0sf8A5HqUaz4rJGfGmrgf9etj/wDI9AGfa/Cjx9bkFW8Nsw6FtRnOP/Jer6fDbxyrbjb+GSf+wlOP/baj+2fFn8PjPVv/AAFsf/keoZNf8WLn/istWP8A262P/wAj0AXX+H3jlgR9m8NAH/qKT/8AyNVcfDTxwGJ8jw3z/wBROf8A+Rqpv4j8YKMjxlqp/wC3Wx/+R6iHifxhn/kctTP/AG6WX/yPQBoy/DTxxIy5g8NAL0H9pz//ACNTpvhx47dQBF4bXH/UTnP/ALbVmHxP4w6/8JjqmP8Ar0sv/keo38V+MR93xjqZPXm0sv8A5HoAsXPwn8c3ClZE8NFT2/tGf/5HrL/4Uj46D7lm8Nqc9r+f/wCR6nbxf4yH/M46l9Psll/8YqE+MvGxbCeLtSY+gs7L/wCMUAall8KfHcK7bhfDU499RnU/+k9OPwq8cc/u/DfPrqU//wAjVmr4p8fMP+Rs1AZ9bSy/+MUybxZ4+jG4eLr8j/rzs/8A4xQBon4SeNiwby/DQI9NSn/+RqtWnww8bwI6tD4bkVux1Ofj/wAlq50+NPHgPPi6+C/9edl/8YqKXx145iPzeLr/ANsWdn/8YoA7JPh343WV3Fr4b+ZNoH9qz8e//HtQ3w88btGqta+GyR3/ALVn/wDkWuKj8feOWYBvF98B/wBedn/8YrTg8Y+MZItx8Y6l/wCAll/8YoA9e+EvhjVfC+l6vHrpsftN9qBu1WzmeVFTyIYwCzIhzmInp3FY3hnQfG2h+GtJ0n+yfDc5sLSG183+2Z137EC7tv2Q4zjOMmvOJPGHjUMwXxfqOQMj/RLLn/yBQ3jDxuu3Pi/Uef8Apzsv/jFAHrYt/GwP/ID8N/8Ag8n/APkOl8jxt/0A/Df/AIPJ/wD5DryOTxf43WLcvjDUM5xg2dlz/wCQK6Wz1LxbL8MfEHiOXxlrC3thbXM0MYtbHy2MURYbh9nyRkc4I/CgDtzB434/4kfhv/weT/8AyHQIPG3/AEA/Df8A4PJ//kOu9ooA4LyPG3/QD8N/+Dyf/wCQ6T7P43/6Afhv/wAHk/8A8iV31FAHn5tfG3/QD8N/+Dyf/wCRKa9l43YEf2J4a/8AB3P/APIlehUUAeUXnhzxvdSF20zw2PQf2xOcf+SlQxeFfGqHnTPDbD0/tif/AORK9dooA8hbwl4yLEjSfDQz/wBRif8A+RKhfwb43Zgy2HhxSDkf8Tef/wCRa9kooA8k/wCEX8aMgWXSvDTHuRrE4z/5K1RvPAvjC4zjTPDaZOf+QvOf/bWvaaKAPALn4XeMZsEWnhtSOn/E1nP/ALa020+FvjS3Eg+zeG2Vx0/tScYP/gNX0DRQB8yat8EPGd/JuQeGofb+0J2/9t6xZ/2dfGsvS58Nr/2+z/8AxivrWigD4+f9mjxqxP8ApvhoZ/6e5/8A4xX1P4I0qfQfBegaRePE9zp+n29pK0RJRnjjVSVJAOMg4yBW1RQB5h8eTjTvCpH/AEGv/bO6rjdI8SXnhD4SfEjXNMUPe2upr5O5dwVntbNAxHfbuz+Fdh8fDjTPCpP/AEGv/bO6rifCPiyw0HTvEuka34c1LVbPVLwzYg+zNFJE1tDGVYSSqc5jbt6c0AeweENP1mCO2vdS8S3Gqw3FqjPBNbQKqSnB3RPEiHZyRhtx6c8HPgXgo/8AFHaEOP8Ajwg/9FrXY+HPGvhbw7OJtK8H+LUdYvIj8+9huBDHkHZGsl2wjXIHCgDgegrj/CsEtp4b0q1uF2Tw2kUbrkHDKgBGRx1FAGwuScnIxQDvbj0pjnIwAT604HkYH096ALUSgnC5qyluhXmQ5J7CqUMnzgj9asBwvHfoBQBObZFj4kOfyqvLbJ1eTnHQd6a8nB5ww5qtJISeCcUAPeCEAYBJ9zUWyEEny1P401m7dc1HvG04PHbigCwPKAwIlNMxHj/Ux/iKhZxk5J9zQzADBPQUAPbywAfKj/AVGWbGVRB+GKaSGGTSZzjknHYUAB8xjhtgGOo60rKrQkDOVHU9KYWC/wAX401phsYZPvmgDKuYnRvukrjqKozxs6Ff5itdpRxlhjt7VUdl6jigDL8oxt8w+atKzcrCMHgd6Y5UsFIyD3qxCiCFiFyRxQBFAWadMZO5sAdya9KHw51Ca1RzPapIRny2J4/GvNo28vDqSjR/MD/dI5Fd/ZfF1YoEXUNNkMqgBnhcYb3welACSfD/AFmOIr5UEv8AuSjn862ta0+fSvgd4otbqLypxpV8zJnOMxPUcXxZ0NgDMl3EfePdj8qyfiB8R/Dt/wDD7xLaw6gBPcaXcxxxvGwLM0TADp6mgD3WiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKv2hCRo3hcjr/bP/ALZ3VeTklnHqK9W/aIONE8MH/qMj/wBI7qvJFbc/oPrQBcB9Kt2rnGO/qazwcHg854qzG+2Pj60AW5Z8NgYqRZA3Q/hWSZssd3NK12qDg4J4AoA1mlVcAnoeTVhXL8+ornPtO49eK07W4LiMc/gaALxc7iSMCo3YAAnj8KbIck8nrULuFHGf/r0AK74I5xUe8nk8jNRF/m69elKDk4HXrQBYLdcH8Kawywz0HXmowCVPHP1p38RH+TQA3ncQCPT6UoO0A56dcGk4GRSTdMKMDtQBHPIVUnBIz0qAyfu3PTjimTZYkAsT3qnK2EkAY9uaAGSzk/KjYGOeOtRrIy9SfUe1QOCSB9315o8wDO3gd/egCyJMg87u/SrkBDWxVc4z1FZKkoV2nnritFLgRQxsD8zZBHtQATqY4WVwdzdRjmsO4IEhUvyB0rauZzOy44OzA+lY93Hxu2/MOKAKjsSTjOT1GawvExP9kXgYH/UOB/3ya1rqXYMKCM9TWPrjGTRr8E5xbu2f+AmgD76ooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDyf9oo40LwyT/0Gh/6SXVePx5Lcc17D+0SM6H4YA/6DQ/9JLqvKoogg4644oAci4YcZNK3CHjtTlXd0pkxCcH7uOlAFKSTHP4VWZ2dtvenXJ/eZBxUCvg84waALJkHHpWtp74RTntWESCwA61r25EcSDvgZzQBpNJzg9hVdmJBwfrTC2RnnnpmmOfvZ/CgBQQzZxn39KkQnd7HrVdTnuASccCp4zxxn/GgCZF9ASO+aUdDxkdc0oOBx3H5UwnB+vpQAjtyQaglkPbgD9KJGwpc+vaqU8hkJxkUANmnO1gOhqvuypP6U6Rj2GT0GKaUwAAfr9aAIZMyNnnimbcA881OxEZ5b5sVEzq3cdaAIi2QRn2yO1LIStvECeeQcUoC7jggH6VYjjSaAozqrA7hQAkLZRc4HYe9Wjb5jMpXO8d6rWyKJyB9wHGc9q0r2QR2K4JwKAMC7sgQ7Y6da5rxDHs0i+A6C2l/9BNdtIFMUmWwMDpXE+LZh/Zd8qD/AJYuCfX5TQB95UUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5V+0J/yB/C//YaH/pHdV5cqn869R/aDONH8L5/6DX/tndV5eHwB60APB2rjr61XmGQB3z0p8h6k9qreaCxbv/SgCKSDgk9aqvHtOSOK0d4PXp6VFKoIGRQBSjjLuAOnUmtAbtwGM/SpraNdgYAYNTBMNkevFADeigZ5FRMc98806QEkCljjxn1oARRyMAc1YACj2PrUax4wcd6mVOCcHNAAxABIBNQlsFi2fwqSQEgHHHaqz47nIHagCOV9wPPANVWJc4+UDqfep5fo2OwNQkEL0/E0AR5IOA3IzTsxiHe3bj6VG5wByc96hunP2M+hbHTtQBQuZy8hIyo7H1qlNceWuSSSamckjjnHAzWfctmTHoKAHrfyA/McCrC3ZcHBINZMpx0ohlZGz2NAHRWbtkPu+ua2bqTfZLuPzYxXOWcmVyemfzrWMu60yRyGoAptdMIZAACelcN4hlL2V4CxP7p/5GuqvHMb7c4yTXK+IVC2d6eMGJ8Y+hoA/QuiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPKP2h/+QJ4Y/7DQ/8ASO6rylCDyxr1D9pJ2Tw/4XK3Fva511FM1wrNHGptrkFiF54BP9eK8o1G31Owslu7m0W405lyNR02T7XasPXcvzKPdlA9zXNUxlClUVKpJJva+l/R7X8txqLauhbiXccKeOgqs7hTjOT0rIe+kmj+0WSNdQIpkkaAhgkYHL+4HGcZwOegJpkd08hDg5UjIINbqSbaT1QjeR+M/rShst1zWfb3GR7+lWwQDznmqAuQTmInHKnqKvQzRsfl/I9ayASTnr/WpVIxQBsCLcu7K5JxzThAVPCmspJ3UY3nHZc04Xsqcq3IoA0WQheh49aTjnr6mqK6rP6jaKkbWmCABV9ztBoAnlJIwvT1FV2UgDAI49Kadbx/CuB/sioJdbQsRsT3+WgBHLE8Z/KmFmI5HB9aVtZgUYMf5UDVbGUjhk+tAEUisT0GRVO8XFnlRxv5rSEsM3zRSIc8daZepCtqyvNGCecZGaAOeYZHJFZdwMStz1rWuPJQEeap465rGuGVpPlPHrQBXcFm4pduKUjmmMce+KANGxfbF9TWxbSK8WxwQDzkVz1tIQpB/Cr9vP8AKM8475oAZqQy2VyUrmdfydNuz/0yfj8DXVziOReRjI6j1rmvEMRXTr3Byvkvz36GgD9A6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8o/aIO3Q/DBHX+2R/wCkd1Xi0Bm028e70a7uNNumO5pLV9okPq6HKv8A8CBr2b9o4keH/DRH/QZH/pJc14t95j/WoqUoVYuFRJp9Hqhp22O1+GWr6JeX0+ueIJ/DNrqMbNHFewXCW0tzkEO0sW7aT2DHk84AHXlfiTp2g6LdvqXh7WNJm0qd/wB5aQ3UbNauT1RQeYyew+6T/d+7mzADjHBqqYgB069TXgYbIZYXGvF0azSenLbS3bV9OnZ+Whq6vNHlaJLDLyxgdCeea6KWzLRh4/mGPyrnrNdtwD0FdHpsskZHOV9D3r6IxKflHdz1z0pwGM9hW48cMql1UKwHSqUsK5PHHXrQBlu+1sd+uKGYAfhU8kIaTIUD8cVEYCPugMPrQBAxOPrVeRiBz0rRNu+z7gx6Cq80AAxgCgDOlm7A496aDxk9+lTG2JIIU/gKlW0Yj/VtQBQfIOcZqJs4xWqLAkdMfU05dOTqw59KAMEuVOVJB9jUDNk5PJ966YaeoxlVUVV1HTYliEhfIP8Ad7UAc47ZOKQ8AYq5LbRqnyg59TVB+CQe1ACE8UIhILHp2pqjLAVZ44BAoAIIyw6DNXIYgkWQCPUmm2aja3FTqcQnGTmgCKMsMqTgdjWN4kXOm3zEc+RJ07fKa2iOmeOeKyPEpC6VeqRz5En/AKCaAPviiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPJP2kOfD3hr/sND/0kua8Y44FezftInHh3w1/2GR/6SXNeLbqAGyrnHHNNCACn5z9fWnKOAaAGQwkTofQ1uW/yqvvWfG6hxuGcVp8eWMYzjNAFq3YEYJ+tR3S4yFGc9xVQSbGyvHrjvUdzqI3bTnOOSKAEl7gnFRxoxNItwHHPf161IssYX5AQaAFY4OKOGzk474POaYZEDZJBz2NMaY9fX9KAJGyo+Vj/KonlkzjA/GmNMcdM/pULzYyOoPvxQBM0z5H3AOmQKa07Duv1quZQeMcCoZJuTjNAFp5W+8T8vTNOlIa3RSoJIyazhKf9rn3p1zO2VXPQY5oAguIQSSMYPT3rJuLKQvlMHPvWo0qnrgEe9QmXuO/5UAZflPFgsMtU0ELF/n6CrDgj5iOe9LGpwTz9TQBJAVAkXv/ACqRwfLAyBjFQWoZi4xz71O0LOpYdc+tAEDElhgjrWL4mkB06+zz+5cZ/wCAmtecmEHH5VzniFv+JfdjIP7p8/8AfJoA/QiiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPIv2lDjw34bP8A1GR/6SXNeIq5Pv6Cvbf2lhnwz4c/7DI/9JLmvEoxtXk5oAfnGCenfFShiRwMjvVdhngVNGQAR3FAEoJ655+taQfEaZ4IXrWMZVDAIck8VaknG1ue3agBbq4PIU8ms4tyST9aZPPk89DTIyXzx7CgCxFNyQ3SrEcpKsR9MetVfL2jHvUi8AYOPXNAExc9B160xm6896ZnA+p6U089jQA4uTz6Ux3H+Iph+YYHeo3b5jkDA9KAFZwWzx/hUW7LEEjOaQnPuCaRRjoMn1Pb3oAcmN+WY7R7VBM53HceKnlGI8se/bvVR8ZIOaAImf0GcdzSpy5C42+/amvkDdnFIrESAP0J7UAW4lGc7c9iDVl4ggZScg4xx0qtC+GLkZI6Vqyxn7NvXAytAGK8m1mVKcJ8xjJ5zUFwMZPX602JuoY4A70ASakysiN3IxXLa42dPuz28p/5GtrU7lQoQHhRXN6tLusbkDp5bfyNAH6M0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5D+0t/yLXhv/ALDS/wDpJc14nk7cDpXtX7TJ2+F/DhP/AEGR/wCklzXhMk22MhaALbuoGWIHriqT3Bd/vYFQmQnOTUG4BuvfigC3GzMxPOB0qcyErgVFChZB6EZ46VP5ZA5GM0AQAHdk5I9DVi3Kgj2ppRgAQOKEjYc0AWt27IAzj1pcfNmo0U7ccfjTypAAHJoARiTk5Ht2pGI+hxyPWlMZPUEmkYELyccYoAhIGcEZPpmoXGTjPvip3yM9DUbfKRjBHegBEjKsWODjjFDLlgFB5o3gAgd+p7inwkNPkt0FAETxkAgfNzySKjeIHg8Y6U6e5jHyK2fpVWW8RDs3ZPsaAEkjKnk5JqKKPLc9c55pr3AcdyKcrYG7nBoAlhIaYJySa6SKIGMIRwo65rEsdnm71GXBragl2oWLLycHP86AMjVIlEbFQC/QCsad1tIszEFuoX1NdDduhV8Nub9K43VnLSnfyaAM67neVy7dz0rP1F82VwP+mbfyq4+elUdQH+h3B/6Zt/KgD9JKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8d/ae/wCRU8O/9hpf/SW5r58updoAUYOK+g/2ncf8Ip4dz/0GV/8ASW5r57utu7FAEAckZbmgMAaVkIHFCxMefWgC7a3RjGMbkznHpWrBdQzAAkBvRqwUBU1KORQB0Cpbl/lfnpg1O9orDCEEfWuZV3ByGP0qxFPJnhz70Ab62Uo5WMn6c4qJ7aZeTG4B56VmHUJFIxI351LFrci53O+PY0AW/nUDf1znpiondc8qf50f25vOD5Tf7y4NSxXdvL/roCvupoAr/KV57+tRyKBjjIrV+zQTf6l1J9M1TuLaSPPcYPPegDOcY7n8aYXxG7nHAxUshI4IGPWq1w2IGHcmgDPmfbuIHQVnsxznvVq4JCdOtVG5GO9AD4ZjvwcYq+hUY3MQtY7k9RViCfHDHINAGzBMM7Uxjse5q2zHZ3z2FY8L7ZUPbNa4IMe4k0AVXmGdvcHFYF+d8r7ugOK1JSFkweuayLxv3khPOaAKDYyapah/x43H/XNv5VckHPvVLUD/AKFcevlt/KgD9I6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8e/acIHhXw6T0/tlf/AElua+eJMNLkGvoL9qY7fB3h8j/oNL/6S3NfOom+bHfvQBM7DIHapA3GKp+b83J4rUs44mCl1LMfU4FAELYxxSA5x61twWls6glFHsKSXTbdv9UwX8cUAZWFPHpTyoVPrVoaZOobbhx7Gqd6k0XytE4x7UAVZZMcdvpUZfPFQuWzyD+NCntQA/qfarMcjIo2MQfY1VzjvT1Yke9AFtLyVDkMDzWhDr0mAlzGrJ0yPSsbqKYxx70AdWht7oDy0IPscis7VYYkOxGBx15rDWR05R2XPoahkdiSSSfrQAt6y5CqchR1qp071LIePaoHJFADHP5VGjYcD3pznIOaizhhj1oA1IjuVSPXmt5GHk9eOtc3E2MDtWykjeSB3IoAr3P+txwR7VjXnDNnnmtl13ghcgjmsi/BWRqAM1xhjk1R1D/jyn/65t/KtCTPXtjis/UB/odx/wBc2/lQB+ktFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeL/tVZHgvQMf9BpP/AEmua+bDJgHmvpH9q048E6Cf+oyn/pNcV8yu/J4oAf5mZBXR2IxHk+grmbZS8wAHHeushASFcdepoAtoQiDHvVaeZhwM/hUjPkA8iqM8oOCvfmgCyk7gZDEehBo+23CEgSE+x5qokn5H2qQsMntg0AWGvFk/19rC/uBg04R6dKOYXj+hzVToMetBbHT9KALTabYSfcnI+vFNGhhj8lypzwMioMgjrz61IjMoyrUAWBobgf61CPY4qObR+obKf7QOc1IJ3KgFiDSFpCcl26+tAGVd6fLavtY5BGQR3rNlJU4NdFqDt5UW4+4Nc/eru+YA4HWgCqzc9ahZiTT29RSKm58Dr1oAhOcfrQqFiCc4HNWBEznp71aS3OAD07igCCIHgjOK0ckBVBIJFMSLBGB36VI3L9Dn3oAdFkls8NWbqC/vFPUYrTjUjlTkD9apaghOMnHHQUAY0vPoB2rO1EH7FcHHHlt/KtOdQoyBxWfqXNlcH/pm3H4UAfpBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHiv7V3/IkaD/2GU/9JrivmcgE8dTX0v8AtXZPgjQcf9BpP/Sa4r5vtImMoYg4HSgC9ZWWxAzdWrZAAUZPaoIBu2Lz1qeYjBwAKAKlxKTwOgqjIx455qadtx2ge9V3+/jkDvxQBJE+Ouf/AK9PLDOOcHnNRpyepGBnAoY8H3x3oAmD8U0vjqaiLZxzg570wHg5556GgCyZe/8AOpFkzgnrVIkE4OA2anHTC9etAF+BwSMk59xUzNlwDnH0qrGB94jgD1pUkBlUZ7etAFm5Akg2n7q/jWTLbHb8hznnB61eM+DxjA7U1XVju2kZ7CgDFawlZiwG361JDZY5YgAda2MCRiqc4/KiWBlwHwKAM8xqgIXgeppvlnGQCR2qeaMqM9PrSIx24PSgBqrg4AOcU/aTnAqQLgDk06Pqc8DFAEDAoCc9RWdeOm07jgj1q5fzKJNq/cUc+9c9eSM7sT0z0oASaVCTg5rN1Ej7Fcf9c2/lUjHGR2zVa+P+h3H/AFzb+VAH6TUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB4v+1V/yJmgf9hpP/Sa4rwG1CqoGK98/at/5EnQf+w0n/pNcV8+2hyg+lAGrbgFyx/hFMncFWAPFNMhWLAHX86rsxIIJ96AEZPm689qidfmxjmpgMsR6Cjbk8kHj1oAaVzkDjtTDHyemMflU5jIORSlCc8DnqRQBTcZPOcDtTeA3I5HernlnA9Mc01oiEOB19etAFEgbvQmrsI6Z54596YITv5XmrUEWPunOOKAHH5QQQMCmMcRswxluBUpX5sEbgOpFJPHtKqR1GaAKb/eJGeecUiFiflH50/YxJwCcfpTApBOSTnoAaAJ1cCMj16Yq7APOtizjDLxg1nIdsuccjtWvZjMUpZf/rUAZd5GcAjA9RUCoQMdc+prRnUM4CrkHjpVBUkaQEcKDg0AWmAEYwetQO+0HOBRcSImFEgLDqPSsu6u8jCkdeTQBHdzb5Cc1kTNlmarU0gCkk81QcljQBE3NVL3/j0nP/TNv5VcNVb4f6HP/wBc2/lQB+k9FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeJ/tYceB9B/7DSf8ApNcV8+6SpkQKc819CftWJ5ngrQFHfWk/9JrivD9GgSEJ5nAPH0oAJo+nYY4quEx1+vNdBc2RIBixnuKpS2kgJBU8UAZgXA596VVJOOMVaaLbjKkH3FKqpuGWHtQBEi4A7g9aCQeuPXOatbUOcMB+FRSQqOAefU0AQj7vIweopdpOMcdqcIzgDp704hgDzzQA1CA5GAfrVuCIMMkACq8SgsOOQOtXRKsacc4HNAD4rIPKAuCM80y7hiUuzsu1Tio2unWKQg7DjFc/fXUu5QWJGc4oA0JrhQeGG2olkidht4J6mqCXKy/KwwalgC+Yfp2oAtGAtKoj9eBW1bRPb2xMpGXx2zWRE7wurqAcc1pm73xhjySOh7UAAh3MxLYA6AelY17NHEZFj3GtOdz5a4OCetYl4MsSTQBk3UpbIHANUmLKOauTAbzVZxkGgCs7Etio25qQr1qMigBhPWql9/x5z/8AXNv5VbNVL7/j0n/65t/KgD9KKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8f8A2mVD+F/Dgbkf20v/AKS3NeFcflXun7TZx4W8OY/6DS/+ktzXhRoAlW/mhO3h1Hr1qz/bK4GFAYdmFZ7LnnqaqzKc0AbP9qFhnYrD6Cmre27t81vFj2rBXcrAozL9KkWaTdyFb/eFAHRBrIr/AKrr6GkZbEkgeYprC8/J5JX2BqVZZFUYZiPbmgDX+yW74McoPseDUckAVOGYY9elZRuJQSRg/hirMGoMuN6t07HOaAJDGytkYORnIOKi37TyOTV9bqCZDn5W7EimyQRyEHI5HBFAFC7bFqPc1g3xJcD0FdHqNs8cYG4FR3rmrs5l4xjpmgCuQT/9arFvPhhnqDUDHBwaYwPWgDaSdShJPPpT7SYM2D6/pWPbv83XOatwNtkU/pQBuOcrkdlJrImJeJj1I5rRJyp5HIrPdcK+eKAMWQks1QPznFTyghiccmq0hwaAImqNl68c1IetMbn2oAgYVVvz/ok//XNv5VdPvVO/H+hz4/55t/KgD9J6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5f4g+C7HxxpdpY6jd31otrdC7jks2jD7wjpg70YYxI3b0rh/+FC6L/wBDH4k/76tP/keiigBT8BdFP/Mx+JP++rT/AOR6YfgFobdfEXiT/vu1/wDjFFFADT+z/oJ6+IfEn/fdr/8AGKP+Gf8AQc/8jD4k/wC+7X/4xRRQAf8ADP2g5z/wkPiT/vu1/wDjFA/Z/wBBByPEPiUf9tLX/wCMUUUAKfgBoR6+IvEv/fdr/wDGKP8AhQGhf9DF4l/77tf/AIxRRQA5PgFoaH5fEXiUf8Dtf/jFSp8CtIQ5XxJ4kB/3rQ/+29FFAEM/wC0O4YtN4j8SsT/00tR/7QqBv2d/Djddf8Sf9/LX/wCMUUUAIf2dfDf/AEHvEn/fy2/+MUH9nTw2T/yHvEn/AH9tv/jFFFACL+zp4aU5GveJM/8AXW2/+MU8fs8eHQeNf8Sf9/LX/wCMUUUASn4AaERg+IvEuP8Aftf/AIxTW/Z90Bs7vEPiU5/6aWv/AMYoooAgb9nLwyx+bXfEh/7a23/ximH9m7wueuueJf8Av7bf/GKKKAE/4Zs8Lf8AQc8Sf9/rb/4xQf2a/Cp6634k/wC/1t/8YoooAQ/s1eFD/wAxvxJ/3+tv/jFMk/Zm8JSIyPrXiUqwIP7636f9+aKKAPdKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The x-rays of the lumbar spine in the AP (A) and lateral projections (B), and magnified view of the lateral view (C), reveal a mild compression fracture of the superior endplate of L2 (red arrow). The white arrow shows a near normal appearing L2 in the AP projection with normal interpedicular distance. Note the step-off deformity of the anterior and superior aspect of the endplate of L2 (yellow arrow) which is a manifestation of the injury. There is less than 20 percent loss of vertebral height.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15666=[""].join("\n");
var outline_f15_19_15666=null;
var title_f15_19_15667="Chondromyxoid fibroma femur";
var content_f15_19_15667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60221&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chondromyxoid fibroma of the proximal femur",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 420px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ovoid, eccentric metaphyseal lucency with thinning of the overlying cortex and a sclerotic inner margin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Eisenberg RL. An Atlas of Differential Diagnosis, Fourth Edition. Philadelphia: Lippincott Williams &amp; Wilkins, 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15667=[""].join("\n");
var outline_f15_19_15667=null;
var title_f15_19_15668="Approach allergic rxs vaccines";
var content_f15_19_15668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F81252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F81252&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Suggested approach to suspected anaphylaxis to a vaccine",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 631px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Original figure modified for this publication. Kelso JM, Li JT. Practice Parameters: Adverse reactions to vaccines. Ann Allergy Asthma Immunol 2009; 103(4 Suppl 2):1-14. Copyright &copy; 2009 American College of Allergy, Asthma and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15668=[""].join("\n");
var outline_f15_19_15668=null;
var title_f15_19_15669="Varicose veins of the thigh and calf";
var content_f15_19_15669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F56463%7EPC%2F68551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F56463%7EPC%2F68551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Varicose veins of the thigh and calf",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Varicose veins are subcutaneous dilated veins three millimeters or greater in size. These varicosities involve both saphenous and non-saphenous tributaries of the thigh and calf.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Bickley, LS and Szilagyi, P. Bates' Guide to Physical Examination and History Taking, 8th Ed. Philadelphia: Lippincott Williams &amp; Wilkins 2003. Copyright &copy;2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Severe varicose veins",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 216px; height: 294px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Prominently dilated and tortuous varicose veins associated with moderate hyperpigmentation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Patrick C Alguire, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15669=[""].join("\n");
var outline_f15_19_15669=null;
var title_f15_19_15670="Anterior view of shoulder anatomy";
var content_f15_19_15670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Anterior view of shoulder anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 436px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15670=[""].join("\n");
var outline_f15_19_15670=null;
var title_f15_19_15671="Prominent U waves tutorial";
var content_f15_19_15671=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57086&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1051px;\">",
"  <div class=\"figure\" style=\"width: 481px\">",
"   <div class=\"ttl\">",
"    Prominent U waves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 461px; height: 110px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A prominent U wave (&gt;0.2 mV) is usually suggestive of hypokalemia, although it may be seen in other circumstances.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal rhythm strip",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 165px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal rhythm strip in lead II. The PR interval is 0.15 sec and the QRS duration is 0.08 sec. Both the P and T waves are upright.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Morton F Arnsdorf, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15671=[""].join("\n");
var outline_f15_19_15671=null;
var title_f15_19_15672="Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams";
var content_f15_19_15672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15672/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15672/contributors\">",
"     Roland Solensky, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15672/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15672/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15672/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/19/15672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin allergy is reported by up to 10 percent of people. A common clinical question is whether these individuals can safely receive structurally-related antibiotics, such as cephalosporins, carbapenems, and monobactams.",
"   </p>",
"   <p>",
"    This topic will discuss cross-reactivity between penicillins and structurally-related antibiotics in patients with type I, IgE-mediated allergy to penicillins. Penicillin allergy, skin testing, graded challenge (test dosing) and desensitization are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"     \"Allergy to penicillins\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link\">",
"     \"Penicillin skin testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Antigenic components of penicillins",
"    </span>",
"    &nbsp;&mdash;&nbsp;In order to understand the possible cross-reactivity among penicillins, cephalosporins, carbapenems and monobactams, it is helpful to review the potential allergens in penicillins. Patients with IgE-mediated allergy to penicillins may be reactive to the beta-lactam ring structure that is common to all penicillins, or to the R-group side chains that distinguish different penicillins from one another. In the United States, most penicillin-allergic patients are sensitive to the beta-lactam core. In contrast, in southern Europe where",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    constitutes 90 percent of antibiotic use in some European countries, up to one-third of patients are said to react to the R group side chain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1965566#H1965566\">",
"     \"Allergy to penicillins\", section on 'Side chain specific reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A beta-lactam structure is also found in cephalosporins, carbapenems, and monobactams (",
"      <a class=\"graphic graphic_figure graphicRef79230 \" href=\"UTD.htm?22/52/23373\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The aminopenicillins",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      each have R-group side chains that are identical to the side chains of certain cephalosporins (",
"      <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Multiple drug allergy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple drug allergy syndrome is a term used to describe individuals who develop allergic reactions (either IgE- or non-IgE-mediated) to two or more non-cross-reacting medications. It identifies a subset of individuals with an increased propensity for reacting to medications, for varied reasons that are only partly understood.",
"   </p>",
"   <p>",
"    In studies of patients with allergies to structurally related antibiotics, the concept of multiple drug allergy syndrome should be considered as a possible confounding factor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/1\">",
"     1",
"    </a>",
"    ]. This was illustrated in several large studies, which yielded unexpected results attributable to multiple drug allergy syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with a previous documented penicillin allergic-like event, the relative risk for an allergic-like event was higher not only for cephalosporins (10.1, confidence interval [CI] 7.4-13.8), but also for the structurally distinct sulfonamides (7.2, CI 3.8-13.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study evaluated the incidence of allergic reactions to antibiotics in patients who had previously undergone penicillin skin testing [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/3\">",
"       3",
"      </a>",
"      ]. Among these penicillin skin test-positive patients, allergic reactions during the first post-testing antibiotic treatment occurred more frequently with non-beta-lactam antibiotics (10.8 percent) than with cephalosporins (2.4 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, multiple drug allergy may confound studies of potential cross-reactivity unless appropriate controls are included. Specifically, patients who are allergic to one drug and are challenged with a potentially related drug should also be challenged with an unrelated drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CEPHALOSPORINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two sources of structural similarity between the penicillins and the cephalosporins, as mentioned previously: the beta-lactam ring common to all penicillins and cephalosporins, and R group side chains that are shared by specific drugs (",
"    <a class=\"graphic graphic_figure graphicRef79230 \" href=\"UTD.htm?22/52/23373\">",
"     figure 1",
"    </a>",
"    ). Based on limited data from Spain, the R group side chains are believed to be most important in predicting cross-reactivity between aminopenicillins and cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    each share R group side chains with several cephalosporins (",
"    <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"     table 1",
"    </a>",
"    ). As an example, amoxicillin and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    have identical side chains, and patients with IgE directed against the R-group would potentially react to these two drugs, but not to penicillin itself.",
"   </p>",
"   <p>",
"    In vitro and skin testing studies with penicillin and cephalosporins showed a high degree of immunologic cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/7-11\">",
"     7-11",
"    </a>",
"    ], although this does not consistently translate into clinical cross-sensitivity, as described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Limitations of clinical cross-reactivity studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies of clinical cross-reactivity between penicillins and cephalosporins have been limited by the following issues:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most cephalosporin challenges in the available studies were carried out in open fashion, rather than single- or double-blinded.",
"     </li>",
"     <li>",
"      All studies are lacking the control groups needed to identify patients with multiple drug allergy syndrome, such as penicillin skin test-positive patients challenged with a non-beta-lactam antibiotic, or patients allergic to a non-beta-lactam antibiotic challenged with cephalosporins [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Multiple drug allergy syndrome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Risk of administration in patients with reported penicillin reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who report penicillin reactions (but do not undergo confirmatory testing), between 0.17 and 8.4 percent will react if given a cephalosporin [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. The higher estimate is based upon retrospective studies in which patients with a history of penicillin allergy were treated with cephalosporins WITHOUT preceding penicillin allergy testing (skin testing or in vitro testing) (",
"    <a class=\"graphic graphic_table graphicRef67205 \" href=\"UTD.htm?15/37/15964\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Such studies are the source of warnings in the package inserts of first and second generation cephalosporins that state the risk of cross-sensitivity in penicillin-allergic patients may be as high as 10 percent. However, these studies have several additional limitations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among the five leading reports, two were from the 1970s, and cephalosporins produced prior to 1980 are known to have been contaminated with trace amounts of penicillin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These reports provided no information on the nature or severity of the cephalosporin reactions. In the best-designed studies, there were two reactions to cephalosporins that were very questionable [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. One of the reactions was worsening of eczema after several days of cephalosporin treatment and the other consisted of documentation in the anesthesia record of preoperative administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      in a patient on chronic glucocorticoid treatment.",
"     </li>",
"     <li>",
"      In addition to the specific issues discussed above, there are some general design limitations:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A significant subset of the patients in these studies were likely not allergic to penicillin at the time they were treated with cephalosporins, since large studies have shown that only about 10 to 15 percent of all patients who report a penicillin reaction in the past are found to have IgE-mediated penicillin allergy upon definitive evaluation [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/20-23\">",
"       20-23",
"      </a>",
"      ]. This is reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There was presumably a selection bias in these real world studies in deciding which patients (ie, probably not the ones with recent or severe penicillin reaction histories) to treat with cephalosporins instead of non-beta-lactam antibiotics.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For all of these reasons, these studies are not definitive regarding the frequency of reactions to cephalosporins in penicillin-allergic subjects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Risk of administration in patients with confirmed penicillin allergy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin-cephalosporin cross-reactivity studies that confirmed penicillin allergy by skin testing are superior in design compared to those that diagnosed penicillin allergy by history alone. Another group of studies evaluated patients with positive penicillin skin tests (to PPL,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MDM) who were challenged with cephalosporins, and found an overall reaction rate of 3.4 percent (",
"    <a class=\"graphic graphic_table graphicRef57958 \" href=\"UTD.htm?18/52/19277\">",
"     table 3",
"    </a>",
"    ). If this analysis is limited to studies published after 1980 (when cephalosporins were no longer contaminated with penicillin), the reaction rate is reduced to 2 percent. Thus, approximately 2 percent of patients with skin-test proven sensitivity to penicillin can be expected to react to cephalosporins.",
"   </p>",
"   <p>",
"    In the studies above, some investigators additionally performed cephalosporin skin testing (on penicillin test-positive patients) prior to cephalosporin administration, and administered cephalosporins only if those tests were negative (since ethical concerns prevented cephalosporin challenges in patients with positive cephalosporin skin tests) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/4,24-26\">",
"     4,24-26",
"    </a>",
"    ]. Because test-positive patients were not challenged with cephalosporins, the positive predictive value of cephalosporin skin testing could not be assessed.",
"   </p>",
"   <p>",
"    The approach outlined in this topic does not involve skin testing to cephalosporins. However, if desired, solutions for this purpose can be prepared from injectable therapeutic preparations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=see_link&amp;anchor=H206010#H206010\">",
"     \"Cephalosporin allergy: Clinical manifestations and diagnosis\", section on 'Skin testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Algorithm for management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to administration of cephalosporins to patients with a history of penicillin allergy can be divided into scenarios when penicillin skin testing is or is not available (",
"    <a class=\"graphic graphic_algorithm graphicRef61102 \" href=\"UTD.htm?25/10/25760\">",
"     algorithm 1",
"    </a>",
"    ). Penicillin skin testing reagents are currently available commercially in the United States and many other parts of the world, although there have been periods of time in which they were not manufactured. The protocol for penicillin skin testing is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H22604333#H22604333\">",
"     \"Penicillin skin testing\", section on 'Procedure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1968768#H1968768\">",
"     \"Allergy to penicillins\", section on 'Penicillin skin testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Penicillin skin testing is available",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of penicillin skin testing can be used to guide management, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If penicillin skin testing is performed and is negative, patients may safely receive cephalosporins (",
"      <a class=\"graphic graphic_algorithm graphicRef61102 \" href=\"UTD.htm?25/10/25760\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If penicillin skin testing is positive, then about 2 percent of these patients can be anticipated to react to cephalosporins. Without precautions, some of these reactions could be severe or life-threatening. Therefore, the options for management are:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administer an unrelated antibiotic (neither a penicillin nor a cephalosporin).",
"     </li>",
"     <li>",
"      Administer a cephalosporin using a graded challenge. This is only necessary the first time a cephalosporin is given after testing and evaluation. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Graded challenge'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Administer a cephalosporin using a rapid desensitization procedure. This is the most conservative approach, and would be reserved for patients who were either at high risk for a recurrent reaction based on clinical characteristics, or who had comorbidities that would make them less likely to be able to withstand a recurrent reaction. Desensitization techniques are reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1969477#H1969477\">",
"       \"Allergy to penicillins\", section on 'Desensitization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Penicillin skin testing is not available",
"    </span>",
"    &nbsp;&mdash;&nbsp;If skin testing is not available, the clinician must estimate the chances of a serious IgE-mediated reaction to a cephalosporin based on the clinical history and time elapsed since the penicillin reaction. Penicillin-specific IgE levels decrease over time, therefore patients with more distant penicillin reactions are less likely to be penicillin-allergic and hence less likely to react to cephalosporins. Based on large studies in which skin testing was performed, only 10 to 15 percent of patients reporting penicillin reactions will have positive penicillin skin tests. Of these, most (99 percent based upon the best-designed studies above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]) will tolerate a cephalosporin, especially one with a side chain group that is dissimilar to the culprit penicillin. Thus, we suggest the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient is at lower risk for reacting to a cephalosporin if the reaction to penicillin occurred more than 10 years ago, and the symptoms involved were not suggestive of an IgE-mediated allergy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H2#H2\">",
"       \"Allergy to penicillins\", section on 'Classification'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Such patients can simply be given the cephalosporin normally, provided the penicillin and cephalosporin in question do not share identical side chains (",
"      <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The patient is at greater risk for reacting to a cephalosporin if the reaction to penicillin occurred within the past 10 years,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      if the symptoms involved were consistent with an IgE-mediated reaction. Such patients may be given a cephalosporin (with a dissimilar side chain) via graded challenge. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Graded challenge'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients whose penicillin reactions were consistent with anaphylaxis are also at higher risk for reacting to cephalosporins, since they are more likely to still be penicillin-allergic when treated with cephalosporins. Therefore, such patients should be given cephalosporins with dissimilar side chains either via graded challenge or via rapid desensitization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Graded challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;The starting dose for a graded challenge is usually",
"    <span class=\"nowrap\">",
"     1/100",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     1/10",
"    </span>",
"    of the full dose. Tenfold increasing doses are administered every 30 to 60 minutes until the full therapeutic dose is reached. An example of a graded challenge to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    would be 2.5 mg, 25 mg, and 250 mg given at 60 minute intervals. The safe performance of graded challenges is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1968789#H1968789\">",
"     \"Allergy to penicillins\", section on 'Graded challenge (test dosing)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Patients selectively allergic to amoxicillin or ampicillin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients confirmed to be selectively allergic to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (ie, who tolerate penicillin) should avoid cephalosporins with identical R group side chains (",
"    <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"     table 1",
"    </a>",
"    ) or receive them via desensitization. They may receive cephalosporins with dissimilar side chains normally. Selective allergy to amoxicillin or ampicillin can only be determined with certainty with skin testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H22605979#H22605979\">",
"     \"Penicillin skin testing\", section on 'Aminopenicillins'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This approach is based upon a small number of reports that evaluated patients proven to be selectively allergic to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    and tolerant to penicillin (via skin testing, in vitro testing, or oral challenge), with challenge to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/7/10357?source=see_link\">",
"     cefadroxil",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    , respectively (",
"    <a class=\"graphic graphic_table graphicRef82718 \" href=\"UTD.htm?30/2/30763\">",
"     table 4",
"    </a>",
"    ). Overall,",
"    <span class=\"nowrap\">",
"     11/45,",
"    </span>",
"    or 24 percent reacted to a cephalosporin with identical R-group side chains [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Thus, based upon limited data from Spain, the rates of cross-sensitivity between agents with identical side chains appear to be significant among patients selectively allergic to aminopenicillins.",
"   </p>",
"   <p>",
"    The data regarding clinical cross-reactivity among drugs with similar (but not identical) side chains are even more sparse. Some investigators have proposed that patients who have reacted to a drug with a specific R group avoid all agents with similar R groups [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/27\">",
"     27",
"    </a>",
"    ], although there are no clinical data regarding cross-sensitivity upon which to base this recommendation.",
"   </p>",
"   <p>",
"    The management of patients who report a reaction to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    but have NOT been skin tested to determine if they are selectively allergic to the aminopenicillin is based upon clinical risk assessment, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Only 10 to 15 percent of patients with a history of penicillin reactions are actually allergic to penicillin.",
"     </li>",
"     <li>",
"      Studies of penicillin-allergic patients in the United States and Europe have demonstrated geographical differences in the allergens to which patients become sensitized. These studies are reviewed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link&amp;anchor=H1965566#H1965566\">",
"       \"Allergy to penicillins\", section on 'Side chain specific reactions'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=see_link&amp;anchor=H22605979#H22605979\">",
"       \"Penicillin skin testing\", section on 'Aminopenicillins'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the United States, less than 0.5 percent of penicillin-allergic patients are sensitized to R group side chains (ie, selectively allergic to aminopenicillins). Thus, these patients have a very small chance of reacting to cephalosporins based on side chain similarity. Therefore, they may be approached in identical fashion as described above for penicillin allergy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Penicillin skin testing is not available'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In southern European populations, up to one-third of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      -allergic patients are sensitized to R group side chains. If a cephalosporin with an identical side chain is required, desensitization or cautious graded challenge is indicated. These patients may receive cephalosporins with dissimilar side chains according to the approach described above. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Penicillin skin testing is not available'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CARBAPENEMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenems (ie, imipenem,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/42/6822?source=see_link\">",
"     doripenem",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/36/41542?source=see_link\">",
"     ertapenem",
"    </a>",
"    ) share a common beta-lactam ring with penicillins and hence the potential for allergic cross-reactivity (",
"    <a class=\"graphic graphic_figure graphicRef79230 \" href=\"UTD.htm?22/52/23373\">",
"     figure 1",
"    </a>",
"    ). In addition, most drug information systems list anaphylactic reactions to beta-lactam antibiotics as a contraindication to the use of carbapenems.",
"   </p>",
"   <p>",
"    Skin test cross-reactivity between these two groups of drugs was evaluated in one study, although patients were not subsequently challenged to confirm clinical reactivity, and skin testing to carbapenems has not been validated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/28\">",
"     28",
"    </a>",
"    ]. In this study, 40 patients with a history of penicillin allergy were skin tested to both penicillin and imipenem determinants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/28\">",
"     28",
"    </a>",
"    ]. Twenty patients were penicillin skin test-negative and these 20 were also negative to testing with imipenem. Twenty were skin test-positive to penicillin, and 10 of these individuals also had positive skin tests to imipenem. This 50 percent skin test cross-reactivity is similar to that found with penicillins and cephalosporins [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/8,11\">",
"     8,11",
"    </a>",
"    ]. Similar to the situation with cephalosporins, this does not appear to translate into clinical cross-reactivity.",
"   </p>",
"   <p>",
"    Retrospective studies of patients with a history of penicillin allergy (but who did not undergo confirmatory testing) show that such patients react to treatment with imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    0 to 11 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/29-33\">",
"     29-33",
"    </a>",
"    ]. These studies have the same limitations discussed earlier for analogous retrospective studies of cephalosporin treatment of patients with a history of penicillin allergy &nbsp;most notably that the patients are not proven to be penicillin-allergic via skin testing or in vitro testing at the time of treatment with carbapenems.",
"   </p>",
"   <p>",
"    Several subsequent studies confirmed penicillin sensitization with skin testing, and then performed carbapenem challenges [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. These studies demonstrated that 99 percent of patients with positive skin tests to penicillin will tolerate a carbapenem, essentially ruling out IgE-mediated allergic cross-reactivity between the drugs. Collectively, more than 500 penicillin skin test-positive adults and children underwent skin testing with imipenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    , were found to be negative, and then tolerated a graded challenge with the respective carbapenem [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/34-37\">",
"     34-37",
"    </a>",
"    ]. A small number of penicillin skin test-positive patients (1 percent of the total group) had positive skin tests to carbapenem and so were not challenged with it [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these data, clinical cross-reactivity between penicillins and carbapenems appears to be much lower than would be expected from skin test data. Hence, the approach to patients with a history of penicillin allergy who require treatment with carbapenems is analogous to what was described above for cephalosporins:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If penicillin skin testing is available and is negative, patients may safely receive carbapenems.",
"     </li>",
"     <li>",
"      If penicillin skin testing is positive, carbapenem may be administered via a 2 or 3 step graded challenge.",
"     </li>",
"     <li>",
"      If penicillin skin testing is unavailable, carbapenems may also be administered via graded challenge. This is based on the fact that only 10 to 15 percent of individuals with a history of penicillin allergy are actually allergic, and of those, over 99 percent are able to tolerate carbapenems.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     MONOBACTAMS (AZTREONAM)",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     Aztreonam",
"    </a>",
"    is the only clinically available monobactam and it has a monocyclic beta-lactam structure (",
"    <a class=\"graphic graphic_figure graphicRef79230 \" href=\"UTD.htm?22/52/23373\">",
"     figure 1",
"    </a>",
"    ). In vitro studies and skin testing studies demonstrated no immunologic cross-reactivity between penicillin and aztreonam [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Likewise, aztreonam challenges of penicillin skin test-positive patients revealed no reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15672/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. Based on this evidence, patients with a history of penicillin allergy may safely receive aztreonam.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=see_link\">",
"       \"Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Penicillin-allergic patients can often be safely treated with other beta-lactam drugs. This requires an understanding of what is known from the literature about cross-reactivity patterns among different beta-lactams, as well as the ability to assess an individual patient's risk.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among all patients reporting penicillin allergy, 85 to 90 percent will tolerate a penicillin, either because they were never allergic or because they had an earlier allergy that subsequently resolved. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=see_link\">",
"       \"Allergy to penicillins\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Past studies of cross-reactivity among beta-lactam antibiotics often overestimated the risk because immunologic evidence of cross-reactivity of IgE antibodies in skin tests and in vitro assays does not always translate into clinical cross-sensitivity with actual treatment. Patients with multiple drug allergy syndrome are another important source of confounding in cross-reactivity studies. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among penicillin skin-test positive patients, approximately 2 percent will react to a cephalosporin. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Risk of administration in patients with confirmed penicillin allergy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The risk of a penicillin-allergic patient reacting to a cephalosporin may be assessed based upon the results of penicillin skin testing (if available), the clinical features of the penicillin reaction, and the time elapsed since the last reaction to penicillin (",
"      <a class=\"graphic graphic_algorithm graphicRef61102 \" href=\"UTD.htm?25/10/25760\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Algorithm for management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who reacted initially to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"       amoxicillin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      should undergo the same risk assessment as penicillin-allergic patients. In addition, they should avoid cephalosporins with identical R group side chains if they have positive skin tests to aminopenicillins, OR receive these cephalosporins via graded challenge or desensitization (",
"      <a class=\"graphic graphic_table graphicRef75589 \" href=\"UTD.htm?32/12/32971\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patients selectively allergic to amoxicillin or ampicillin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      More than 99 percent of penicillin skin test-positive patients tolerate treatment with carbapenems, despite a significant rate of cross-reactivity between penicillins and carbapenems on skin testing.",
"     </li>",
"     <li>",
"      An individual patient's risk of reacting to a carbapenem may be assessed based upon the results of penicillin skin testing, the clinical features of the penicillin reaction, and the time elapsed since the last reaction to penicillin. The approach is identical to that for cephalosporins. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Carbapenems'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       Aztreonam",
"      </a>",
"      is the only monobactam currently available for clinical use. There is no evidence of immunologic cross-reactivity between penicillins and monobactams, and penicillin-allergic patients may receive aztreonam normally. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Monobactams (aztreonam)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/1\">",
"      Asero R. Detection of patients with multiple drug allergy syndrome by elective tolerance tests. Ann Allergy Asthma Immunol 1998; 80:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/2\">",
"      Apter AJ, Kinman JL, Bilker WB, et al. Is there cross-reactivity between penicillins and cephalosporins? Am J Med 2006; 119:354.e11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/3\">",
"      Macy E, Burchette RJ. Oral antibiotic adverse reactions after penicillin skin testing: multi-year follow-up. Allergy 2002; 57:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/4\">",
"      Audicana M, Bernaola G, Urrutia I, et al. Allergic reactions to betalactams: studies in a group of patients allergic to penicillin and evaluation of cross-reactivity with cephalosporin. Allergy 1994; 49:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/5\">",
"      Miranda A, Blanca M, Vega JM, et al. Cross-reactivity between a penicillin and a cephalosporin with the same side chain. J Allergy Clin Immunol 1996; 98:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/6\">",
"      Sastre J, Quijano LD, Novalbos A, et al. Clinical cross-reactivity between amoxicillin and cephadroxil in patients allergic to amoxicillin and with good tolerance of penicillin. Allergy 1996; 51:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/7\">",
"      Abraham GN, Petz LD, Fudenberg HH. Immunohaematological cross-allergenicity between penicillin and cephalothin in humans. Clin Exp Immunol 1968; 3:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/8\">",
"      Assem ES, Vickers MR. Tests for penicillin allergy in man. II. The immunological cross-reaction between penicillins and cephalosporins. Immunology 1974; 27:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/9\">",
"      Batchelor FR, Dewdney JM, Weston RD, Wheeler AW. The immunogenicity of cephalosporin derivatives and their cross-reaction with penicillin. Immunology 1966; 10:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/10\">",
"      Levine BB. Antigenicity and cross-reactivity of penicillins and cephalosporins. J Infect Dis 1973; 128:Suppl:S364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/11\">",
"      Girard JP. Common antigenic determinants of penicillin G, ampicillin and the cephalosporins demonstrated in men. Int Arch Allergy Appl Immunol 1968; 33:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/12\">",
"      Moseley EK, Sullivan TJ. Allergic reactions to antimicrobial drugs in patients with a history of prior drug allergy (abstract). J Allergy Clin Immunol 1991; 87:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/13\">",
"      Smith JW, Johnson JE, Cluff LE. Studies on the epidemiology of adverse drug reactions. II. An evaluation of penicillin allergy. N Engl J Med 1966; 274:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/14\">",
"      Petz LD. Immunologic cross-reactivity between penicillins and cephalosporins: a review. J Infect Dis 1978; 137 Suppl:S74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/15\">",
"      Dash CH. Penicillin allergy and the cephalosporins. J Antimicrob Chemother 1975; 1:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/16\">",
"      Daulat S, Solensky R, Earl HS, et al. Safety of cephalosporin administration to patients with histories of penicillin allergy. J Allergy Clin Immunol 2004; 113:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/17\">",
"      Goodman EJ, Morgan MJ, Johnson PA, et al. Cephalosporins can be given to penicillin-allergic patients who do not exhibit an anaphylactic response. J Clin Anesth 2001; 13:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/18\">",
"      Fonacier L, Hirschberg R, Gerson S. Adverse drug reactions to a cephalosporins in hospitalized patients with a history of penicillin allergy. Allergy Asthma Proc 2005; 26:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/19\">",
"      Pederson-Bjergaard J. Cephalothin in the treatment of penicillin sensitive patients. Acta Allergol 1967; 22:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/20\">",
"      Park M, Markus P, Matesic D, Li JT. Safety and effectiveness of a preoperative allergy clinic in decreasing vancomycin use in patients with a history of penicillin allergy. Ann Allergy Asthma Immunol 2006; 97:681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/21\">",
"      Mendelson LM, Ressler C, Rosen JP, Selcow JE. Routine elective penicillin allergy skin testing in children and adolescents: study of sensitization. J Allergy Clin Immunol 1984; 73:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/22\">",
"      Sogn DD, Evans R 3rd, Shepherd GM, et al. Results of the National Institute of Allergy and Infectious Diseases Collaborative Clinical Trial to test the predictive value of skin testing with major and minor penicillin derivatives in hospitalized adults. Arch Intern Med 1992; 152:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/23\">",
"      Gadde J, Spence M, Wheeler B, Adkinson NF Jr. Clinical experience with penicillin skin testing in a large inner-city STD clinic. JAMA 1993; 270:2456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/24\">",
"      Romano A, Gu&eacute;ant-Rodriguez RM, Viola M, et al. Cross-reactivity and tolerability of cephalosporins in patients with immediate hypersensitivity to penicillins. Ann Intern Med 2004; 141:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/25\">",
"      Novalbos A, Sastre J, Cuesta J, et al. Lack of allergic cross-reactivity to cephalosporins among patients allergic to penicillins. Clin Exp Allergy 2001; 31:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/26\">",
"      Warrington RJ, Simons FE, Ho HW, Gorski BA. Diagnosis of penicillin allergy by skin testing: the Manitoba experience. Can Med Assoc J 1978; 118:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/27\">",
"      Pichichero ME. A review of evidence supporting the American Academy of Pediatrics recommendation for prescribing cephalosporin antibiotics for penicillin-allergic patients. Pediatrics 2005; 115:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/28\">",
"      Saxon A, Adelman DC, Patel A, et al. Imipenem cross-reactivity with penicillin in humans. J Allergy Clin Immunol 1988; 82:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/29\">",
"      Cunha BA, Hamid NS, Krol V, Eisenstein L. Safety of meropenem in patients reporting penicillin allergy: lack of allergic cross reactions. J Chemother 2008; 20:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/30\">",
"      McConnell SA, Penzak SR, Warmack TS, et al. Incidence of imipenem hypersensitivity reactions in febrile neutropenic bone marrow transplant patients with a history of penicillin allergy. Clin Infect Dis 2000; 31:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/31\">",
"      Prescott WA Jr, DePestel DD, Ellis JJ, Regal RE. Incidence of carbapenem-associated allergic-type reactions among patients with versus patients without a reported penicillin allergy. Clin Infect Dis 2004; 38:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/32\">",
"      Prescott WA Jr, Kusmierski KA. Clinical importance of carbapenem hypersensitivity in patients with self-reported and documented penicillin allergy. Pharmacotherapy 2007; 27:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/33\">",
"      Sodhi M, Axtell SS, Callahan J, Shekar R. Is it safe to use carbapenems in patients with a history of allergy to penicillin? J Antimicrob Chemother 2004; 54:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/34\">",
"      Atanaskovi-Markovi M, Gaeta F, Medjo B, et al. Tolerability of meropenem in children with IgE-mediated hypersensitivity to penicillins. Allergy 2008; 63:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/35\">",
"      Romano A, Viola M, Gu&eacute;ant-Rodriguez RM, et al. Brief communication: tolerability of meropenem in patients with IgE-mediated hypersensitivity to penicillins. Ann Intern Med 2007; 146:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/36\">",
"      Romano A, Viola M, Gu&eacute;ant-Rodriguez RM, et al. Imipenem in patients with immediate hypersensitivity to penicillins. N Engl J Med 2006; 354:2835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/37\">",
"      Atanaskovi-Markovi M, Gaeta F, Gavrovi-Jankulovi M, et al. Tolerability of imipenem in children with IgE-mediated hypersensitivity to penicillins. J Allergy Clin Immunol 2009; 124:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/38\">",
"      Saxon A, Swabb EA, Adkinson NF Jr. Investigation into the immunologic cross-reactivity of aztreonam with other beta-lactam antibiotics. Am J Med 1985; 78:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/39\">",
"      Adkinson NF Jr, Saxon A, Spence MR, Swabb EA. Cross-allergenicity and immunogenicity of aztreonam. Rev Infect Dis 1985; 7 Suppl 4:S613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/40\">",
"      Adkinson NF Jr. Immunogenicity and cross-allergenicity of aztreonam. Am J Med 1990; 88:12S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/41\">",
"      Vega JM, Blanca M, Garc&iacute;a JJ, et al. Tolerance to aztreonam in patients allergic to beta-lactam antibiotics. Allergy 1991; 46:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15672/abstract/42\">",
"      Patriarca G, Schiavino D, Lombardo C, et al. Tolerability of aztreonam in patients with IgE-mediated hypersensitivity to beta-lactams. Int J Immunopathol Pharmacol 2008; 21:375.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2087 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-61.234.146.186-F0BCE44B44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15672=[""].join("\n");
var outline_f15_19_15672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Antigenic components of penicillins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Multiple drug allergy syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CEPHALOSPORINS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Limitations of clinical cross-reactivity studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Risk of administration in patients with reported penicillin reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Risk of administration in patients with confirmed penicillin allergy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Algorithm for management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Penicillin skin testing is available",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Penicillin skin testing is not available",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Graded challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Patients selectively allergic to amoxicillin or ampicillin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CARBAPENEMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      MONOBACTAMS (AZTREONAM)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2087\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2087|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?25/10/25760\" title=\"algorithm 1\">",
"      Admin of a cephalosporin to a patient with a hx of PCN allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2087|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/52/23373\" title=\"figure 1\">",
"      Beta-lactam drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2087|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/12/32971\" title=\"table 1\">",
"      Side chains amp amox ceph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/37/15964\" title=\"table 2\">",
"      PCN all hx given ceph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/52/19277\" title=\"table 3\">",
"      PCN all st given ceph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/2/30763\" title=\"table 4\">",
"      Amos amp all given ceph",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/46/23274?source=related_link\">",
"      Allergy to penicillins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/55/11130?source=related_link\">",
"      Cephalosporin allergy: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/37/22098?source=related_link\">",
"      Patient information: Allergy to penicillin and related antibiotics (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/7/20600?source=related_link\">",
"      Penicillin skin testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_19_15673="Treatment of relapsing polychondritis";
var content_f15_19_15673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of relapsing polychondritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Clement J Michet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15673/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/19/15673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to predict the clinical course of relapsing polychondritis (RPC) because there is a marked inter-patient variability. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=see_link\">",
"     \"Clinical manifestations of relapsing polychondritis\"",
"    </a>",
"    .) The patterns that may be seen include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Episodic disease activity",
"     </li>",
"     <li>",
"      Smoldering disease with ever-changing severity",
"     </li>",
"     <li>",
"      A fulminant downhill course resulting in death",
"     </li>",
"     <li>",
"      A relatively benign course that is free of clinically evident visceral involvement and is easily managed. It is not possible to estimate the prevalence of this self-limited pattern, since it is likely that many of these cases are not diagnosed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the variable course, other issues that may affect therapeutic decisions are concurrent systemic symptoms, the sites of involvement, the duration of disease activity, the initial response to therapy, and the frequency of relapse.",
"   </p>",
"   <p>",
"    This topic discusses the management of patients with RPC. The approach to diagnosis, and the etiology and pathogenesis, of this disease are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=see_link\">",
"     \"Diagnostic evaluation of relapsing polychondritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=see_link\">",
"     \"Etiology and pathogenesis of relapsing polychondritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29187?source=see_link\">",
"     \"Pathology of relapsing polychondritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative rarity of RPC has not permitted clinical trials to determine the efficacy and safety of different therapies. The pharmacologic approach in current use is largely empiric, being based upon a large series of anecdotal single or multiple case reports. No form of therapy has been shown to modify the natural history of the disease, although successful suppression of the clinical features can be achieved.",
"   </p>",
"   <p>",
"    The inability to predict patient response is particularly frustrating and limits our understanding of the relevance of certain pathophysiologic mechanisms. As an example, the administration of immunosuppressive agents is one of the mainstays of therapy in severe disease (see below). However, de novo RPC has been reported in a renal transplant recipient (in whom the cause of end-stage renal disease was unknown) despite potent immunosuppression with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Decisions about therapy should not be made until potential subclinical disease involving major visceral sites has been appropriately investigated. Active cardiac, tracheobronchial, and large artery involvement, which generally indicate the need for aggressive therapy, are at times asymptomatic or difficult to detect. We therefore recommend the following evaluation prior to the institution of therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Careful cardiac auscultation and electrocardiography. Consideration should also be given to echocardiography to look for possible aortic or mitral valve thickening or regurgitation if there is clinical evidence or suspicion of valvular disease.",
"     </li>",
"     <li>",
"      A chest radiograph and baseline pulmonary function testing.",
"     </li>",
"     <li>",
"      If clinically indicated, CT scanning to determine the site and degree of suspected airway stenosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, careful and continuous long-term monitoring is indicated. It is important to appreciate that patients in apparent clinical remission may have ongoing and important subclinical disease activity. One patient, for example, developed aortic valve inflammation despite apparent remission of RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/2\">",
"     2",
"    </a>",
"    ]. This observation has raised the question of whether early prophylactic treatment with a second-line immunosuppressive agent should be considered in all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MEDICAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of medical therapy given varies with the clinical estimate of disease activity and severity (",
"    <a class=\"graphic graphic_figure graphicRef68221 \" href=\"UTD.htm?2/40/2702\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Lack of visceral involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have active disease which does not significantly compromise organ function. They can present with features such as auricular or nasal chondritis and peripheral or axial arthritis. A nonsteroidal antiinflammatory drug (NSAID) may be sufficient in this setting if it is given in sufficient quantity to suppress clinical evidence of inflammation. &nbsp;Analgesic supplementation may be necessary.",
"   </p>",
"   <p>",
"    There are several choices if an adequate response is not achieved within seven to 10 days, usually beginning with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , which appears to be equally effective in patients without visceral involvement. Both drugs decrease disease activity and reduce the incidence of recurrence. A response is evident in the majority of patients within one to two weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Dapsone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Institution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    (a sulfone), based upon its presumed enzyme inhibitory and immunomodulatory properties [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. We initiate therapy at a dose of 50 to 100 mg, once daily. The dose is increased, if necessary, in 25 mg increments every one to two weeks to a maximum dose 200",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    In one small series, for example, improvement was seen in all seven patients treated with dapsone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/4\">",
"     4",
"    </a>",
"    ]. The average dose was 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for four months (range 25 mg to 200",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    duration, one week to two years). Once the desired response is obtained, the dose should be gradually tapered to the lowest effective maintenance level. An attempt should be made to discontinue the drug if there has been persistent clinical stabilization and normalization of laboratory parameters such as the erythrocyte sedimentation rate (ESR).",
"   </p>",
"   <p>",
"    The physician should be alert for potential side effects, particularly hemolytic anemia, blood dyscrasias, hypersensitivity reactions, exfoliative dermatitis, peripheral neuropathy, hepatic damage, or changes in mental status.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     Dapsone",
"    </a>",
"    should not be used if there be a history of allergy to sulfonamides, severe anemia, or glucose-6-phosphate dehydrogenase deficiency or if the patient is pregnant or breast feeding.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are also effective, with the initial dose being dependent upon the severity of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Most patients respond to 30 to 60",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (or its equivalent) in divided doses. Once the disease activity has remitted, the dose should be tapered to the lowest maintenance level and eventually discontinued.",
"   </p>",
"   <p>",
"    Alternate-day dosing is",
"    <strong>",
"     not",
"    </strong>",
"    recommended in RPC. The possible use of a second-line agent with potential glucocorticoid-sparing activity should be considered in patients requiring continued glucocorticoid therapy (see below). On occasion, an intraarticular glucocorticoid injection may be efficacious.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who do not respond to initial therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      can be treated with a combination of these two drugs. Alternatively, a second-line agent such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      can be given, either as monotherapy or in conjunction with dapsone",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      prednisone (see",
"      <a class=\"local\" href=\"#H8\">",
"       'Second-line drugs'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are sporadic reports of the use of other drugs to manage the more benign forms of RPC. However, their efficacy is uncertain. A favorable response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/13/32983?source=see_link\">",
"     colchicine",
"    </a>",
"    has been occasionally reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. We have not used this agent in the management of RPC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Organ-threatening disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A less conservative approach should be taken in the presence of laryngotracheal, bronchial, cardiovascular, renal, ocular or neurologic disease. Patients with relatively mild organ involvement should be started on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (60 to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in divided doses), followed by gradual tapering to a maintenance level of 7.5 to 10",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    in contrast, those with compromised organ function should also be begun on a second-line agent (see below).",
"   </p>",
"   <p>",
"    Relapses tend to occur when the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    dose is reduced too rapidly or if prednisone is prematurely discontinued. Although an attempt should be made to withdraw medication once clinical and laboratory parameters have stabilized, this may not be possible without concomitant use of a second-line agent (see below). Because of the unpredictable relapsing nature of RPC, there are no definitive guidelines indicating how long maintenance therapy with steroids or alternative agents should be continued before attempting withdrawal. We empirically initiate a conservative pattern of tapering leading to discontinuation once the clinical course has remained stable for at least three months and laboratory parameter, such as the ESR, are normal. Medication should be reinstituted or the dosage increased should symptoms recur.",
"   </p>",
"   <p>",
"    Given the toxicities of prolonged glucocorticoid use, prophylactic treatments should be provided for bone loss (calcium and vitamin D or, if appropriate, a bisphosphonate). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"     \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"     dapsone",
"    </a>",
"    in patients with organ-threatening disease has not been clearly defined. Preliminary observations suggest that it may be less effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/4,9\">",
"     4,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Second-line drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of immunomodulatory and antiinflammatory drug regimens have been used as an adjunct to steroids in RPC. The response to these agents cannot be predicted and the potential benefit must be weighed against possible toxicity.",
"   </p>",
"   <p>",
"    A second-line agent should be added in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The severity of involvement significantly compromises organ function (such as laryngotracheobronchial involvement), posing the potential of irreversible damage. The second-line agent should be given with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      at the initiation of therapy in such patients.",
"     </li>",
"     <li>",
"      A satisfactory clinical response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      is not achieved within one to two weeks.",
"     </li>",
"     <li>",
"      The required maintenance dose of glucocorticoid is excessive and a glucocorticoid-sparing effect is desired.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The choice of agent is largely empiric, since there is insufficient published evidence to strongly support one regimen versus another in RPC. Nevertheless, some recommendations can be provided based upon usage in RPC and in other forms of autoimmune and connective tissue disease in which comparable pathophysiologic mechanisms are thought to be operative.",
"   </p>",
"   <p>",
"    The major second-line drugs in RPC include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and other newer therapies. Response to",
"    <span class=\"nowrap\">",
"     antiinflammatory/immunomodulatory",
"    </span>",
"    compounds with potential efficacy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , soluble tumor necrosis factor alpha receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ) or anti-tumor necrosis factor antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ), anti-interleukin 1 receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    ), anti-interleukin 6 receptor antibody (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ), and T cell costimulatory inhibition (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ) have been largely limited to individual case reports.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cyclophosphamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    , in an oral dose of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two weeks, is the",
"    <strong>",
"     preferred",
"    </strong>",
"    second-line agent primarily because of its proven value in the management of systemic necrotizing vasculitis, rather than evidence from controlled studies demonstrating its efficacy in RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If a favorable clinical response is seen, the dose is kept at this level with readjustment to maintain a total white blood cell count above 3000 per mm3 with a total neutrophil count of 1000 to 1500 mm3. If, on the other hand, there is no clinical response, the daily dose should be increased in 25 mg increments every two weeks to a maximum of 150 mg daily until a response is achieved or drug toxicity is apparent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"    </a>",
"    .) An attempt should be made to reduce the dose to a stable maintenance level once the disease activity is controlled (as defined by clinical and laboratory parameters, such as a significant reduction in the usually elevated erythrocyte sedimentation rate). Although definitive guidelines have yet to be established, we prefer to continue maintenance therapy for at least six months. At this point, if the disease is controlled, consideration is given to substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    or intravenous pulsed cyclophosphamide every one to two months to reduce the risk of toxicity associated with long term oral use of cyclophosphamide. Full dose cyclophosphamide is reinstituted should a significant flare occur.",
"   </p>",
"   <p>",
"    Given the toxicities of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , prophylactic therapy should be provided for Pneumocystis pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     Cyclophosphamide",
"    </a>",
"    may cause amenorrhea in women of child-bearing age, and bladder cancer. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"     \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H12#H12\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of gonadal toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H16#H16\">",
"     \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Prevention of bladder toxicity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of initiating treatment using monthly intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    therapy is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The possible efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    , another alkylating agent, is also uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Azathioprine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    , in an oral dose of 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, is a potentially effective alternate to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. A clinical response should be evident within three to four weeks. Once the disease is controlled, the dose should be tapered to a maintenance level of 50 to 75",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    The dose must be adjusted according to the degree of myelosuppression and the duration of therapy is similar to that recommended with cyclophosphamide.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    , in a dose of 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, should be considered if the patient fails to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/16\">",
"     16",
"    </a>",
"    ]. A clinical response should be seen within one month. If clinical and laboratory parameters have remained stable over a three month period, an attempt should be made to achieve a lower maintenance dose to minimize nephrotoxicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .) Cyclosporine may be particularly useful in the treatment of refractory ocular disease, especially nodular sclerosing relapsing scleritis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/17\">",
"     17",
"    </a>",
"    ]. The optimal duration of therapy is uncertain. Individual case reports have indicated both successful discontinuation after one year as well as the need for continued maintenance for more than two years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Pulse methylprednisolone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited observations suggest that intravenous pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (1 gm bolus per day for three consecutive days) may be beneficial in selected patients with RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/18\">",
"     18",
"    </a>",
"    ]. This approach should be considered as an adjunct in patients refractory to the above immunosuppressive measures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Methotrexate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulsed weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been successfully used in the management of rheumatoid arthritis with a relative paucity of severe side effects. The limited information currently available is discordant as to its benefit in RPC, although it may have a glucocorticoid-sparing effect [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Methotrexate should be initiated in refractory cases at a dose of 5 to 7.5 mg per week, increasing by 2.5 mg increments every four to six weeks until the desired clinical response is achieved or a level of 25 mg per week is reached. Maintenance therapy may be required for a period of years. A disease flare should be managed by the addition of supplemental",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or by adjusting the dose of methotrexate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Tumor necrosis factor (TNF)-alpha antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports and small case series have supported the efficacy of TNF antagonists refractory to other anti-inflammatory",
"    <span class=\"nowrap\">",
"     /immunomodulatory",
"    </span>",
"    drugs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . Successful treatments with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    by intravenous infusion at two, four, and then eight-week intervals) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (50 mg weekly) have been reported. Potential efficacy has been shown in refractory RPC associated laryngotracheal disease, necrotizing vasculitis,",
"    <span class=\"nowrap\">",
"     episcleritis/scleritis,",
"    </span>",
"    aortic valve disease, synovitis, and auricular and nasal cartilage inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. These promising uncontrolled results warrant further investigation to assess the role of anti-TNF alpha therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Hematopoietic stem cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of hematopoietic stem cell transplantation in conjunction with myeloablation has been suggested in patients with RPC (and other putative autoimmune diseases) and reversible life or organ threatening disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/24\">",
"     24",
"    </a>",
"    ]. Its successful use has been described in refractory RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Major advances in this technique (such as the use of growth factors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    pulse",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , aggressive supportive care prior to cellular reconstitution, and refinement in the cryopreservation of blood products) have significantly reduced the mortality associated with this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=see_link\">",
"     \"Hematopoietic support after hematopoietic cell transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;One or more case reports have suggested possible beneficial effects of each of the following drugs or interventions:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/27\">",
"     27",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/28\">",
"     28",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/29\">",
"     29",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/30\">",
"     30",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/31\">",
"     31",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/32\">",
"     32",
"    </a>",
"    ], and oral tolerization with a preparation of bovine Type II collagen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/33\">",
"     33",
"    </a>",
"    ]. However, these modalities remain of unproven benefit. In a retrospective case series of nine patients with severe manifestations of RP, the addition of rituximab to ongoing therapies did not result in any patients achieving disease remission [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     GENERAL MEASURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with RPC are at increased risk for infection, which is a leading cause of death in this disorder. At least two factors contribute to this problem: the use of immunosuppressive drugs; and obstruction associated with inherent features of the disease, such as laryngotracheal and bronchial involvement, leading to abnormal drainage of respiratory secretions and ineffective cough due to dynamic upper airway collapse. Although use of immunosuppressive drugs precludes the use of live vaccines and may impair the antibody response to other vaccinations, we suggest the administration of influenza and pneumococcal vaccines for patients with significant laryngotracheobronchial disease.",
"   </p>",
"   <p>",
"    Although increasing the dose of steroid may be sufficient for control of an exacerbation of many features of disease, delay in its onset of action poses a particular hazard in patients with airway compromise due to inflammation. The use of nebulized racemic ephedrine may be effective in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/35\">",
"     35",
"    </a>",
"    ], while there is insufficient information concerning the use of inhaled steroids. In some cases, tenacious secretions may contribute to the airway obstruction and should be treated appropriately [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few surgical options are available for patients with diffuse respiratory tract disease, as described in the next section. In such patients, nasal continuous positive airway pressure may represent an effective, although temporary, therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=see_link\">",
"     \"Adherence with continuous positive airway pressure (CPAP)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SURGICAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be indicated for some of the visceral manifestations of RPC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Airway obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laryngotracheal and bronchial chondritis can cause potentially fatal airway narrowing. Three factors can contribute to this problem: inflammation; fibrosis-induced contractures;",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    loss of cartilaginous structural support which results in dynamic airway collapse during forced inspiration (larynx) or expiration (trachea). Involvement of glottic, subglottic, and upper tracheal regions may necessitate tracheostomy. It is important to appreciate, however, that tracheostomy may be ineffective in patients with more distal focal or diffuse airway narrowing. Furthermore, tracheostomy, by inducing inflammation, may increase the tendency to fatal airway obstruction.",
"   </p>",
"   <p>",
"    Regions of segmental collapse, due to tracheomalacia, refractory stenosis, or inflammatory masses, may be surgically resected or treated with an expandable metal stent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/38-41\">",
"     38-41",
"    </a>",
"    ]. Stents eventually become epithelialized, preventing migration and permitting continued ciliary activity. Significant complications of stenting include airway inflammation, stent migration, airway erosion and stent fracture and airway collapse proximal and distal to the stent. The use of BiPAP after surgical management may help keep narrowed airways from collapsing, especially at night [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=see_link\">",
"     \"Airway stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=see_link\">",
"     \"Noninvasive positive pressure ventilation in acute respiratory failure in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    More extensive tracheobronchial collapse may require tracheal reconstruction with any of a variety of techniques. These include external tracheal fixation by suspension to the vascular adventitia of the aorta using pericardium, dura, or Gore-Tex implants [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/43\">",
"     43",
"    </a>",
"    ], the use of silastic tube prostheses, or esophageal tracheoplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/44\">",
"     44",
"    </a>",
"    ]. Localized inflammatory and mucosal fibrotic lesions leading to severe main stem bronchial obstruction have been successfully treated with NdYAG laser ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reported results of laryngotracheal reconstruction procedures are poor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/46\">",
"     46",
"    </a>",
"    ]. If such techniques are to be considered for isolated segments of tracheal or subglottic stenosis, timing of the operation is critical. Surgery should only be contemplated when the disease is well-controlled or in remission. There must be meticulous pre- and postoperative medical management of the disease process to avoid complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Valvular and aortic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valve replacement or valvuloplasty should be considered in the presence of intractable heart failure due to valvular involvement in RPC [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Aortic aneurysms have also been successfully resected. However, a high incidence of surgical failure has been reported, perhaps due to contiguous active inflammation at operative sites or even induction of activity in regions of surgical trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of valvular problems remains controversial because the preferred procedures and the optimal time for surgical intervention remain unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/49\">",
"     49",
"    </a>",
"    ]. Since 'silent inflammation' progresses both in the aortic wall and the aortic or mitral annuli despite corticosteroid treatment, the complete replacement of the ascending aorta using a composite graft and reimplantation of the coronary arteries in patients with disease involving the ascending aorta has been recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/50\">",
"     50",
"    </a>",
"    ]. Optimal medical control of inflammation must be obtained prior to performing such elective surgery.",
"   </p>",
"   <p>",
"    Although corticosteroids may be efficacious in cardiac complications such as acute inflammatory heart block, the development of an atrioventricular block late in the course of disease may require placement of a permanent pacemaker. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"     \"Indications for permanent cardiac pacing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Anesthesia considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of settings in which general anesthesia may be required in the management of RPC including bronchoscopy, tracheostomy, and the surgical procedures noted above. Laryngeal or tracheobronchial disease can cause major anesthetic problems [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/39,51\">",
"     39,51",
"    </a>",
"    ]. As an example, a small glottis destroyed by inflammation may lead to difficulty with intubation. There is also concern that intratracheal manipulation can lead to life-threatening post-anesthetic deterioration of the respiratory system by inducing additional glottal or subglottal inflammation. Local and regional anesthetics are therefore preferred. If general anesthesia be indispensable, a surgical standby should be available for emergency cricothyrotomy, especially if laryngeal obstruction is suspected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pattern of case reporting in RPC prevents an accurate assessment of the overall prognosis. Among the problems are often incomplete documentation in single or a limited series of patients, large series derived from tertiary care centers to which more severely ill patients are referred, and the under reporting, lack of reporting, or failure of recognition of milder forms of the disease. The limited information available suggests what may be an unnecessarily ominous outlook.",
"   </p>",
"   <p>",
"    Although the course of RPC can on occasion be rapidly fatal, the more frequent patterns reflect either a relatively benign or chronic indolent disease process, extending over many years with ultimate death stemming from unrelated causes. Some form of disability is common in later stages of RPC; this may include visual impairment, audiovestibular dysfunction, and cardiopulmonary disease.",
"   </p>",
"   <p>",
"    The largest study reported a comprehensive analysis of 112 patients followed for approximately six years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/52\">",
"     52",
"    </a>",
"    ]. Intermittent inflammatory manifestations were noted by 86 percent of patients, with a median of five episodes per patent; the remaining 14 percent had continuous disease activity. The median survival from the time of diagnosis was 11 years, with 5- and 10-year probabilities of survival 74 percent and 55 percent, respectively (",
"    <a class=\"graphic graphic_figure graphicRef59909 \" href=\"UTD.htm?26/6/26733\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    However, a more favorable prognosis was reported in a more recent series [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/20\">",
"     20",
"    </a>",
"    ]. In this review of 66 patients with an average disease duration of eight years, the survival rate was 94 percent.",
"   </p>",
"   <p>",
"    The age at presentation appears to predict mortality. The death rate in younger patients (&lt;50 years of age) with aggressive disease ranges from 28 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. The most frequent causes of death are infection, laryngotracheal or bronchial involvement (especially stricture or collapse with resultant respiratory failure or superimposed pneumonia), and vasculitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Valvular heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional adverse prognostic features include valvular heart disease with intractable heart failure, renal disease, intercurrent malignancy, and anemia. A recent literature review of valvular heart disease in 440 patients with RPC made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15673/abstract/47\">",
"     47",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The mean time from the onset of RPC to the need for operative intervention was 6.5 years (range five months to 21 years).",
"     </li>",
"     <li>",
"      Surgery was performed an average of one year after the diagnosis of valvular incompetence.",
"     </li>",
"     <li>",
"      Reoperation was required in 24 percent of cases in the first four postoperative years. The primary problem was leakage around the prosthetic valve due to friability at the site of prosthesis anchorage and aneurysm formation.",
"     </li>",
"     <li>",
"      Fifty three percent of patients died of a cardiovascular event during this four-year period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The approach to treatment of patients with RPC is largely empiric and tailored based upon the severity of disease. Pretreatment evaluation is necessary to assess symptomatic and subclinical disease. &nbsp;Suggested examinations include: cardiac auscultation, electrocardiography, echocardiography, a plain chest radiograph, pulmonary function testing, and, if clinically indicated by respiratory symptoms or abnormal pulmonary function, a chest CT that includes images of major airways at both full inhalation and exhalation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nasal, auricular, and/or articular chondritis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with nasal, auricular,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      articular chondritis but",
"      <strong>",
"       no",
"      </strong>",
"      visceral involvement (ie, no major airway inflammation, stenosis, or collapse; cardiac disease; vasculitis; ocular; renal; or neurologic disease attributable to RPC), we suggest initial treatment with a nonsteroidal antiinflammatory drug (NSAID) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Lack of visceral involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For those with an inadequate response to seven to ten days of an NSAID,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      are options. &nbsp;If oral glucocorticoids are selected , prednisone 30 to 60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      can be instituted (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If disease activity is controlled, the dose is tapered to the lowest level necessary to maintain remission. Glucocorticoids may eventually be discontinued. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Organ-threatening disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If there is no contraindication to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      (eg, allergy to sulfonamides, severe anemia, G6PD-deficiency, pregnancy or desire to breast feed an infant), we suggest dapsone (initial dose 50 to 100",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Dapsone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Alternatives for those who do not respond to therapeutic trials of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/59/32688?source=see_link\">",
"       dapsone",
"      </a>",
"      or glucocorticoids include: a combination of both agents or addition of a second-line drug such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      , either as monotherapy or in combination with dapsone or glucocorticoid. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Second-line drugs'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Life or organ threatening disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with ocular, laryngotracheal, bronchial, cardiovascular, renal, ocular or neurologic disease, the initial treatment is determined by the assessment of disease severity. For those with relatively mild involvement, we suggest oral glucocorticoids be used initially (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We typically use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (60 to 100",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      &nbsp;For those with life-threatening disease or significant visceral damage, we suggest a combination of a glucocorticoid and another immunosuppressive or immunomodulatory agent as initial therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Organ-threatening disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The choice of immunosuppressive (second-line) agent in RPC is largely empiric, since there is insufficient published evidence to support one regimen versus another strongly. We suggest a two week trial of daily oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If there is no response after two weeks of treatment, the dose may be increased by 25 mg increments every two weeks, to a maximum of 200 mg daily. Dose titration should maintain an acceptable absolute neutrophil count. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Cyclophosphamide'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prophylactic measures include use of calcium and vitamin D or a bisphosphonate for the prevention of glucocorticoid-induced bone loss and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      for opportunistic infection by Pneumocystis carinii (P. jirovecii). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\", section on 'Prophylaxis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Women of child bearing potential need to be aware of the adverse effects of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      on fertility and the risk of teratogenicity. Pretreatment pregnancy testing and use of an effective method of contraception are appropriate for such women. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=see_link\">",
"       \"General principles of the use of cyclophosphamide in rheumatic and renal disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Airway obstruction may require surgical intervention. Involvement of glottic, subglottic, and upper tracheal regions may necessitate tracheostomy. Regions of segmental collapse due to tracheomalacia, refractory stenosis, and inflammatory masses may be resected or treated with expandable metal stents. The use of BiPAP after surgical management may help prevent airway collapse. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Airway obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Surgical management may also be necessary for intractable heart failure due to valvular regurgitation, and for aortic aneurysms. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Valvular and aortic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endotracheal intubation of patients with RPC may be difficult or impossible. In addition, intratracheal manipulation can lead to life-threatening post-anesthetic deterioration by causing further glottal or subglottal inflammation. Local and regional anesthesia is preferred. When general anesthesia is unavoidable, surgical standby should be available for emergency cricothyrotomy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Anesthesia considerations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although the course of RPC can on occasion be rapidly fatal, the more frequent patterns reflect either a relatively benign or chronic indolent disease process, extending over many years with ultimate death stemming from unrelated causes. Some form of disability is common in later stages of RPC; this may include visual impairment, audiovestibular dysfunction, and cardiopulmonary disease. The most frequent causes of death are infection, laryngotracheal or bronchial involvement (especially stricture or collapse with resultant respiratory failure or superimposed pneumonia), and vasculitis. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Valvular heart and aortic disease are associated with a worse prognosis, particularly in those with intractable heart failure, renal disease, intercurrent malignancy, and significant anemia. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Valvular heart disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/1\">",
"      Khan GA, Glicklich DG, Iskaros BF, Posner L. Relapsing polychondritis occurring de novo in a renal transplant patient. Transplantation 1994; 58:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/2\">",
"      Buckley LM, Ades PA. Progressive aortic valve inflammation occurring despite apparent remission of relapsing polychondritis. Arthritis Rheum 1992; 35:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/3\">",
"      Ridgway HB, Hansotia PL, Schorr WF. Relapsing polychondritis: unusual neurological findings and therapeutic efficacy of dapsone. Arch Dermatol 1979; 115:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/4\">",
"      Damiani JM, Levine HL. Relapsing polychondritis--report of ten cases. Laryngoscope 1979; 89:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/5\">",
"      KAYE RL, SONES DA. RELAPSING POLYCHONDRITIS. CLINICAL AND PATHOLOGIC FEATURES IN FOURTEEN CASES. Ann Intern Med 1964; 60:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/6\">",
"      Dolan DL, Lemmon GB Jr, Teitelbaum SL. Relapsing polychondritis. Analytical literature review and studies on pathogenesis. Am J Med 1966; 41:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/7\">",
"      Askari AD. Colchicine for treatment of relapsing polychondritis. J Am Acad Dermatol 1984; 10:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/8\">",
"      Mark KA, Franks AG Jr. Colchicine and indomethacin for the treatment of relapsing polychondritis. J Am Acad Dermatol 2002; 46:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/9\">",
"      Hoang-Xaun T, Foster CS, Rice BA. Scleritis in relapsing polychondritis. Response to therapy. Ophthalmology 1990; 97:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/10\">",
"      Ruhlen JL, Huston KA, Wood WG. Relapsing polychondritis with glomerulonephritis. Improvement with prednisone and cyclophosphamide. JAMA 1981; 245:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/11\">",
"      Chang-Miller A, Okamura M, Torres VE, et al. Renal involvement in relapsing polychondritis. Medicine (Baltimore) 1987; 66:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/12\">",
"      Stewart KA, Mazanec DJ. Pulse intravenous cyclophosphamide for kidney disease in relapsing polychondritis. J Rheumatol 1992; 19:498.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/13\">",
"      Trepel RJ, Lipnick RN, D'Angelo L. Relapsing polychondritis in an adolescent. J Adolesc Health Care 1989; 10:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/14\">",
"      Hughes RA, Berry CL, Seifert M, Lessof MH. Relapsing polychondritis. Three cases with a clinico-pathological study and literature review. Q J Med 1972; 41:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/15\">",
"      Irani BS, Martin-Hirsch DP, Clark D, et al. Relapsing polychondritis--a study of four cases. J Laryngol Otol 1992; 106:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/16\">",
"      Ormerod AD, Clark LJ. Relapsing polychondritis--treatment with cyclosporin A. Br J Dermatol 1992; 127:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/17\">",
"      Priori R, Paroli MP, Luan FL, et al. Cyclosporin A in the treatment of relapsing polychondritis with severe recurrent eye involvement. Br J Rheumatol 1993; 32:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/18\">",
"      Lipnick RN, Fink CW. Acute airway obstruction in relapsing polychondritis: treatment with pulse methylprednisolone. J Rheumatol 1991; 18:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/19\">",
"      Park J, Gowin KM, Schumacher HR Jr. Steroid sparing effect of methotrexate in relapsing polychondritis. J Rheumatol 1996; 23:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/20\">",
"      Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med 1998; 129:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/21\">",
"      Richez C, Dumoulin C, Coutouly X, Schaeverbeke T. Successful treatment of relapsing polychondritis with infliximab. Clin Exp Rheumatol 2004; 22:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/22\">",
"      Cazabon S, Over K, Butcher J. The successful use of infliximab in resistant relapsing polychondritis and associated scleritis. Eye (Lond) 2005; 19:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/23\">",
"      Carter JD. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol 2005; 32:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/24\">",
"      Tyndall A. Hematopoietic stem cell transplantation in rheumatic diseases other than systemic sclerosis and systemic lupus erythematosus. J Rheumatol Suppl 1997; 48:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/25\">",
"      Rosen O, Thiel A, Massenkeil G, et al. Autologous stem-cell transplantation in refractory autoimmune diseases after in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Res 2000; 2:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/26\">",
"      K&ouml;tter I, Daikeler T, Amberger C, et al. Autologous stem cell transplantation of treatment-resistant systemic vasculitis--a single center experience and review of the literature. Clin Nephrol 2005; 64:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/27\">",
"      Goldenberg G, Sangueza OP, Jorizzo JL. Successful treatment of relapsing polychondritis with mycophenolate mofetil. J Dermatolog Treat 2006; 17:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/28\">",
"      Vounotrypidis P, Sakellariou GT, Zisopoulos D, Berberidis C. Refractory relapsing polychondritis: rapid and sustained response in the treatment with an IL-1 receptor antagonist (anakinra). Rheumatology (Oxford) 2006; 45:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/29\">",
"      Handler RP. Leflunomide for relapsing polychondritis: successful longterm treatment. J Rheumatol 2006; 33:1916; author reply 1916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/30\">",
"      Trentham DE, Dynesius-Trentham RA. Antibiotic therapy for rheumatoid arthritis. Scientific and anecdotal appraisals. Rheum Dis Clin North Am 1995; 21:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/31\">",
"      Kawai M, Hagihara K, Hirano T, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) 2009; 48:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/32\">",
"      Moulis G, Sailler L, Astudillo L, Arlet P. Abatacept for relapsing polychondritis. Rheumatology (Oxford) 2010; 49:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/33\">",
"      Navarro MJ, Higgins GC, Lohr KM, Myers LK. Amelioration of relapsing polychondritis in a child treated with oral collagen. Am J Med Sci 2002; 324:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/34\">",
"      Leroux G, Costedoat-Chalumeau N, Brihaye B, et al. Treatment of relapsing polychondritis with rituximab: a retrospective study of nine patients. Arthritis Rheum 2009; 61:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/35\">",
"      Gaffney RJ, Harrison M, Blayney AW. Nebulized racemic ephedrine in the treatment of acute exacerbations of laryngeal relapsing polychondritis. J Laryngol Otol 1992; 106:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/36\">",
"      Carri&oacute;n M, Gir&oacute;n JA, Ventura J, et al. Airway complications in relapsing polychondritis. J Rheumatol 1993; 20:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/37\">",
"      Adliff M, Ngato D, Keshavjee S, et al. Treatment of diffuse tracheomalacia secondary to relapsing polychondritis with continuous positive airway pressure. Chest 1997; 112:1701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/38\">",
"      Eng J, Sabanathan S. Airway complications in relapsing polychondritis. Ann Thorac Surg 1991; 51:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/39\">",
"      Dunne JA, Sabanathan S. Use of metallic stents in relapsing polychondritis. Chest 1994; 105:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/40\">",
"      Faul JL, Kee ST, Rizk NW. Endobronchial stenting for severe airway obstruction in relapsing polychondritis. Chest 1999; 116:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/41\">",
"      Sarodia BD, Dasgupta A, Mehta AC. Management of airway manifestations of relapsing polychondritis: case reports and review of literature. Chest 1999; 116:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/42\">",
"      Ishikawa S, Yamazaki M, Takei Y, et al. [A case of relapsing polychondritis with oculobulbar symptoms and successful treatment of respiratory failure with BiPAP]. Rinsho Shinkeigaku 1999; 39:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/43\">",
"      Lehman JD, Gordon RL, Kerlan RK Jr, et al. Expandable metallic stents in benign tracheobronchial obstruction. J Thorac Imaging 1998; 13:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/44\">",
"      Niwa H, Masaoka A, Yamakawa Y, et al. Esophageal tracheobronchoplasty for diseases of the central airway. J Thorac Cardiovasc Surg 1996; 112:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/45\">",
"      Sacco O, Fregonese B, Oddone M, et al. Severe endobronchial obstruction in a girl with relapsing polychondritis: treatment with Nd YAG laser and endobronchial silicon stent. Eur Respir J 1997; 10:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/46\">",
"      Spraggs PD, Tostevin PM, Howard DJ. Management of laryngotracheobronchial sequelae and complications of relapsing polychondritis. Laryngoscope 1997; 107:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/47\">",
"      Lang-Lazdunski L, Hvass U, Paillole C, et al. Cardiac valve replacement in relapsing polychondritis. A review. J Heart Valve Dis 1995; 4:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/48\">",
"      Lang-Lazdunski L, Pansard Y, Hvass U. Aortic valve replacement in relapsing polychondritis. J Thorac Cardiovasc Surg 1997; 114:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/49\">",
"      Del Rosso A, Petix NR, Pratesi M, Bini A. Cardiovascular involvement in relapsing polychondritis. Semin Arthritis Rheum 1997; 26:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/50\">",
"      Dib C, Moustafa SE, Mookadam M, et al. Surgical treatment of the cardiac manifestations of relapsing polychondritis: overview of 33 patients identified through literature review and the Mayo Clinic records. Mayo Clin Proc 2006; 81:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/51\">",
"      Biro P, Rohling R, Schmid S, et al. Anesthesia in a patient with acute respiratory insufficiency due to relapsing polychondritis. J Clin Anesth 1994; 6:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/52\">",
"      Michet CJ Jr, McKenna CH, Luthra HS, O'Fallon WM. Relapsing polychondritis. Survival and predictive role of early disease manifestations. Ann Intern Med 1986; 104:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/53\">",
"      McAdam LP, O'Hanlan MA, Bluestone R, Pearson CM. Relapsing polychondritis: prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976; 55:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15673/abstract/54\">",
"      Cohen PR, Rapini RP. Relapsing polychondritis. Int J Dermatol 1986; 25:280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5587 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.69.132.100-C55D250E76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15673=[""].join("\n");
var outline_f15_19_15673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MEDICAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Lack of visceral involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Dapsone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Organ-threatening disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Second-line drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cyclophosphamide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Azathioprine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Pulse methylprednisolone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Methotrexate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Tumor necrosis factor (TNF)-alpha antagonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Hematopoietic stem cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      GENERAL MEASURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SURGICAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Airway obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Valvular and aortic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Anesthesia considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Valvular heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nasal, auricular, and/or articular chondritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Life or organ threatening disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/5587\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/5587|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/40/2702\" title=\"figure 1\">",
"      Rx of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/6/26733\" title=\"figure 2\">",
"      Survival in polychondritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/62/44006?source=related_link\">",
"      Adherence with continuous positive airway pressure (CPAP)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/0/34823?source=related_link\">",
"      Airway stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/63/26616?source=related_link\">",
"      Clinical manifestations of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/47/4856?source=related_link\">",
"      Diagnostic evaluation of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/59/42935?source=related_link\">",
"      Etiology and pathogenesis of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/40/16008?source=related_link\">",
"      General principles of the use of cyclophosphamide in rheumatic and renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/54/34664?source=related_link\">",
"      Hematopoietic support after hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/51/1850?source=related_link\">",
"      Noninvasive positive pressure ventilation in acute respiratory failure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/32/29187?source=related_link\">",
"      Pathology of relapsing polychondritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_19_15674="Approach to the adult patient with thrombocytopenia";
var content_f15_19_15674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the adult patient with thrombocytopenia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15674/contributors\">",
"     James N George, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/19/15674/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/19/15674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician is frequently faced by a patient presenting with a low platelet count, the cause of which is not immediately apparent. This topic will provide a structure through which the cause(s) of such thrombocytopenia can be assessed. A related topic describes the most common outpatient and inpatient presentations of adults with newly recognized",
"    <strong>",
"     isolated",
"    </strong>",
"    thrombocytopenia (ie, patients in whom the remainder of the blood count is normal, and who may or may not have signs of systemic disease) and provides a general guideline for the evaluation and management of thrombocytopenic patients in the office and hospital settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link\">",
"     \"Evaluation and management of thrombocytopenia by primary care physicians\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other issues related to thrombocytopenia are presented separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Thrombocytopenia in pregnancy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"       \"Thrombocytopenia in pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Evaluation of the patient with a bleeding diathesis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link\">",
"       \"Approach to the adult patient with a bleeding diathesis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS AND NORMAL VALUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The normal platelet count in adults ranges from 150,000 to",
"    <span class=\"nowrap\">",
"     450,000/microL,",
"    </span>",
"    with mean values of 237,000 and",
"    <span class=\"nowrap\">",
"     266,000/microL",
"    </span>",
"    in males and females, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/1\">",
"     1",
"    </a>",
"    ]. Thrombocytopenia is defined as a platelet count less than",
"    <span class=\"nowrap\">",
"     150,000/microL",
"    </span>",
"    (150 x",
"    <span class=\"nowrap\">",
"     10",
"     <sup>",
"      9",
"     </sup>",
"     /L),",
"    </span>",
"    keeping in mind that 2.5 percent of the normal population will have a platelet count lower than this.",
"   </p>",
"   <p>",
"    A recent fall in the platelet count by one-half, while still in the normal range, may herald severe clinical problems (see below), and requires active follow-up. However, thrombocytopenia is not usually detected clinically (see below) until the platelet count has fallen to levels below",
"    <span class=\"nowrap\">",
"     100,000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Variation of the platelet count in a given individual is limited; differences in the absolute platelet count greater than 70 to",
"    <span class=\"nowrap\">",
"     90,000/microL",
"    </span>",
"    will occur by chance less than 1 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/1\">",
"     1",
"    </a>",
"    ]. As an example, even if the patient's platelet count is within the normal range, if the count has recently fallen 50 percent or more from a prior value, this should immediately raise the possibility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia in any patient begun on heparin therapy within the preceding 5 to 10 days. If confirmed, this constitutes a medical emergency, requiring appropriate urgent action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical bleeding due solely to a reduction in the number of platelets does not generally occur until the platelet count is less than",
"    <span class=\"nowrap\">",
"     50,000/microL,",
"    </span>",
"    and clinical or spontaneous bleeding does not occur until the platelet count is less than 10,000 to",
"    <span class=\"nowrap\">",
"     20,000/microL.",
"    </span>",
"    In a study of patients with immune thrombocytopenia (ITP), for example, minimal bleeding after trauma was uncommon unless the platelet count was less than",
"    <span class=\"nowrap\">",
"     60,000/microL,",
"    </span>",
"    whereas self-limited bleeding, spontaneous bleeding requiring special attention (eg, nasal packing for epistaxis), and severe life threatening bleeding did not occur until platelet counts were &lt;40,000, &lt;12,000, and",
"    <span class=\"nowrap\">",
"     &lt;6000/microL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     OVERVIEW OF PLATELET KINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelets are produced in the bone marrow from megakaryocytes which are derived from more primitive precursors (",
"    <a class=\"graphic graphic_picture graphicRef55409 \" href=\"UTD.htm?20/12/20675\">",
"     picture 1",
"    </a>",
"    ). The megakaryocyte produces platelets by cytoplasmic shedding directly into bone marrow sinusoids (",
"    <a class=\"graphic graphic_picture graphicRef67199 \" href=\"UTD.htm?23/53/24402\">",
"     picture 2",
"    </a>",
"    ). It has been estimated that about 1000 to 5000 platelets are produced by each megakaryocyte. In normal individuals, platelet production is approximately 35,000 to",
"    <span class=\"nowrap\">",
"     50,000/microL",
"    </span>",
"    of whole blood per day [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]; this value can be increased up to eight-fold during times of increased demand [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=see_link\">",
"     \"Megakaryocyte biology and the production of platelets\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Platelets survive in the circulation for 8 to 10 days, after which they are removed from the circulation by cells of the monocyte-macrophage system, perhaps as a result of programmed apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In normal individuals, approximately one-third of the total platelet mass is found in the spleen, in equilibrium with the circulating pool of platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Distributional thrombocytopenia caused by splenomegaly'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Young versus old platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The youngest platelets in the circulation are larger and appear to be more hemostatically active.",
"   </p>",
"   <p>",
"    Two observations are of interest in this regard:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenic patients with immune thrombocytopenia (ITP) do not usually have serious bleeding, suggesting that the small numbers of young platelets in these patients are more hemostatically active than mixed age platelets in normal subjects. Patients with ITP also appear to have less bleeding than patients with similar severities of thrombocytopenia caused by marrow failure, such as subjects with thrombocytopenia following chemotherapy, who also have a population of platelets of mixed age.",
"     </li>",
"     <li>",
"      Aged platelets in dogs are less responsive to thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/8\">",
"       8",
"      </a>",
"      ] and collagen [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/9\">",
"       9",
"      </a>",
"      ] than younger platelets.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reticulated platelets",
"    </span>",
"    &nbsp;&mdash;&nbsp;The youngest platelets in the circulation contain RNA and have been called reticulated platelets or the &ldquo;immature platelet fraction&rdquo; (IPF); they are analogous to the young, RNA-containing red cells (reticulocytes). This property allows them to be specifically analyzed by automated instrumentation. The clinical usefulness of analyzing for the IPF is currently being evaluated (",
"    <a class=\"graphic graphic_figure graphicRef51649 \" href=\"UTD.htm?8/22/8558\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=see_link&amp;anchor=H12#H12\">",
"     \"Automated hematology instrumentation\", section on 'Reticulated platelets'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=see_link&amp;anchor=H30#H30\">",
"     \"Platelet function testing\", section on 'Reticulated platelets'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example, the IPF was determined in three groups of patients, with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/12\">",
"     12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal subjects &mdash; 1.3 percent (95% CI 1.1-1.5)",
"     </li>",
"     <li>",
"      Thrombocytopenia with \"normal or decreased thrombopoietic activity\" &mdash; 7.5 percent (95% CI 5.3-9.7)",
"     </li>",
"     <li>",
"      Thrombocytopenia with \"increased platelet turnover\" &mdash; 30 percent (95% CI 25-35)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been suggested that analysis of the IPF can be used to determine the mechanism through which the platelet count is increased following the use of therapeutic agents in patients with immune thrombocytopenia (ITP). Thus, agents that decrease destruction of circulating platelets should result in little or no increase in the IPF, while those that stimulate platelet production should increase the IPF [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/11\">",
"     11",
"    </a>",
"    ]. Additional studies will be required in order to substantiate these results and to determine the clinical utility of this measurement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MECHANISMS OF THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Analogous to the red blood cell system, the major mechanisms for a reduced platelet count are decreased production and increased destruction. Two additional mechanisms include dilutional or distributional thrombocytopenia. However, before the evaluation of the mechanism of thrombocytopenia is considered, it is imperative to validate the platelet count to exclude the possibility of spurious or pseudothrombocytopenia and be certain that actual thrombocytopenia exists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pseudothrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The platelet count can be falsely low in a number of settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If anticoagulation of the blood sample is inadequate, the resulting thrombin-induced platelet clumps can be counted as leukocytes by automated cell counters. In these circumstances, the WBC count is rarely increased by more than 10 percent and there is usually an associated spurious thrombocytopenia [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On occasion, pseudothrombocytopenia can be caused by platelet rosetting around neutrophils, monocytes, and rarely, around circulating lymphoma cells [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/14-18\">",
"       14-18",
"      </a>",
"      ]. This in vitro phenomenon, induced at room temperature in EDTA-anticoagulated blood has been called &ldquo;platelet satellitism&rdquo;. In one case this resulted from the presence of an EDTA-dependent antibody with dual reactivity against both the platelet glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      complex and the neutrophil Fc gamma receptor III [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pseudothrombocytopenia can also occur after the administration of the murine monoclonal antibody",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      , which is directed against the GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H7#H7\">",
"       \"Drug-induced thrombocytopenia\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2817248\">",
"    <span class=\"h3\">",
"     Platelet clumping in EDTA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 0.1 percent of normal subjects have EDTA- dependent agglutinins which can lead to platelet clumping and spurious thrombocytopenia and spurious leukocytosis. This is thought to result from a \"naturally occurring\" platelet autoantibody directed against a normally concealed epitope on the platelet membrane glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa,",
"    </span>",
"    which becomes exposed by EDTA-induced dissociation of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/20-26\">",
"     20-26",
"    </a>",
"    ]. Pseudothrombocytopenia then occurs because EDTA is the anticoagulant employed in the tubes used for routine complete blood counts.",
"   </p>",
"   <p>",
"    EDTA-induced platelet clumping can be diagnosed by examination of the peripheral smear (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 3",
"    </a>",
"    ). This is an established routine for laboratory technologists, but sometimes the physician only receives the report of the falsely low platelet count number, without the note about clumping or a repeat count in a non-EDTA anticoagulant.",
"   </p>",
"   <p>",
"    If platelet clumping is observed, the platelet count is repeated using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or sodium citrate as an anticoagulant. If citrate is used, one should remember to correct the platelet count for dilution caused by the amount of citrate solution used; no such correction is needed for heparin. Alternatively, one can use freshly-shed non-anticoagulated blood pipetted directly into platelet counting diluent fluid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Decreased platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Platelet production by the bone marrow can be impaired when the marrow is suppressed or damaged. In almost all disorders caused by marrow suppression or damage, white cell and red cell production are also affected. Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After viral infections (eg, rubella, mumps, varicella, parvovirus, hepatitis C, and Epstein-Barr virus). Decreased platelet counts also regularly occur in children receiving live attenuated measles vaccination, but the thrombocytopenia is rarely clinically important [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/27\">",
"       27",
"      </a>",
"      ]. However, when viral infections occur in a patient who already has marrow suppression from another etiology, such as chemotherapy, the ensuing thrombocytopenia may be severe.",
"     </li>",
"     <li>",
"      Certain infectious agents are capable of damaging megakaryocytes directly, such as the human immunodeficiency virus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H5#H5\">",
"       \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Ineffective platelet production'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following chemotherapy or radiation therapy to sites of platelet production (eg, total nodal irradiation).",
"     </li>",
"     <li>",
"      In cases of congenital or acquired bone marrow aplasia or hypoplasia, such as Fanconi anemia, acquired pure megakaryocytic aplasia, and thrombocytopenia with absent radius (TAR) syndrome. Although congenital thrombocytopenias are more commonly diagnosed in children, many conditions are mild and not recognized until an adult has a routine blood count including a platelet count. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"       \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Direct alcohol toxicity. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=see_link\">",
"       \"Alcohol abuse and hematologic disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Vitamin B12 and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=see_link\">",
"       \"Etiology and clinical manifestations of vitamin B12 and folate deficiency\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Increased platelet destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased platelet destruction is seen in a number of conditions, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immune thrombocytopenia (ITP) and systemic lupus erythematosus, in which the mechanism in many cases is presumed to be due to the presence of autoimmune anti-platelet antibodies. However, ineffective platelet production may also contribute to thrombocytopenia in patients with ITP [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]. This observation has led to the development of new treatments for ITP that stimulate platelet production. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link&amp;anchor=H2#H2\">",
"       \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\", section on 'Pathogenesis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link&amp;anchor=H18#H18\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\", section on 'Thrombocytopenia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=see_link&amp;anchor=H5#H5\">",
"       \"Chronic refractory immune thrombocytopenia (ITP) in adults\", section on 'Thrombopoiesis-stimulating agents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain drugs, most notably",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       quinine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"      , and valproic acid (see below) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Alloimmune destruction (post-transfusion, neonatal, post- transplantation) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC) (",
"      <a class=\"graphic graphic_table graphicRef58104 \" href=\"UTD.htm?8/28/8652\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=see_link\">",
"       \"Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The antiphospholipid syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=see_link\">",
"       \"Clinical manifestations of the antiphospholipid syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The HELLP syndrome (",
"      <strong>",
"       h",
"      </strong>",
"      emolytic anemia,",
"      <strong>",
"       e",
"      </strong>",
"      levated",
"      <strong>",
"       l",
"      </strong>",
"      iver function tests, and",
"      <strong>",
"       l",
"      </strong>",
"      ow",
"      <strong>",
"       p",
"      </strong>",
"      latelet count) in pregnant women (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=see_link\">",
"       \"HELLP syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Following certain infections (eg, infectious mononucleosis, cytomegalovirus)",
"     </li>",
"     <li>",
"      Patients infected with HIV have a high incidence of thrombocytopenia, which bears a similarity to ITP (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=see_link&amp;anchor=H3#H3\">",
"       \"Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities\", section on 'Primary HIV-associated thrombocytopenia'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Physical destruction of platelets during cardiopulmonary bypass, within giant cavernous hemangiomata (Kasabach-Merritt syndrome), occasionally in large aortic aneurysms, and rarely in intravascular or intracardiac metastatic lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Dilutional thrombocytopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who have had massive blood loss and transfusional support with packed RBC will have dilutional thrombocytopenia due to absence of viable platelets in packed RBC products. The usual platelet count in patients receiving 15 or 20 red blood cell units in 24 hours is 47,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL",
"    </span>",
"    and 25,000 to",
"    <span class=\"nowrap\">",
"     61,000/microL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. This problem can be obviated by giving platelet concentrates to patients receiving more than 20 units of packed RBC in a 24-hour period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Distributional thrombocytopenia caused by splenomegaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normally, about one-third of circulating platelets are sequestered in the spleen, where they are in equilibrium with circulating platelets. Splenic sequestration of platelets can be increased to as high as 90 percent in patients with congestive splenomegaly due to portal hypertension (",
"    <a class=\"graphic graphic_figure graphicRef52400 \" href=\"UTD.htm?7/24/7566\">",
"     figure 2",
"    </a>",
"    ), although total platelet mass and overall platelet survival remain relatively normal [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, patients with cirrhosis, portal hypertension, and splenomegaly may have significant degrees of \"apparent\" thrombocytopenia (with or without leukopenia and anemia), but rarely have clinical bleeding, since their total available platelet mass is usually normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thrombocytopenia may be asymptomatic and thrombocytopenia may be first detected on a routine complete blood count. The symptomatic presentation of thrombocytopenia is bleeding, characteristically mucosal and cutaneous. Mucosal bleeding may be manifest as epistaxis and gingival bleeding, and large bullous hemorrhages may appear on the buccal mucosa due to the lack of vessel protection afforded by the submucosal tissue. Bleeding into the skin is manifested as petechiae or superficial ecchymoses. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Menorrhagia (menstrual flow that does not taper after more than three days) and metrorrhagia (uterine bleeding between periods) are also common and there may be persistent, profuse bleeding from superficial cuts. Patients with thrombocytopenia tend to bleed immediately after vascular trauma; they do not experience the delayed bleeding that is characteristic of patients with coagulation disorders such as hemophilia. Posttraumatic or postoperative surgical bleeding usually responds to local measures, but may persist for hours or days after small injuries. Bleeding into the central nervous system rarely occurs; when it does there is often preceding trauma, but it is the most common cause of death due to thrombocytopenia.",
"   </p>",
"   <p>",
"    The pattern of bleeding in patients with thrombocytopenia (and in patients with disordered platelet function) differs from that seen in patients with coagulation disorders such as hemophilia, in that the latter group has delayed bleeding that begins several hours or a day after trauma, because normal platelet function can provide temporary hemostasis. Patients with coagulation disorders also have deep bleeding (into tissues, muscles, and joints), minimal bleeding after minor cuts, more delayed bleeding, more postsurgical bleeding, and tend not to have petechiae (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Petechiae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Petechiae are pinhead sized, red, flat, discrete lesions often occurring in crops in dependent areas (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 4",
"    </a>",
"    ); they are most dense on the feet and ankles, where the hydrostatic pressure on the small superficial vessels is greatest, and fewer are present on the legs. Petechiae are not found on the sole of the foot where the vessels are protected by the strong subcutaneous tissue. Petechiae are due to the presence of red cells which have extravasated from capillaries; they are nontender and do not blanch under pressure. They are asymptomatic and not palpable, and should be distinguished from small telangiectasias, angiomas, and vasculitic purpura (",
"    <a class=\"graphic graphic_picture graphicRef62546 \" href=\"UTD.htm?29/6/29794\">",
"     picture 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Purpura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Purpura is a purplish discoloration of the skin due to the presence of confluent petechiae. Two types of purpura are generally recognized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dry purpura is the term used when the only bleeding is in the skin, as in frame A of the picture (",
"      <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Wet purpura is the term used when there is extensive mucous membrane bleeding, as in frame B of the picture (",
"      <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is generally felt that the presence of wet purpura is the more serious, and is a prognostic sign for potentially life-threatening hemorrhage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Ecchymoses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ecchymoses are nontender areas of bleeding into the skin, usually associated with multiple colors, due to the presence of extravasated blood (red, purple) plus the colors due to breakdown of heme pigment by skin macrophages (green, orange, yellow). Ecchymotic lesions characteristically are small, multiple, and superficial. They usually develop without noticeable trauma and do not spread into deeper tissues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INITIAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no substitute for an accurate, comprehensive history and physical examination. However, a platelet count that does not make sense within the context of the clinical picture should be repeated before extensive evaluation is undertaken. For extremely low platelet counts in symptomatic patients, such re-testing should be performed immediately; for asymptomatic patients with modest reductions in platelet count (eg, 75,000 to",
"    <span class=\"nowrap\">",
"     100,000/microL),",
"    </span>",
"    testing may be repeated in one to two weeks, provided that the patient is advised to immediately report any changes in clinical status during this interval.",
"   </p>",
"   <p>",
"    If, after initial evaluation and retesting, the cause of the thrombocytopenia is not apparent, hematologic consultation is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The general history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain conditions associated with thrombocytopenia are obvious and can be immediately recognized by the clinician:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recent new drugs or drugs that are only taken intermittently",
"     </li>",
"     <li>",
"      Recent infection (viral, bacterial, rickettsial, etc.)",
"     </li>",
"     <li>",
"      Previously diagnosed hematologic disease (eg, acute and chronic leukemias, chronic myeloproliferative or myelodysplastic diseases)",
"     </li>",
"     <li>",
"      Nonhematologic diseases known to decrease platelet counts (eg, eclampsia, sepsis, DIC, anaphylactic shock, hypothermia, massive transfusions)",
"     </li>",
"     <li>",
"      A positive family history of bleeding",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia",
"     </li>",
"     <li>",
"      Recent live virus vaccination",
"     </li>",
"     <li>",
"      Poor nutritional status, especially in the elderly and alcoholics",
"     </li>",
"     <li>",
"      Pregnancy, especially late in the third trimester or at onset of labor (see below), but also with a prior history of ITP or TTP-HUS, or with preeclampsia or eclampsia (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"       \"Thrombocytopenia in pregnancy\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Recent organ transplantation from a donor sensitized to platelet alloantigens [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Recent transfusion of a platelet-containing product in an allosensitized recipient (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H18#H18\">",
"       \"Immunologic blood transfusion reactions\", section on 'Posttransfusion purpura'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799532\">",
"    <span class=\"h2\">",
"     The bleeding history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with a suspected bleeding disorder should be questioned about past bleeding problems, a history of iron-responsive anemia, bleeding outcomes with surgical procedures and tooth extractions, history of transfusion, character of menses, and dietary habits or antibiotic use that might predispose to deficiencies of vitamin K, vitamin B12, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . A history of intermittent acute purpura suggests a drug (or herbal remedy, or food) induced thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=see_link&amp;anchor=H2#H2\">",
"     \"Approach to the adult patient with a bleeding diathesis\", section on 'Patient history'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=see_link&amp;anchor=H4#H4\">",
"     \"Preoperative assessment of hemostasis\", section on 'Patient questionnaires'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medications, herbal remedies, diet supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical to review the list of ALL medications taken by the patient which might be associated with the development of thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef73618 \" href=\"UTD.htm?36/3/36924\">",
"     table 3",
"    </a>",
"    ). This list should also include any over-the-counter and herbal products,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"     quinine",
"    </a>",
"    containing beverages,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and non-steroidal antiinflammatory agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link&amp;anchor=H10#H10\">",
"     \"Drug-induced thrombocytopenia\", section on 'History of drug ingestion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although medications may cause thrombocytopenia via induction of peripheral platelet destruction or production of bone marrow aplasia or hypoplasia, the most common cause is immune-mediated platelet destruction by drug-dependent, platelet-reactive antibodies. Some drugs can also exacerbate an underlying platelet disorder. Examples include the platelet dysfunction induced by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and many other anti-inflammatory drugs; and the co-ingestion of drugs that potentiate the anticoagulant effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=see_link\">",
"     \"Nonselective NSAIDs: Overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The timing of onset of clinical bleeding or first recognition of the thrombocytopenia with use of medications should be explored in depth, since it may focus attention on the most likely agent(s). Explicit questions about over-the-counter medicines, medicines taken irregularly or not prescribed by a physician (eg, medicines prescribed for a friend or a family member but taken by the patient), and herbal remedies are required, because patients are often reluctant to report their use of these medicines. It is good practice to review each of the patient's medications for the possibility of drug-induced thrombocytopenia, especially if a drug taken daily has been started within the past several weeks, if it is taken only occasionally for a longer period of time,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if its side effects are not generally known.",
"   </p>",
"   <p>",
"    The spectrum of drugs reported as causing drug-induced thrombocytopenia is continually increasing, reflecting both changes in drug consumption as well as increased recognition of drug-induced thrombocytopenia. A complete list and analysis of all published reports of drug-induced thrombocytopenia, as well as drugs identified as causes of thrombocytopenia by the documentation of drug-dependent, platelet-reactive antibodies is available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/35\">",
"     35",
"    </a>",
"    ]. These data are continuously updated and can be accessed at",
"    <a class=\"external\" href=\"file://www.ouhsc.edu/platelets\">",
"     www.ouhsc.edu/platelets",
"    </a>",
"    (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=see_link\">",
"     \"Drug-induced thrombocytopenia\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    As an example, the list of thrombocytopenia-inducing agents in Denmark contains 110 different drugs (excluding cytotoxic drugs); 20 percent of reported cases concerned drugs not previously listed, and 25 percent were caused by drugs which appeared on the list only sporadically [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/36\">",
"     36",
"    </a>",
"    ]. Some of the most commonly cited agents causing thrombocytopenia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"       \"Heparin-induced thrombocytopenia\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Valproic acid",
"     </li>",
"     <li>",
"      Gold salts (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=see_link\">",
"       \"Major side effects of gold\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/46/15080?source=see_link\">",
"       Quinine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"       quinidine",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       Trimethoprim-sulfamethoxazole",
"      </a>",
"      and other sulfonamides",
"     </li>",
"     <li>",
"      Interferons",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/0/14343?source=see_link\">",
"       Measles-mumps-rubella vaccine",
"      </a>",
"     </li>",
"     <li>",
"      Glycoprotein",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitors (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hospitalized patients often do not know what medications have been prescribed. In addition to reviewing the hospital chart for active medications and nursing notes and bedside flow sheets concerning the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    flushes of vascular access lines, it may be important to review anesthesia records. In many medical centers, anesthesiologists give medications directly to the patient without the need for entering a medication order. Important medicines may also be contained in materials used in surgery, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    mixed into joint replacement cement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H799624\">",
"    <span class=\"h2\">",
"     Recent travel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever and thrombocytopenia in an adult or child with a history of recent travel may indicate infection; malaria or dengue virus infection are common causes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Other infections that may be associated with recent travel and thrombocytopenia include leptospirosis, meningococcemia, rat-bite fever, rickettsial infections, hantavirus, and other viral hemorrhagic fevers (eg, Ebola, Lassa fever). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\", section on 'Laboratory findings'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=see_link&amp;anchor=H14#H14\">",
"     \"Evaluation of fever in the returning traveler\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Thrombocytopenia in the ICU patient",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common cause of thrombocytopenia developing for the first time in a patient in an intensive care unit (ICU) setting is sepsis, accounting for one-half of the cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/40\">",
"     40",
"    </a>",
"    ]. However, many ICU patients have more than one cause of thrombocytopenia. The following conditions are likely contributors to this picture:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infection, sepsis, septic shock",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation (DIC)",
"     </li>",
"     <li>",
"      Massive blood transfusion",
"     </li>",
"     <li>",
"      Post-transfusion purpura",
"     </li>",
"     <li>",
"      Cardiopulmonary resuscitation",
"     </li>",
"     <li>",
"      Cardiopulmonary bypass",
"     </li>",
"     <li>",
"      Adult respiratory distress syndrome",
"     </li>",
"     <li>",
"      Pulmonary embolism",
"     </li>",
"     <li>",
"      Use of intravascular catheters",
"     </li>",
"     <li>",
"      Solid organ allograft rejection",
"     </li>",
"     <li>",
"      Use of drugs associated with thrombocytopenia (eg, antibiotics, chemotherapy, antiplatelet agents such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study, evolution of DIC, cardiopulmonary resuscitation as the admission category, and signs of organ failure at admission were independently associated with the development of thrombocytopenia, while septic shock, a higher APACHE II score, and a &ge;30 percent decrease in platelet counts were significant risk factors for ICU death [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     The physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of critical areas which must be examined. These include, but are not limited to:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Examination of the ocular fundus for evidence of bleeding, since CNS bleeding is the most common cause of death in the thrombocytopenic patient",
"     </li>",
"     <li>",
"      Examination for lymphadenopathy, hepatosplenomegaly, and other masses which might suggest the presence of a disseminated disorder",
"     </li>",
"     <li>",
"      Examination of the stool for occult blood",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Examination of the skin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since bleeding into the skin is one of the most common findings in thrombocytopenia, this part of the examination should be the most detailed. Sites of bleeding should be noted, especially in the dependent parts of the body. This is normally the feet and ankles in ambulatory patients, as in panel A of the picture (",
"    <a class=\"graphic graphic_picture graphicRef71480 \" href=\"UTD.htm?10/8/10372\">",
"     picture 4",
"    </a>",
"    ), but may be the presacral area in bedridden patients. Sites of indwelling catheters and drains, areas of previous trauma, incision sites, and exit sites of venous access devices should be carefully examined.",
"   </p>",
"   <p>",
"    It is good practice to outline areas of bleeding with a marking pen, or to mark out involved and uninvolved skin areas and serially note changes in the number of petechiae or bleeding pattern within those sites, in order to obtain insight into the patient's progress. As noted above, the sites and timing of bleeding with thrombocytopenia differ from those in coagulation disorders (",
"    <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     CBC AND PERIPHERAL SMEAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory examination should start with the complete blood count (CBC). The \"gold standard\" for evaluation of thrombocytopenia of any cause is examination of a peripheral smear prepared from a freshly-shed sample of non- anticoagulated blood. The importance of a careful examination of the peripheral smear for estimation of platelet numbers, morphology, presence or absence of platelet clumping, as well as evaluation of associated white and red blood cell changes cannot be overemphasized.",
"   </p>",
"   <p>",
"    It is especially important to use the CBC and blood smear to help rule in or out thrombotic thrombocytopenic purpura and acute leukemia as expeditiously as possible, since inordinate delay in making these diagnoses and initiating appropriate treatment may prove fatal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pseudothrombocytopenia and artifacts",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is critical to confirm that the reported thrombocytopenia is true and not a falsely low platelet count due to artifact, or represents blood taken from a different individual.",
"   </p>",
"   <p>",
"    A spuriously low platelet count owing to inadequate sample anticoagulation or to EDTA-induced platelet clumping can be confirmed by evaluation of the peripheral smear (preferably prepared from freshly-shed non-anticoagulated blood) for the presence of platelet clumps (",
"    <a class=\"graphic graphic_picture graphicRef68949 \" href=\"UTD.htm?26/15/26872\">",
"     picture 3",
"    </a>",
"    ). Repeat blood sampling and the use of an alternate anticoagulant, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or sodium citrate, helps to make this diagnosis. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pseudothrombocytopenia'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The following findings can give clues to the genesis of the thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/42\">",
"     42",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Abnormal platelet morphology",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a number of congenital thrombocytopenic disorders. These can often be diagnosed following examination of the peripheral smear by virtue of alterations in platelet size, abnormal platelet granules,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    neutrophilic inclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/43\">",
"     43",
"    </a>",
"    ]. Many of these patients have been initially (and erroneously) diagnosed as having immune thrombocytopenia (ITP)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     May-Hegglin anomaly",
"    </span>",
"    &nbsp;&mdash;&nbsp;The May-Hegglin anomaly is an autosomal dominant trait characterized by giant platelets, mild to moderate thrombocytopenia, and leukocyte inclusions. Platelets are large (30 to 80 fL, normal: 7 to 10 fL) and some may be larger than red cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/44-47\">",
"     44-47",
"    </a>",
"    ]. Because of their large size, the platelets may not be recognized by the laboratory particle counter; therefore the reported platelet count may be falsely low. Inclusions in neutrophils, eosinophils, and some monocytes resemble D&ouml;hle bodies seen in infection.",
"   </p>",
"   <p>",
"    The disorder has been linked to mutations of the non-muscle myosin heavy chain gene, MYH9, found on chromosome 22q [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. Unlike the Fechtner, Sebastian, and Epstein syndromes, disorders also associated with mutations of the MYH9 gene, nephritis, deafness, and cataracts are not seen in patients with the May-Hegglin anomaly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients are asymptomatic, discovered incidentally (eg, at the time of a routine blood count), and require no specific treatment. The bleeding tendency, if present, is usually mild, but severe hemorrhages have been reported. Case reports suggest that infusions of DDAVP or platelets have been effective in controlling or preventing operative bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/51-55\">",
"     51-55",
"    </a>",
"    ]. Similarly, use of antifibrinolytic agents or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/42/30373?source=see_link\">",
"     recombinant human factor VIIa",
"    </a>",
"    may be transiently helpful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other MYH9 syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Related conditions, which vary according to the presence or absence of nephritis, neutrophilic inclusions, cataracts, and deafness have also been described (eg, Sebastian platelet syndrome, Fechtner syndrome, Epstein syndrome) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/43,45\">",
"     43,45",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef72433 \" href=\"UTD.htm?17/31/17911\">",
"     picture 6",
"    </a>",
"    ). These conditions are all associated with mutations in the MYH9 gene. They should not be confused with Alport syndrome, which may also be associated with nephritis, deafness, and cataracts, but which is due to mutations in type IV collagen and does not have associated platelet abnormalities. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=see_link\">",
"     \"Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Bernard-Soulier syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Bernard-Soulier syndrome is an autosomal recessive disorder presenting with mild thrombocytopenia, circulating \"giant\" platelets, marked platelet dysfunction, and bleeding. The bleeding is disproportionately more severe than suggested by the thrombocytopenia, and is explained by the absence of the platelet glycoprotein (GP) Ib-IX-V, a receptor for von Willebrand factor. Most patients with autosomal dominant macrothrombocytopenia share clinical and molecular features with heterozygous Bernard-Soulier syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/56\">",
"     56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Wiskott-Aldrich syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wiskott-Aldrich syndrome is a rare X-linked disorder which presents as a clinical triad of immunodeficiency, eczema, and moderate to severe thrombocytopenia with small (3 to 5 fL) platelets. Some male subjects with mutations of the Wiskott-Aldrich Syndrome Protein (WASP) gene may have only thrombocytopenia (which may be intermittent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/57\">",
"     57",
"    </a>",
"    ]) and small platelets, without immunodeficiency or eczema, a condition termed X-linked (congenital) thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/58\">",
"     58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=see_link\">",
"     \"Severe combined immunodeficiency (SCID): An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link&amp;anchor=H24194171#H24194171\">",
"     \"Wiskott-Aldrich syndrome\", section on 'X-linked thrombocytopenia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=see_link&amp;anchor=H22658193#H22658193\">",
"     \"Wiskott-Aldrich syndrome\", section on 'Thrombocytopenia and platelet abnormalities'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Other inherited thrombocytopenic disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;These disorders, which are uncommon, some of which are associated with giant platelets, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=see_link&amp;anchor=H27#H27\">",
"     \"Congenital and acquired disorders of platelet function\", section on 'Giant platelet disorders'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Decreased platelet production",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings that suggest reduced production of platelets as the cause for the patient's thrombocytopenia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Circulating blast cells, indicating the presence of acute leukemia (",
"      <a class=\"graphic graphic_picture graphicRef78291 \" href=\"UTD.htm?17/50/18214\">",
"       picture 7",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A leukoerythroblastic blood picture (teardrop RBCs, nucleated RBCs, and early myeloid forms in the blood) suggests marrow invasion with tumor, fibrosis, or granulomatous infection, such as tuberculosis (",
"      <a class=\"graphic graphic_picture graphicRef68110 graphicRef55274 \" href=\"UTD.htm?18/50/19242\">",
"       picture 8A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Other cytopenias, with or without macrocytosis, monocytosis, or decreased neutrophil lobulation (Pelger-Huet anomaly) (",
"      <a class=\"graphic graphic_picture graphicRef71990 \" href=\"UTD.htm?4/45/4816\">",
"       picture 9",
"      </a>",
"      ), suggest the presence of a myelodysplastic state",
"     </li>",
"     <li>",
"      Oval macrocytic RBCs along with hypersegmentation of neutrophils suggest vitamin B12 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency (",
"      <a class=\"graphic graphic_picture graphicRef74901 graphicRef58820 \" href=\"UTD.htm?6/38/6762\">",
"       picture 10A-B",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Platelets that are normal sized or small, in contrast to large sized platelets, suggest a reduced bone marrow response to need [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Increased peripheral destruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings that suggest increased peripheral destruction of platelets as the cause of thrombocytopenia include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microangiopathic blood picture, with fragmented RBCs, hemolytic anemia, and increased serum concentration of lactate dehydrogenase, as in disseminated intravascular coagulation (DIC) or thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS) (",
"      <a class=\"graphic graphic_picture graphicRef70851 \" href=\"UTD.htm?37/50/38694\">",
"       picture 11",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Large platelets (megathrombocytes) on the peripheral smear without significant bleeding suggest the presence of young, hemostatically active platelets in response to peripheral destruction [",
"      <a class=\"abstract\" href=\"UTD.htm?15/19/15674/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Associated autoimmune disease, especially in a young women (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=see_link\">",
"       \"Hematologic manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Underlying lymphoproliferative disease (eg, chronic lymphocytic leukemia or Hodgkin lymphoma) especially when a leukoerythroblastic blood picture is absent (see above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     BONE MARROW EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bone marrow aspiration and biopsy may be helpful in some patients to determine the presence or absence of megakaryocytes, indicating thrombocytopenia caused by increased platelet destruction or decreased platelet production, respectively. Bone marrow aspiration and biopsy may be more helpful in older patients in whom isolated thrombocytopenia may be the initial abnormality of myelodysplasia. (See",
"    <a class=\"local\" href=\"#H37\">",
"     'Diagnosis of ITP'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The following items need the most careful attention when examining the bone marrow in a thrombocytopenic patient:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of normal to increased numbers of megakaryocytes indicates that the patient's thrombocytopenia is due, at least in part, to increased peripheral destruction.",
"     </li>",
"     <li>",
"      Decreased numbers of megakaryocytes on the bone marrow biopsy, along with overall decreased or absent cellularity (",
"      <a class=\"graphic graphic_picture graphicRef63867 \" href=\"UTD.htm?34/43/35513\">",
"       picture 12",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef63378 \" href=\"UTD.htm?37/47/38646\">",
"       picture 13",
"      </a>",
"      ), is consistent with thrombocytopenia due to decreased bone marrow production, as in aplastic anemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=see_link\">",
"       \"Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a hypercellular marrow, the presence of megaloblastic changes in the red cell and granulocytic series suggests vitamin B12 or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"       folic acid",
"      </a>",
"      deficiency (",
"      <a class=\"graphic graphic_picture graphicRef68005 \" href=\"UTD.htm?23/25/23955\">",
"       picture 14",
"      </a>",
"      ), while the presence of dysplastic changes in the red cell, granulocytic, and megakaryocytic lineages suggests a myelodysplastic disorder (",
"      <a class=\"graphic graphic_picture graphicRef59897 \" href=\"UTD.htm?14/52/15173\">",
"       picture 15",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef65887 \" href=\"UTD.htm?0/44/705\">",
"       picture 16",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=see_link\">",
"       \"Clinical manifestations and diagnosis of the myelodysplastic syndromes\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of granulomata, increased reticulin or collagen fibrosis (",
"      <a class=\"graphic graphic_picture graphicRef57384 \" href=\"UTD.htm?17/34/17961\">",
"       picture 17",
"      </a>",
"      and",
"      <a class=\"graphic graphic_picture graphicRef69139 \" href=\"UTD.htm?24/19/24886\">",
"       picture 18",
"      </a>",
"      ), or infiltration with malignant cells (",
"      <a class=\"graphic graphic_picture graphicRef70576 \" href=\"UTD.htm?2/11/2228\">",
"       picture 19",
"      </a>",
"      ) establishes the diagnosis of marrow invasion, especially when a leukoerythroblastic blood picture is also present (see above).",
"     </li>",
"     <li>",
"      In rare cases, severe reduction or absence of megakaryocytes with no other abnormalities (ie, acquired amegakaryocytic thrombocytopenia, acquired pure megakaryocytic aplasia), may be due to the presence of an autoantibody directed against the thrombopoietin receptor, most often reported in patients with systemic lupus erythematosus. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=see_link&amp;anchor=H5#H5\">",
"       \"Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes\", section on 'Amegakaryocytic thrombocytopenia'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF GESTATIONAL THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidental thrombocytopenia of pregnancy, also termed gestational thrombocytopenia, is defined by the following five criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mild and asymptomatic thrombocytopenia",
"     </li>",
"     <li>",
"      No past history of thrombocytopenia (except possibly during a previous pregnancy)",
"     </li>",
"     <li>",
"      Occurrence during late gestation",
"     </li>",
"     <li>",
"      No association with fetal thrombocytopenia",
"     </li>",
"     <li>",
"      Spontaneous resolution after delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Platelet counts are typically greater than",
"    <span class=\"nowrap\">",
"     70,000/microL,",
"    </span>",
"    with about two-thirds being 130,000 to",
"    <span class=\"nowrap\">",
"     150,000/microL.",
"    </span>",
"    The frequency of gestational thrombocytopenia in the largest series of consecutive women admitted for labor and delivery is 5 percent. Neonatal thrombocytopenia did not occur in infants born to mothers with gestational thrombocytopenia (except in one infant with congenital myelodysplasia). Gestational thrombocytopenia is considered to be benign and any change from routine obstetrical care is discouraged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=see_link\">",
"     \"Thrombocytopenia in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF ITP",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no \"gold standard\" test that can establish the diagnosis of ITP, and testing for antiplatelet antibodies is not recommended. The diagnosis is based on exclusion of other causes of thrombocytopenia (",
"    <a class=\"graphic graphic_table graphicRef67855 \" href=\"UTD.htm?32/19/33084\">",
"     table 4",
"    </a>",
"    ). Few diagnostic studies other than the history, physical examination, complete blood count, and examination of the blood smear are necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=see_link\">",
"     \"Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A presumptive diagnosis of ITP is made when the history (eg, lack of ingestion of a drug that can cause thrombocytopenia), physical examination, complete blood count, and examination of the peripheral blood smear do not suggest other etiologies for the isolated thrombocytopenia. The only recommended further tests in such patients are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      HIV testing in patients with risk factors for HIV infection",
"     </li>",
"     <li>",
"      Bone marrow aspiration to rule out myelodysplastic syndrome, especially in patients &gt;60 years of age",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While thrombocytopenia can be caused by a myriad of conditions including systemic disease, infection, drugs, beverages, foods, and primary hematologic disorders, a number of salient points will help the physician in determining its cause:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thrombocytopenia is defined as a platelet count less than",
"      <span class=\"nowrap\">",
"       150,000/microL",
"      </span>",
"      (150 x",
"      <span class=\"nowrap\">",
"       10",
"       <sup>",
"        9",
"       </sup>",
"       /L),",
"      </span>",
"      keeping in mind that 2.5 percent of the normal population will have a platelet count lower than this. A fall in platelet count to levels less than",
"      <span class=\"nowrap\">",
"       150,000/microL",
"      </span>",
"      may herald severe clinical problems, and requires active follow-up, although thrombocytopenia is not usually detected clinically until the platelet count has fallen to levels significantly below",
"      <span class=\"nowrap\">",
"       100,000/microL.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions and normal values'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The importance of a careful examination of the peripheral smear for estimation of platelet numbers, morphology, presence or absence of platelet clumping, as well as evaluation for red and white blood cell abnormalities cannot be overemphasized. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pseudothrombocytopenia'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H26\">",
"       'Pseudothrombocytopenia and artifacts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings that suggest reduced production of platelets as the cause for the patient's thrombocytopenia include the presence of small platelets, malignant cells, a leukoerythroblastic blood picture, leukopenia, anemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      large (macrocytic) red cells. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Decreased platelet production'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large platelets (megathrombocytes) on the peripheral smear without significant bleeding suggest the presence of young, hemostatically active platelets in response to peripheral destruction. However, very large platelets, approaching the size of red cells, suggest a congenital thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Increased platelet destruction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Young versus old platelets'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other findings that suggest increased peripheral destruction of platelets as the cause of thrombocytopenia include the presence of fragmented red cells, hemolytic anemia, and an increased serum concentration of lactate dehydrogenase. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Increased platelet destruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A presumptive diagnosis of immune thrombocytopenia (ITP) is made when the history (eg, lack of ingestion of a drug, beverage, or food that can cause thrombocytopenia), physical examination, complete blood count, and examination of the peripheral blood smear do not suggest other etiologies for the isolated thrombocytopenia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Initial approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Diagnosis of ITP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Bone marrow aspiration and biopsy is indicated in virtually all patients with",
"      <strong>",
"       unexplained",
"      </strong>",
"      thrombocytopenia severe enough to constitute a risk for major bleeding. The only valid exclusion to this requirement is the patient less than 60 years of age with a presumptive diagnosis of ITP. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Bone marrow examination'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H37\">",
"       'Diagnosis of ITP'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Management issues for patients with thrombocytopenia, including activity restrictions, indications for treatment, and management of invasive procedures, are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=see_link&amp;anchor=H27#H27\">",
"       \"Evaluation and management of thrombocytopenia by primary care physicians\", section on 'Patient management'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/1\">",
"      Buckley MF, James JW, Brown DE, et al. A novel approach to the assessment of variations in the human platelet count. Thromb Haemost 2000; 83:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/2\">",
"      Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemost 1977; 3:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/3\">",
"      Wessels P, Heyns AD, Pieters H, et al. An improved method for the quantification of the in vivo kinetics of a representative population of 111In-labelled human platelets. Eur J Nucl Med 1985; 10:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/4\">",
"      Harker LA, Finch CA. Thrombokinetics in man. J Clin Invest 1969; 48:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/5\">",
"      Mason KD, Carpinelli MR, Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/6\">",
"      Dowling MR, Josefsson EC, Henley KJ, et al. Platelet senescence is regulated by an internal timer, not damage inflicted by hits. Blood 2010; 116:1776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/7\">",
"      Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of \"hypersplenic\" thrombocytopenia. J Clin Invest 1966; 45:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/8\">",
"      Peng J, Friese P, Heilmann E, et al. Aged platelets have an impaired response to thrombin as quantitated by P-selectin expression. Blood 1994; 83:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/9\">",
"      Alberio L, Friese P, Clemetson KJ, Dale GL. Collagen response and glycoprotein VI function decline progressively as canine platelets age in vivo. Thromb Haemost 2002; 88:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/10\">",
"      Wang C, Smith BR, Ault KA, Rinder HM. Reticulated platelets predict platelet count recovery following chemotherapy. Transfusion 2002; 42:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/11\">",
"      Barsam SJ, Psaila B, Forestier M, et al. Platelet production and platelet destruction: assessing mechanisms of treatment effect in immune thrombocytopenia. Blood 2011; 117:5723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/12\">",
"      Monteagudo M, Amengual MJ, Mu&ntilde;oz L, et al. Reticulated platelets as a screening test to identify thrombocytopenia aetiology. QJM 2008; 101:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/13\">",
"      Solanki DL, Blackburn BC. Spurious leukocytosis and thrombocytopenia. A dual phenomenon caused by clumping of platelets in vitro. JAMA 1983; 250:2514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/14\">",
"      Cesca C, Ben-Ezra J, Riley RS. Platelet satellitism as presenting finding in mantle cell lymphoma. A case report. Am J Clin Pathol 2001; 115:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/15\">",
"      Montague N, Blackwelder P, Alsayegh H, et al. Platelet satellitism and dual surface immunoglobulin light-chain expression in circulating splenic marginal zone lymphoma cells. Ann Diagn Pathol 2013; 17:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/16\">",
"      Bobba RK, Doll DC. Platelet satellitism as a cause of spurious thrombocytopenia. Blood 2012; 119:4100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/17\">",
"      Bizzaro N, Goldschmeding R, von dem Borne AE. Platelet satellitism is Fc gamma RIII (CD16) receptor-mediated. Am J Clin Pathol 1995; 103:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/18\">",
"      Podda GM, Pugliano M, Femia EA, et al. The platelet count in EDTA-anticoagulated blood from patients with thrombocytopenia may be underestimated when measured in routine laboratories. Am J Hematol 2012; 87:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/19\">",
"      Sane DC, Damaraju LV, Topol EJ, et al. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. J Am Coll Cardiol 2000; 36:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/20\">",
"      Savage RA. Pseudoleukocytosis due to EDTA-induced platelet clumping. Am J Clin Pathol 1984; 81:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/21\">",
"      Payne BA, Pierre RV. Pseudothrombocytopenia: a laboratory artifact with potentially serious consequences. Mayo Clin Proc 1984; 59:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/22\">",
"      Pegels JG, Bruynes EC, Engelfriet CP, von dem Borne AE. Pseudothrombocytopenia: an immunologic study on platelet antibodies dependent on ethylene diamine tetra-acetate. Blood 1982; 59:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/23\">",
"      Garcia Suarez J, Calero MA, Ricard MP, et al. EDTA-dependent pseudothrombocytopenia in ambulatory patients: clinical characteristics and role of new automated cell-counting in its detection. Am J Hematol 1992; 39:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/24\">",
"      Vicari A, Banfi G, Bonini PA. EDTA-dependent pseudothrombocytopaenia: a 12-month epidemiological study. Scand J Clin Lab Invest 1988; 48:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/25\">",
"      Bartels PC, Schoorl M, Lombarts AJ. Screening for EDTA-dependent deviations in platelet counts and abnormalities in platelet distribution histograms in pseudothrombocytopenia. Scand J Clin Lab Invest 1997; 57:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/26\">",
"      Fiorin F, Steffan A, Pradella P, et al. IgG platelet antibodies in EDTA-dependent pseudothrombocytopenia bind to platelet membrane glycoprotein IIb. Am J Clin Pathol 1998; 110:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/27\">",
"      Oski FA, Naiman JL. Effect of live measles vaccine on the platelet count. N Engl J Med 1966; 275:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/28\">",
"      Ballem PJ, Segal GM, Stratton JR, et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/29\">",
"      Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol 2009; 146:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/30\">",
"      West KA, Anderson DR, McAlister VC, et al. Alloimmune thrombocytopenia after organ transplantation. N Engl J Med 1999; 341:1504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/31\">",
"      Malouf MA, Milliken S, Glanville AR. Successful management of profound thrombocytopenia after lung and heart-lung transplantation. J Heart Lung Transplant 2000; 19:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/32\">",
"      Fishman AD, Hoffman A, Volterra F, et al. Intracaval and intracardiac metastatic nonseminomatous germ cell tumor: a rare cause of hemolytic anemia and thrombocytopenia. Cancer Invest 2002; 20:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/33\">",
"      Leslie SD, Toy PT. Laboratory hemostatic abnormalities in massively transfused patients given red blood cells and crystalloid. Am J Clin Pathol 1991; 96:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/34\">",
"      Counts RB, Haisch C, Simon TL, et al. Hemostasis in massively transfused trauma patients. Ann Surg 1979; 190:91.",
"     </a>",
"    </li>",
"    <li>",
"     Available at: file://www.ouhsc.edu/platelets. Accessed on February 28, 2011.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/36\">",
"      Pedersen-Bjergaard U, Andersen M, Hansen PB. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 1996; 239:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/37\">",
"      O'Donnell E, Shepherd C, Neff A. Immune thrombocytopenia from vancomycin in orthopedic cement. Am J Hematol 2007; 82:1122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/38\">",
"      Ladhani S, Khatri P, El-Bashir H, Shingadia D. Imported malaria is a major cause of thrombocytopenia in children presenting to the emergency department in east London. Br J Haematol 2005; 129:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/39\">",
"      Patel U, Gandhi G, Friedman S, Niranjan S. Thrombocytopenia in malaria. J Natl Med Assoc 2004; 96:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/40\">",
"      Vanderschueren S, De Weerdt A, Malbrain M, et al. Thrombocytopenia and prognosis in intensive care. Crit Care Med 2000; 28:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/41\">",
"      Strauss R, Wehler M, Mehler K, et al. Thrombocytopenia in patients in the medical intensive care unit: bleeding prevalence, transfusion requirements, and outcome. Crit Care Med 2002; 30:1765.",
"     </a>",
"    </li>",
"    <li>",
"     Mazur, EM. Platelets. In: Hematologic Pathophysiology, Schiffman, FJ (Ed), Lipincott-Raven, Philadelphia, 1998, p.140.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/43\">",
"      Drachman JG. Inherited thrombocytopenia: when a low platelet count does not mean ITP. Blood 2004; 103:390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/44\">",
"      Coller BS, Zarrabi MH. Platelet membrane studies in the May-Hegglin anomaly. Blood 1981; 58:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/45\">",
"      Greinacher A, Mueller-Eckhardt C. Hereditary types of thrombocytopenia with giant platelets and inclusion bodies in the leukocytes. Blut 1990; 60:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/46\">",
"      Noris P, Spedini P, Belletti S, et al. Thrombocytopenia, giant platelets, and leukocyte inclusion bodies (May-Hegglin anomaly): clinical and laboratory findings. Am J Med 1998; 104:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/47\">",
"      Hamilton RW, Shaikh BS, Ottie JN, et al. Platelet function, ultrastructure, and survival in the May-Hegglin anomaly. Am J Clin Pathol 1980; 74:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/48\">",
"      Deutsch S, Rideau A, Bochaton-Piallat ML, et al. Asp1424Asn MYH9 mutation results in an unstable protein responsible for the phenotypes in May-Hegglin anomaly/Fechtner syndrome. Blood 2003; 102:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/49\">",
"      Dong F, Li S, Pujol-Moix N, et al. Genotype-phenotype correlation in MYH9-related thrombocytopenia. Br J Haematol 2005; 130:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/50\">",
"      Saito H, Kunishima S. May-Hegglin anomaly: morphologic and clinical manifestations. Clin Adv Hematol Oncol 2009; 7:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/51\">",
"      Sehbai AS, Abraham J, Brown VK. Perioperative management of a patient with May-Hegglin anomaly requiring craniotomy. Am J Hematol 2005; 79:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/52\">",
"      Everlien M, Knoch K, Farah I, Greve H. [Coronary bypass surgery in May-Hegglin anomaly]. Dtsch Med Wochenschr 2001; 126:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/53\">",
"      Binder T, Salaj P, Sosna O, H&aacute;jek Z. [The May-Hegglin anomaly in pregnancy. 2 case reports]. Ceska Gynekol 2003; 68:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/54\">",
"      Urato AC, Repke JT. May-Hegglin anomaly: a case of vaginal delivery when both mother and fetus are affected. Am J Obstet Gynecol 1998; 179:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/55\">",
"      Suzuki H, Fukuda H, Hirabayashi Y, et al. [Anesthetic management of a patient with May-Hegglin anomaly]. Masui 2000; 49:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/56\">",
"      Savoia A, Balduini CL, Savino M, et al. Autosomal dominant macrothrombocytopenia in Italy is most frequently a type of heterozygous Bernard-Soulier syndrome. Blood 2001; 97:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/57\">",
"      Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood 2002; 99:2268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/58\">",
"      Ho LL, Ayling J, Prosser I, et al. Missense C168T in the Wiskott--Aldrich Syndrome protein gene is a common mutation in X-linked thrombocytopenia. Br J Haematol 2001; 112:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/19/15674/abstract/59\">",
"      Kaito K, Otsubo H, Usui N, et al. Platelet size deviation width, platelet large cell ratio, and mean platelet volume have sufficient sensitivity and specificity in the diagnosis of immune thrombocytopenia. Br J Haematol 2005; 128:698.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6680 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-122.72.80.101-E34D2EC933-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15674=[""].join("\n");
var outline_f15_19_15674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H38\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS AND NORMAL VALUES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      OVERVIEW OF PLATELET KINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Young versus old platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reticulated platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MECHANISMS OF THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pseudothrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2817248\">",
"      - Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Decreased platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Increased platelet destruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Dilutional thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Distributional thrombocytopenia caused by splenomegaly",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Petechiae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Purpura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Ecchymoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INITIAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The general history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799532\">",
"      The bleeding history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medications, herbal remedies, diet supplements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H799624\">",
"      Recent travel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Thrombocytopenia in the ICU patient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      The physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Examination of the skin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      CBC AND PERIPHERAL SMEAR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pseudothrombocytopenia and artifacts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Abnormal platelet morphology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - May-Hegglin anomaly",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other MYH9 syndromes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Bernard-Soulier syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Other inherited thrombocytopenic disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Decreased platelet production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Increased peripheral destruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      BONE MARROW EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      DIAGNOSIS OF GESTATIONAL THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      DIAGNOSIS OF ITP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6680\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6680|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/22/8558\" title=\"figure 1\">",
"      Predicting platelet recovery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/24/7566\" title=\"figure 2\">",
"      Splenic platelet pooling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6680|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/12/20675\" title=\"picture 1\">",
"      Megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/53/24402\" title=\"picture 2\">",
"      Megakaryocytes and platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/15/26872\" title=\"picture 3\">",
"      Platelet clumping in EDTA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?10/8/10372\" title=\"picture 4\">",
"      Petechiae in immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/6/29794\" title=\"picture 5\">",
"      Petechiae in Henoch Schonlein purpura IgA vasculitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17911\" title=\"picture 6\">",
"      Giant platelets",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/50/18214\" title=\"picture 7\">",
"      Myeloblasts with Auer rod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?29/43/30390\" title=\"picture 8A\">",
"      Leukoerythroblastic blood smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/37/43606\" title=\"picture 8B\">",
"      Tear drop cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/45/4816\" title=\"picture 9\">",
"      Pelger Huet anomaly",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/45/9942\" title=\"picture 10A\">",
"      Macroovalocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/47/4854\" title=\"picture 10B\">",
"      Megaloblastic smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/50/38694\" title=\"picture 11\">",
"      Schistocytes on peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/43/35513\" title=\"picture 12\">",
"      Aplastic anemia bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?37/47/38646\" title=\"picture 13\">",
"      Hypocellular marrow aspirate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/25/23955\" title=\"picture 14\">",
"      Megaloblastic erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/52/15173\" title=\"picture 15\">",
"      MDS abnormal megakaryocytes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/44/705\" title=\"picture 16\">",
"      Ring sideroblasts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/34/17961\" title=\"picture 17\">",
"      Myelofibrosis bone marrow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/19/24886\" title=\"picture 18\">",
"      Myelofibrosis marrow collagen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/11/2228\" title=\"picture 19\">",
"      Metastatic cancer marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6680|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/28/8652\" title=\"table 1\">",
"      Major causes of DIC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 2\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?36/3/36924\" title=\"table 3\">",
"      Drugs associated with immune thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/19/33084\" title=\"table 4\">",
"      Differential dx of ITP",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/38/4710?source=related_link\">",
"      Alcohol abuse and hematologic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/586?source=related_link\">",
"      Aplastic anemia: Pathogenesis; clinical manifestations; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/3/5178?source=related_link\">",
"      Approach to the adult patient with a bleeding diathesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/54/35690?source=related_link\">",
"      Automated hematology instrumentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/61/36826?source=related_link\">",
"      Causes of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"./chronic-refractory-immune-thrombocytopenia-itp-in-adults?source=related_link\">",
"      Chronic refractory immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/13/30938?source=related_link\">",
"      Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/57/41882?source=related_link\">",
"      Clinical manifestations and diagnosis of the myelodysplastic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23034?source=related_link\">",
"      Clinical manifestations of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/9/29850?source=related_link\">",
"      Congenital and acquired disorders of platelet function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11786?source=related_link\">",
"      Etiology and clinical manifestations of vitamin B12 and folate deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/59/19385?source=related_link\">",
"      Evaluation and management of thrombocytopenia by primary care physicians",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/24/39304?source=related_link\">",
"      Evaluation of fever in the returning traveler",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24663?source=related_link\">",
"      Genetics, pathogenesis, and pathology of hereditary nephritis (Alport syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/30/17897?source=related_link\">",
"      HELLP syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/11/14522?source=related_link\">",
"      Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/49/14106?source=related_link\">",
"      Hematologic manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/4/19525?source=related_link\">",
"      Major side effects of gold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/22/4458?source=related_link\">",
"      Megakaryocyte biology and the production of platelets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/49/17177?source=related_link\">",
"      Nonselective NSAIDs: Overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/59/23482?source=related_link\">",
"      Platelet function testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/43/32439?source=related_link\">",
"      Preoperative assessment of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/24/12680?source=related_link\">",
"      Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/30/42471?source=related_link\">",
"      Severe combined immunodeficiency (SCID): An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/56/38793?source=related_link\">",
"      Thrombocytopenia in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36313?source=related_link\">",
"      Wiskott-Aldrich syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_19_15675="Contrib factors vasoocclusion";
var content_f15_19_15675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F74933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F74933&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Possible contributory factors in sickle cell vasoocclusion",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        HbS polymer formation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell deformability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell whole blood viscosity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fraction of dense irreversibly sickled cells",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Red cell function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sickle cell adherence to vascular endothelium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Endothelial cell activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hemostatic activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet activation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        White blood cell numbers and activity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vasoregulatory factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vascular architecture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Environmental factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychosocial adaptation",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15675=[""].join("\n");
var outline_f15_19_15675=null;
var title_f15_19_15676="Snake venom syndromes";
var content_f15_19_15676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Site of action of venom, clinical features, tests, and management",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Site of action",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features",
"       </td>",
"       <td class=\"subtitle1\">",
"        Laboratory tests",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Local",
"       </td>",
"       <td>",
"        <p>",
"         Pain",
"        </p>",
"        <p>",
"         Fang marks",
"        </p>",
"        <p>",
"         Swelling",
"        </p>",
"        <p>",
"         Ecchymoses",
"        </p>",
"        <p>",
"         Lymphadenitis",
"        </p>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Antivenom",
"        </p>",
"        <p>",
"         Compartment syndrome",
"        </p>",
"        <p>",
"         Rare",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Neurotoxicity",
"       </td>",
"       <td>",
"        <p>",
"         Ptosis, diplopia",
"        </p>",
"        <p>",
"         Dysphagia",
"        </p>",
"        <p>",
"         Bulbar palsy: \"drooling\"&nbsp;pooling of secretions in pharynx",
"        </p>",
"        <p>",
"         Dyspnea",
"        </p>",
"        <p>",
"         Limb weakness",
"        </p>",
"       </td>",
"       <td>",
"        \"Tensilon\" test where appropriate",
"       </td>",
"       <td>",
"        <p>",
"         Antivenom",
"        </p>",
"        <p>",
"         Supportive; ventillatory support",
"        </p>",
"        <p>",
"         Anticholinesterase depending on snake",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Coagulopathy",
"       </td>",
"       <td>",
"        <p>",
"         Epistaxis, gingival ooze",
"        </p>",
"        <p>",
"         Bleeding from venipuncture site",
"        </p>",
"        <p>",
"         Ecchymoses and bruising",
"        </p>",
"        <p>",
"         Clinically evident bleeding(hemoptysis, hematemasis, hematuria, intracranial hemorrhage)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Whole blood clotting test",
"        </p>",
"        <p>",
"         Thrombocytopenia",
"        </p>",
"        <p>",
"         Prolonged INR, aPTT",
"        </p>",
"        <p>",
"         Decreased fibrinogen",
"        </p>",
"        <p>",
"         Raised fibrin degradation products, D-dimers",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Antivenom",
"        </p>",
"        <p>",
"         Blood products",
"        </p>",
"        <p>",
"         Heparin, e-ACA not shown to be helpful",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shock",
"       </td>",
"       <td>",
"        Hypotension, tachycardia",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        <p>",
"         Antivenom",
"        </p>",
"        <p>",
"         Intravenous fluids",
"        </p>",
"        <p>",
"         Central pressure monitoring",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15676=[""].join("\n");
var outline_f15_19_15676=null;
var title_f15_19_15677="LMW heparin pediatric doses";
var content_f15_19_15677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64075&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Low molecular weight heparin and dose adjustment in pediatric patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Age-dependent dose of enoxaparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;2 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ge;2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial treatment dose",
"       </td>",
"       <td>",
"        1.5 mg/kg/dose*",
"        <sup>",
"         &Delta;",
"        </sup>",
"        every 12 hours",
"       </td>",
"       <td>",
"        1 mg/kg/dose*",
"        <sup>",
"         &loz;",
"        </sup>",
"        every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic dose",
"       </td>",
"       <td>",
"        0.75 mg/kg/dose every 12 hours",
"       </td>",
"       <td>",
"        0.5 mg/kg/dose every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Weight-dependent dose of dalteparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial treatment dose",
"       </td>",
"       <td colspan=\"2\">",
"        129 &plusmn; 43 units/kg*",
"        <sup>",
"         &sect;",
"        </sup>",
"        every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic dose",
"       </td>",
"       <td colspan=\"2\">",
"        92 &plusmn; 52 units/kg every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Age-dependent dose of tinzaparin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;2 months",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ge;2 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial treatment dose",
"       </td>",
"       <td>",
"        275 units/kg* every 24 hours",
"       </td>",
"       <td>",
"        <ul>",
"         <li>",
"          2 to 12 months: 250 units/kg*",
"         </li>",
"         <li>",
"          1 to 5 years: 240 units/kg",
"         </li>",
"         <li>",
"          5 to 10 years: 200 units/kg",
"         </li>",
"         <li>",
"          10 to 16 years: 175 units/kg",
"          <sup>",
"           &sect;",
"          </sup>",
"         </li>",
"        </ul>",
"        These doses are given every 24 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Weight-dependent dose of reviparin",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        &lt;5 kg",
"       </td>",
"       <td class=\"subtitle2\">",
"        &ge;5 kg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Initial treatment dose",
"       </td>",
"       <td>",
"        150 units/kg/dose* every 12 hours",
"       </td>",
"       <td>",
"        100 units/kg/dose* every 12 hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prophylactic dose",
"       </td>",
"       <td>",
"        50 units/kg/dose every 12 hours",
"       </td>",
"       <td>",
"        30 units/kg/dose every 12 hours",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * For therapeutic",
"     <strong>",
"      treatment",
"     </strong>",
"     , the dose is adjusted as needed to achieve anti-Factor Xa levels between 0.5 and 1.0 U/mL in samples taken four hours after the last subcutaneous injection. For",
"     <strong>",
"      prophylaxis",
"     </strong>",
"     , there is no need for monitoring or dose adjustment. All doses are given subcutaneously.",
"     <br>",
"      &Delta; For enoxaparin, can also use 1.75 mg/kg/dose for term infants and 2 mg/kg/dose for preterm infants, if therapeutic level is desired with less dose adjustment. 1 mg enoxaparin = 100 anti Xa units.",
"      <br>",
"       <font class=\"lozenge\">",
"        &loz;",
"       </font>",
"       For obese patients treated with enoxaparin, it is reasonable to use initial enoxaparin doses based on actual body weight (rather than doses based on ideal body weight).",
"       <sup>",
"        [4]",
"       </sup>",
"       Doses should be adjusted based on anti-factor Xa levels, as for all patients.",
"       <sup>",
"        &nbsp;",
"        <br/>",
"       </sup>",
"       &sect; For tinzaparin and dalteparin, we use a maximum of 18,000 units initial treatment dose for heavier patients, but we then adjust this up or down as needed to achieve target anti-Factor Xa levels.",
"       <br>",
"        &yen;&nbsp;Reviparin is not currently available in the United States.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br>",
"      <ol>",
"       <li>",
"        Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children. Chest 2008; 133:887S.",
"       </li>",
"       <li>",
"        Kuhle S, Massicotte P, Dinyari M, et al. Dose-finding and pharmacokinetics of therapeutic doses of tinzaparin in pediatric patients with thromboembolic events. Thromb Haemost 2005; 94:1164.",
"       </li>",
"       <li>",
"        Nohe N, Flemmer A, Rumler R, et al. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158:S134.",
"       </li>",
"       <li>",
"        Richard AA, Kim S, Moffett BS, et al. Comparison of anti-Xa levels in obese and non-obese peditatric patients receiving treatment doses of enoxaparin. J Pediatr 2012; 162:293.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15677=[""].join("\n");
var outline_f15_19_15677=null;
var title_f15_19_15678="Nonscarring alopecias";
var content_f15_19_15678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F88346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F88346&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonscarring alopecias",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Epidemiology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical features on scalp",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-scalp involvement",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pathology",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hair pull test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Focal hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia areata*",
"       </td>",
"       <td>",
"        Onset most common in childhood or young adulthood",
"       </td>",
"       <td>",
"        Round patches of alopecia with&nbsp;exclamation point hairs; may extend to&nbsp;total hair loss on scalp (alopecia totalis) or loss of all body hair (alopecia universalis); uncommon is a diffuse hair loss presentation",
"       </td>",
"       <td>",
"        Other hair-bearing sites may be affected, nail pitting, trachyonychia",
"       </td>",
"       <td>",
"        Peribulbar lymphocytic infiltrate resembling \"swarm of bees\"; multiple miniaturized hair follicles; in chronic disease, increased catagen/telogen follicles",
"       </td>",
"       <td>",
"        Postive hair pull test, telogen hairs and dystrophic anagen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Traction alopecia",
"       </td>",
"       <td>",
"        Individuals with chronic use of traction-inducing hairstyles",
"       </td>",
"       <td>",
"        Loss of terminal hairs in areas of traction; prolonged traction may lead to cicatricial alopecia",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        <p>",
"         Acute: increased catagen/telogen hairs, occasional pigment casts",
"        </p>",
"        Chronic: reduction in terminal hairs, occasional fibrous tracts, retained sebaceous glands",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alopecia syphilitica",
"       </td>",
"       <td>",
"        Most common in young adults; occurs due to secondary syphilis",
"       </td>",
"       <td>",
"        Patchy hair loss, \"moth-eaten\" appearance",
"       </td>",
"       <td>",
"        Other mucocutaneous manifestations of secondary syphilis",
"       </td>",
"       <td>",
"        Increase in catagen/telogen follicles, perifollicular inflammation with plasma cells",
"       </td>",
"       <td>",
"        Positive for telogen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Temporal triangular alopecia",
"       </td>",
"       <td>",
"        Lifelong, usually detected in infancy or childhood",
"       </td>",
"       <td>",
"        Triangular or oval area with absent terminal hair in temporal region that is a few centimeters in diameter; vellus hairs visible on close inspection",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Predominance of vellus hairs",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pressure-induced (postoperative) alopecia",
"       </td>",
"       <td>",
"        Most commonly seen in surgical patients",
"       </td>",
"       <td>",
"        Hair loss localized to area of prolonged pressure, such as the posterior scalp after prolonged general anesthesia",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Nearly all hairs in catagen/telogen phase, trichomalacia",
"        <sup>",
"         &bull;",
"        </sup>",
"        , melanin in the collapsed outer root sheath, thrombosis, necrosis",
"       </td>",
"       <td>",
"        Normal or positive",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Patterned hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Male pattern hair loss (androgenetic alopecia in men)",
"       </td>",
"       <td>",
"        Most common in adult men, prevalence increases with age",
"       </td>",
"       <td>",
"        Slow, progressive terminal hair loss on the frontal, temporal, and/or vertex scalp",
"       </td>",
"       <td>",
"        N/A",
"       </td>",
"       <td>",
"        Marked variation in follicular size, increased proportion of vellus follicles, slight increase in telogen follicles, fibrous streamers beneath miniaturized hairs",
"       </td>",
"       <td>",
"        Generally normal; may be positive in areas of active hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Female pattern hair loss*",
"       </td>",
"       <td>",
"        Most common in adult women, prevalence increases with age",
"       </td>",
"       <td>",
"        Slow, progressive terminal hair loss on the crown of the scalp; frontal hairline is often relatively spared",
"       </td>",
"       <td>",
"        If related to hyperandrogenism signs of hirsutism or virilization may be present",
"       </td>",
"       <td>",
"        Same as in male pattern hair loss",
"       </td>",
"       <td>",
"        Generally normal; may be postive in areas of active hair loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Trichotillomania",
"       </td>",
"       <td>",
"        May occur in children and adults",
"       </td>",
"       <td>",
"        Broken hairs often distributed in a bizarre pattern",
"       </td>",
"       <td>",
"        May be associated with ingestion of hair and risk for trichobezoar",
"       </td>",
"       <td>",
"        Follicular distortion, pigment casts, trichomalacia",
"        <sup>",
"         &bull;",
"        </sup>",
"        , melanin pigment in collapsed root sheaths, fractured hairs, follicular hemorrhage",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"6\">",
"        Diffuse hair loss*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Telogen effluvium",
"       </td>",
"       <td>",
"        Women more likely to present for evaluation than men",
"       </td>",
"       <td>",
"        Acute or chronic diffuse hair thinning",
"       </td>",
"       <td>",
"        Findings associated with underlying cause may be present",
"       </td>",
"       <td>",
"        Increase in the proportion of telogen follicles (20 to 50 percent of follicles are in telogen)",
"       </td>",
"       <td>",
"        Positive in active phase; telogen hairs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anagen effluvium",
"       </td>",
"       <td>",
"        Seen in association with chemotherapy, radiation, toxins",
"       </td>",
"       <td>",
"        Acute loss of hair",
"       </td>",
"       <td>",
"        Findings associated with underlying cause may be present; hair loss in other sites",
"       </td>",
"       <td>",
"        Increased proportion of telogen follicles, dystrophic anagen hairs; rare cases of permanent hair loss may demonstrate linear basaloid structures",
"       </td>",
"       <td>",
"        Postive in active phase, dystrophic anagen hairs or broom-shaped anagen hairs with a pigmented bulb",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Loose anagen syndrome",
"       </td>",
"       <td>",
"        Affects children; most common in girls; often blond hair",
"       </td>",
"       <td>",
"        Hair is easily dislodged from follicles without pain; hair density appears normal or reduced",
"       </td>",
"       <td>",
"        May be solitary or associated with developmental defects",
"       </td>",
"       <td>",
"        Dystrophic anagen hairs",
"       </td>",
"       <td>",
"        Very positive; majority of hairs are anagen hairs with a ruffled cuticle and absent inner root sheath",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Atrichia with papular lesions",
"       </td>",
"       <td>",
"        Autosomal dominant disorder, presents in infancy",
"       </td>",
"       <td>",
"        Hair normal at birth, hair loss in infancy due to&nbsp;abnormality in first hair cycle (defect in catagen phase); papular follicular cysts develop later",
"       </td>",
"       <td>",
"        Hair loss and follicular cysts in other sites",
"       </td>",
"       <td>",
"        Absence of mature hair follicles, cysts present",
"       </td>",
"       <td>",
"        Normal; may be positive in initial stages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypotrichosis simplex",
"       </td>",
"       <td>",
"        Group of hypotrichosis disorders; usually autosomal dominant",
"       </td>",
"       <td>",
"        Usually progressive loss of scalp hair during childhood",
"       </td>",
"       <td>",
"        May or may not have involvement of other hair-bearing sites",
"       </td>",
"       <td>",
"        Reduced number of follicles, follicular miniaturization",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Alopecia areata and female pattern hair loss occasionally present with diffuse hair loss.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      Trichomalacia is a histological finding of distortion of the hair shaft and pigment that results from repeated hair&nbsp;plucking or other&nbsp;injury.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Otberg N, Shapiro J. Hair growth disorders. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill 2012.",
"      </li>",
"      <li>",
"       Childs JM, Sperling LC. Histopathology of scarring and nonscarring hair loss. Dermatol Clin 2013; 31:43.",
"      </li>",
"      <li>",
"       Michailidis E, Theos A, Zlotogorski A, et al. Atrichia with papular lesions resulting from novel compound heterozygous mutations in the human hairless gene. Pediatr Dermatol 2007; 24:E79.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15678=[""].join("\n");
var outline_f15_19_15678=null;
var title_f15_19_15679="Calculator: 10 year risk of developing cardiovascular disease in women (Patient information)";
var content_f15_19_15679=[" <div id=\"disclaimer\">",
"  The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"  <a href=\"/home/terms-use\" target=\"_blank\">",
"   UpToDate Terms of Use",
"  </a>",
"  &copy;2013 UpToDate, Inc.",
" </div>",
" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"Framingham08_F_Patient_form\" name=\"Framingham08_F_Patient_form\" onkeydown=\"clrResults();\" onkeyup=\"Framingham08_F_Patient_fx();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: 10 year risk of developing cardiovascular disease in women (Patient information)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"Framingham08_F_Patient_fx(); minMaxCheck();\" onchange=\"Framingham08_F_Patient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Systolic Blood Pressure",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Systolic_Blood_Pressure_param\" onblur=\"Framingham08_F_Patient_fx(); minMaxCheck();\" onchange=\"Framingham08_F_Patient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Systolic_Blood_Pressure_unit\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:105px;\">",
"              <option value=\"0.00750063755419211|0|Pascal\">",
"               Pascal",
"              </option>",
"              <option value=\"760.002100178515|0|atm\">",
"               atm",
"              </option>",
"              <option value=\"750.063755419211|0|bar\">",
"               bar",
"              </option>",
"              <option value=\"0.735561538478802|0|cmH2O\">",
"               cmH2O",
"              </option>",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option value=\"22.4199156928339|0|ftH2O\">",
"               ftH2O",
"              </option>",
"              <option value=\"0.735561538478802|0|gm/sqcm\">",
"               gm/sqcm",
"              </option>",
"              <option value=\"1.86832630773616|0|inH2O\">",
"               inH2O",
"              </option>",
"              <option value=\"25.4000840071406|0|inHg\">",
"               inHg",
"              </option>",
"              <option value=\"7.50063755419211|0|kPa\">",
"               kPa",
"              </option>",
"              <option value=\"0.750063755419211|0|mbar\">",
"               mbar",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"              <option value=\"51.7150957831416|0|psi\">",
"               psi",
"              </option>",
"              <option value=\"1|0|torr\">",
"               torr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Total Cholesterol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Total_Cholesterol_param\" onblur=\"Framingham08_F_Patient_fx(); minMaxCheck();\" onchange=\"Framingham08_F_Patient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Total_Cholesterol_unit\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_Chol\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_Chol\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              HDL Cholesterol",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"HDL_Cholesterol_param\" onblur=\"Framingham08_F_Patient_fx(); minMaxCheck();\" onchange=\"Framingham08_F_Patient_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"HDL_Cholesterol_unit\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|mg/dL_HDL\">",
"               mg/dL",
"              </option>",
"              <option value=\"38.6697602474865|0|mmol/L_HDL\">",
"               mmol/L",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              On blood pressure medication",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Sys_BP_Factor_pulldown\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:170px;\">",
"              <option value=\"2.76157\">",
"               No",
"              </option>",
"              <option value=\"2.82263\">",
"               Yes",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Cigarette smoker",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"Cig_pulldown\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No",
"              </option>",
"              <option value=\"0.52873\">",
"               Yes",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Diabetes present",
"             </span>",
"            </td>",
"            <td align=\"left\" colspan=\"2\">",
"             &nbsp;&nbsp;",
"             <select class=\"medCalcFontSelect\" name=\"DM_pulldown\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:170px;\">",
"              <option value=\"0\">",
"               No",
"              </option>",
"              <option value=\"0.69154\">",
"               Yes",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Risk",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Risk_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"            <td valign=\"top\">",
"             <span class=\"medCalcFontOne\">",
"              <select class=\"medCalcFontSelect\" name=\"Risk_unit\" onchange=\"Framingham08_F_Patient_fx();\" style=\"width:105px;\">",
"               <option selected=\"selected\" value=\"1|0|%\">",
"                %",
"               </option>",
"               <option value=\"100|0|fraction\">",
"                fraction",
"               </option>",
"               <option value=\"100|0|ratio\">",
"                ratio",
"               </option>",
"              </select>",
"             </span>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOneBold\">",
"      Notes",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       This calculator may be applied to women who have had no prior history of cardiovascular disease.",
"      </li>",
"      <li>",
"       A person with cardiovascular disease is someone who has (now or in the past) blocked coronary arteries, a heart attack,",
"a stroke or blocked carotid arteries, peripheral arterial disease (blocked arteries to the legs) or heart failure.",
"      </li>",
"      <li>",
"       Systolic blood pressure is the top number (eg, 120 if BP is 120/80.)",
"      </li>",
"     </ul>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        D'Agostino RB Sr, Vasan RS, Pencina MJ, et. al. General Cardiovascular Risk Profile for  Use in Primary Care. The Framingham Heart Study.",
"        <i>",
"         Circulation",
"        </i>",
"        . 2008 Jan 22.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_19_15679=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function Framingham08_F_Patient_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.Framingham08_F_Patient_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Systolic_Blood_Pressure_param.value.indexOf(',') >= 0){ Systolic_Blood_Pressure_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Systolic_Blood_Pressure_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Systolic_Blood_Pressure_unit.options[Systolic_Blood_Pressure_unit.selectedIndex].value.split('|');",
"Systolic_Blood_Pressure = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Total_Cholesterol_param.value.indexOf(',') >= 0){ Total_Cholesterol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Total_Cholesterol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Total_Cholesterol_unit.options[Total_Cholesterol_unit.selectedIndex].value.split('|');",
"Total_Cholesterol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (HDL_Cholesterol_param.value.indexOf(',') >= 0){ HDL_Cholesterol_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(HDL_Cholesterol_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = HDL_Cholesterol_unit.options[HDL_Cholesterol_unit.selectedIndex].value.split('|');",
"HDL_Cholesterol = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"Sys_BP_Factor = parseFloat(Sys_BP_Factor_pulldown.options[Sys_BP_Factor_pulldown.selectedIndex].value);",
"Cig = parseFloat(Cig_pulldown.options[Cig_pulldown.selectedIndex].value);",
"DM = parseFloat(DM_pulldown.options[DM_pulldown.selectedIndex].value);",
"dp = 1;",
"Risk_Factors =  (ln(Age) * 2.32888) + (ln(Total_Cholesterol) * 1.20904) - (ln(HDL_Cholesterol) * 0.70833) +  (ln(Systolic_Blood_Pressure) * Sys_BP_Factor) + Cig + DM - 26.1931;",
"",
"Risk =  100 * (1 - power(0.95012, eTo(Risk_Factors)));",
"",
"unit_parts = Risk_unit.options[Risk_unit.selectedIndex].value.split('|');",
"if (doCalc) Risk_param.value = fixDP((Risk - parseFloat(unit_parts[1])) / parseFloat(unit_parts[0]), dp);",
"",
"",
"",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_F_Patient_form){",
"",
"if (Age_param.value && Age < 19) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 19 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 80) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 80 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.Framingham08_F_Patient_form){",
"",
"Risk_param.value = '';",
"",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"",
""].join("\n");
var outline_f15_19_15679=null;
